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Abstract 
 
GENE EXPRESSION PROFILING: A FAILURE SIGNATURE 
PREDICTIVE OF RIGHT HEART FAILURE 
By Jennifer I. Drake, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2011 
 
Major Director: Paul M. Fawcett, Ph.D. 
Assistant Professor, Department of Internal Medicine and Director of Research 
Resources, Massey Cancer Center at Virginia Commonwealth University 
 
 
Pulmonary arterial hypertension (PAH) is a disease of the lung vessels that causes severe 
effects on the right ventricle of the heart; ultimately, most patients with severe PAH die 
as a result of right heart failure.  However, little is known about the causes of right heart 
failure. 
 
Here, we describe a pattern of gene expression that differs between the normal rat left 
ventricle (LV) and right ventricle (RV).  These genes are known to be involved in the 
xviii 
xix 
development of the heart as well as adaptations to the heart during stress.  This gene 
expression pattern is used as a baseline to describe changes in gene expression the occur 
in the RV as a result of adaptive hypertrophy, stimulated by chronic hypoxia, or right 
ventricular failure (RVF), caused by administration of Su5416 and hypoxia.  The genes 
differing between RVF and hypertrophy encode glycolytic enzymes, mitochondrial 
electron transport chain complexes, cell-growth promoting proteins, and angiogenic 
capillary maintenance proteins.  Additionally, we show that RVF is associated with an 
increase in the serum cytokine production of IL-1β, IL-10, TNF-α, and VEGF.  Finally, 
we show that treatment with the β-adrenergic receptor blocker carvedilol partially 
changed the gene expression pattern seen with RVF.  The most profound effects were on 
the genes encoding glycolytic enzymes and mitochondrial electron transport chain 
complexes. 
 
Together, these results show that the normal LV and RV have a distinct pattern of 
expression and that the failing RV is characterized by changes in cell growth, 
angiogenesis, and energy utilization.  Treatment with carvedilol can partially reverse 
these gene expression changes in the failing RV. 
  
 

  
 
 
Chapter 1: Pulmonary Hypertension, the Heart, and their Interactions 
 
 
1.1 Pulmonary Hypertension 
 
1.1.1 Overview 
 
Pulmonary hypertension refers to an increase in pressure in the lung circulation 
frequently causing in patients symptoms of dizziness, fatigue, peripheral leg edema, and 
shortness of breath.  It is diagnosed by measurements obtained during right heart 
catheterization.  Patients with pulmonary hypertension have a mean pulmonary artery 
pressure of greater than 25 mmHg at rest or greater than 30 mmHg with exercise[1].  A 
normal mean pulmonary artery pressure is 8 – 20 mmHg at rest.   
 
1.1.2 Classification schemes 
 
Pulmonary hypertension is categorized according to a World Health Organization 
classification scheme, the first of which was proposed in 1973 at an international 
conference on primary pulmonary hypertension.  Based on the presence or absence of 
21 
identifiable causes and risk factors, patients were classified as having either primary or 
secondary pulmonary hypertension[2, 3].  In 1998, the second world symposium on 
pulmonary arterial hypertension (PAH) was held in Evian, France.  Here, five major 
categories of pulmonary hypertension were created based on shared pathological and 
clinical features and therapeutic options[4].  The third world symposium was held in 
Venice, Italy in 2003.  During this conference, the primary pulmonary hypertension 
group was subdivided into idiopathic pulmonary arterial hypertension, familial 
pulmonary arterial hypertension, or associated pulmonary arterial hypertension[5].  
During the fourth world symposium held in Dana Point, California in 2008, modifications 
of the Venice classifications were made to reflect current publications and treatments[5] 
(Table 1).  The groups as described following are based on the Venice classification 
scheme. 
 
1.1.3 Pulmonary arterial hypertension 
 
Pulmonary arterial hypertension (PAH) may arise spontaneously and have no familial 
connection (idiopathic PAH), have a familial connection (familial PAH), or be associated 
with other diseases such as connective tissue disease or HIV (associated PAH).  The PAH 
subgroup of PH adds an additional diagnostic criterion of a mean pulmonary wedge 
pressure, an indirect measure of left arterial pressure and an indication of left ventricular 
failure, greater than or equal to 15 mmHg[1].  Idiopathic PAH has an estimated incidence 
of approximately 2 cases per million per year.[6, 7]  The mean age at presentation in 
adults ranges from 36 – 50, although individuals of any age can be affected.[7, 8]  In a  
22 
Table 1: Venice classification scheme of pulmonary hypertension 
Reprinted from Journal of the American College of Cardiology, vol. 54, G. Simonneau et 
al., “Updated Clinical Classification of Pulmonary Hypertension,” S43-S54, 
Copyright 2009, with permission from Elsevier. 
 
1. Pulmonary arterial hypertension (PAH) 
  1.1 Idiopathic PAH 
  1.2 Heritable PAH 
    1.2.1 BMPR2 
    1.2.2 ALK1, endoglin (with or without hereditary hemorrhagic telanglectasia) 
    1.2.3 unknown 
  1.3 Drug- and toxin-induced 
  1.4 Associated with 
    1.4.1 Connective tissue diseases 
    1.4.2 HIV infection 
    1.4.3 Portal hypertension 
    1.4.4 Congenital heart diseases 
    1.4.5 Schistosomiasis 
    1.4.6 Chronic hemolytic anemia 
  1.5 Persistent pulmonary hypertension of the newborn 
1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) 
2. Pulmonary hypertension owing to left heart disease 
  2.1 Systolic dysfunction 
  2.2 Diastolic dysfunction 
  2.3 Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
  3.1 Chronic obstructive pulmonary disease 
  3.2 Interstitial lung disease 
  3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
  3.4 Sleep-disordered breathing 
  3.5 Alveolar hypoventilation disorders 
  3.6 Chronic exposure to high altitude 
  3.7 Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
  5.1 Hematologic disorders: myeloproliferative disorders, splenectomy 
  5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis,  
         lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
  5.3 Metabolic disorders: glycogen storage disease, Gaucer disease, thyroid 
        disorders 
  5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on  
        dialysis 
23 
study of  194 patients with PAH conducted by the NIH from 1981 to 1985, the estimated 
median life span after diagnosis was 2.8 years with 1-, 3-, and 5-year survival rates of 
68%, 48%, and 34%[8].  A more recent study estimates 1-, 2-, and 3-year survival rates at 
77%, 69%, and 35%.[9].  Irrespective of the causes, most PAH patients die from 
intractable right heart failure. 
 
Histological findings of PAH are: intimal hyperplasia, medial hypertrophy, adventitial 
proliferation and fibrosis, occlusion of small arteries, in situ thrombosis, and infiltration 
of inflammatory and progenitor cells.  Plexiform lesions are a hallmark of PAH and are 
found only in patients with PAH Group 1 and also in patients with myeloproliferative 
disease and patients with sarcoidosis (Group 5), but not those with other PH categories 
(Figure 1).  These complex vascular lesions are typically composed of proliferating 
endothelial cells and perivascular inflammatory cells and are located downstream from 
the occluded arteries.  They express growth and transcription factors observed in tissues 
undergoing angiogenesis, including vascular endothelial growth factor (VEGF) and 
hypoxia inducible factor 1α (HIF-1α)[10].  It is hypothesized that widespread early 
endothelial apoptosis seen in PAH culminates in selection of apoptosis-resistant 
endothelial precursor cells that proliferate and eventually form plexiform lesions[11]. 
 
In familial PAH patients, bone morphogeneic protein receptor type 2 (BMPR2) germline 
mutations are seen in 70% of patients[12, 13]. In addition, 11% - 40% of idiopathic PAH 
patients also have BMPR2 mutations[14, 15]. It has been suggested that patients with 
BMPR2 mutations may present a subgroup of PAH patients with a more severe form of  
24 
Figure 1: Plexiform lesions of pulmonary arterial hypertension 
 
Pulmonary blood vessels in the normal (left) and pulmonary arterial hypertension (right) 
lung.  The plexiform lesions seen in the pulmonary hypertension lung are formed due to 
increased cell proliferation and decreased apoptosis leading to occlusion of the 
pulmonary vascular lumen. 
 
Reprinted from Journal of the American College of Cardiology, vol. 54, P.M. Hassoun et 
al., “Inflammation, Growth Factors, and Pulmonary Vascular Remodeling,” S10-
S19, Copyright 2009, with permission from Elsevier. 
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the disease and are less likely to demonstrate vasoreactivity than the idiopathic PAH 
patients without BMPR2 mutations.[16-18]  Other, more rare, germline mutations are in 
endoglin and activin receptor-like kinase type 1 occuring predominantly with hereditary 
hemorrhagic telangiectasia,[19, 20] also known as Osler-Weber-Rendu disease, which is 
characterized by abnormal blood vessel formation in the skin and organs. 
 
A number of risk factors relating to drugs or toxins are included in the classifications of 
PAH and were categorized as “definite,” “very likely,” “possible,” or “unlikely” based on 
their association with PAH (Table 2).  A “definite” association is one defined as an 
epidemic or a large, multi-center epidemiologic study demonstrating an association 
between the drug and PAH.  A “likely” association is one revealed by a single-center, 
case-controlled study.  “Possible” is defined as drugs with similar mechanisms or actions 
as those in the “definite” or “likely” categories, but has not yet been studied.  Those drugs 
termed “unlikely” have been studied and no association has been revealed.[4]  The only 
identified definite risk factors for PAH are aminorex, amphetamine, fenfluramine, and 
toxic rapeseed oil[4, 21].  Aminorex and fenfluramine are drugs used in anti-obesity 
medication.  Toxic rapeseed oil is rapeseed oil contaminated with oleoanilide, a chemical 
by-product formed when industrial grade rapeseed oil interacts with anilide and 
acetanilide[22].  Between 1998 and 2001, the Surveillance of Pulmonary Hypertension in 
America (SOPHIA) study enrolled 1,335 patients across the US and determined the 
association of fenfluramine or dexfenfluramine intake with the development of PAH[23]. 
It also studied St. John’s Wort and over-the-counter anti-obesity drugs containing 
phenylpropanolamine, both of which were shown to increase the risk of developing  
27 
Table 2: Risk factors for development of pulmonary arterial hypertension  
Definite 
       -aminorex 
       -fenfluramine, dexfenfluramine 
       -toxic rapeseed oil 
Likely 
       -amphetamines 
       -methamphetamines 
Possible 
       -chemotherapeutic agents 
       -cocaine 
       -phenylpropanolamine 
       -SSRIs 
       -St. John’s Wort 
Unlikely 
       -cigarette smoking 
       -estrogen therapy 
       -oral contraceptives 
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PAH[23].  While the SOPHIA study showed no increase risk for developing PAH with 
intake of non-selective monoamine reuptake inhibitors (MAOIs), selective serotonin 
reuptake inhibitors (SSRIs), antidepressants, or anxiolytics[23], a case-controlled study of 
pregnant women using SSRIs after 20 weeks of gestation showed an increased risk for 
the newborn developing persistent PH of the newborn, a form of PH[24].  As such, SSRIs 
have been placed in the “possible” risk category. 
 
Another subgroup of PAH is the PAH associated with other diseases, including 
connective tissues diseases, HIV, portal hypertension, congenital heart disease, 
schistosomiasis, and chronic hemolytic anemias.  PAH occurs in 7% - 12% of patients 
with scleroderma[25, 26], a chronic systemic autoimmune disease characterized by 
fibrosis and vascular alterations, while the prevalence of PAH associated with systemic 
lupus erythematosis (SLE), a systemic autoimmune disease that can affect any part of the 
body[27, 28], and mixed connective tissue disease[29, 30] is unknown, but likely occur 
less often than with scleroderma.  PAH is a rare complication of HIV infection with an 
incidence of 1 in 200 AIDS patients, and HIV-associated PAH has clinical, 
hemodynamic, and histological characteristics similar to those found in idiopathic 
PAH[5].  In the early 1990s before antiretroviral therapy was widely available, 0.5% of 
patients with HIV also had PAH[31].  A more recent study shows the percent of HIV 
patients with PAH to be 0.46%[32].  Untreated congenital heart disease (CHD), in 
particular those patients with systemic-to-pulmonary shunts, presents a significant risk 
for developing PAH.  Eisenmenger syndrome, defined as CHD with an initial large 
systemic-to pulmonary shunt that induces progressive pulmonary vascular disease and 
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PAH, presents the most advanced form of PAH associated with CHD[33].  The 
prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Europe 
and North America has been estimated to be between 1.6 and 12.5 cases per million 
adults, 25% - 50% of which have Eisenmenger syndrome[34].  PAH associated with 
schistosomiasis, an infection caused by a parasitic worm of the genus Schistosoma, can 
have similar clinical presentation to idiopathic PAH[35], including similar histological 
findings and the development of plexiform lesions[36]. It is estimated that more than 200 
million people worldwide are infected by one of the three species of Schistosoma, of 
which 4% - 8% develop hepatosplenic disease, which is characterized by an enlarged 
liver and spleen and block of portal bloodflow[37].  Of patients with hepatosplenic 
disease, 4.6% also develop PAH[38].  PAH can also be a complication of chronic 
hereditary and acquired hemolytic anemias, including sickle cell disease[39, 40]; 
thalassemia, an autosomal recessive disorder that causes a reduced rate of synthesis or 
lack of synthesis of globin molecules[41]; hereditary spherocytosis, an autosomal 
dominant disorder in which red blood cells are sphere-shaped rather than bi-concave disc 
shaped[42, 43]; stomatocytosis, an autosomal dominant disorder in which the membrane 
of the red blood cells leak sodium and potassium[44]; and microangiopathic hemolytic 
anemia, which causes destruction of the red blood cells by a fibrin mesh that forms due to 
increased coagulation activity[45].  PH has been described most often in patients with 
sickle cell disease and presents with histological lesions similar to those seen in 
idiopathic PAH, including plexiform lesions.  In the largest study of patients with sickle 
cell disease, 32% also had PAH[40].  However, a recent study by a French group has 
revised this incidence to 6%[46].  
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 Three classes of drugs are currently being used to treat PAH: prostanoids, such as 
prostacyclin, endothelin receptor antagonists, such as bosentan or ambristentan, and 
phosphodiesterase-5 inhibitors, such as sildenafil.  These drugs are used to induce 
pulmonary vasodilation with the additional hope that they reverse pulmonary vascular 
remodeling[47, 48].  While these drugs may be advantageous for the lungs, they can have 
negative effects on the heart by increasing the contractility of the RV.  Increased 
contractility causes an increase oxygen demand and can reduce RV dilation[48].  In 
addition to vasodilator therapy, based on empirical evidence most patients also receive 
anti-coagulants, such as warfarin, to prevent thrombosis in situ and diuretics to prevent 
edema[47].  
 
1.1.4 Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis 
 
While pulmonary veno-occlusive disease (PVOD) and pulmonary capillary 
hemangiomatosis (PCH) are very rare, PVOD is increasingly recognized as causes of 
PAH[49]. PVOD is described as any disease that causes the veins of the lung to become 
blocked or narrowed.  PCH is characterized by thin-walled microvessels infiltrating the 
perivascular interstitium, the lung parenchyma, and the pleura[50].  Pathological studies 
indicate that PVOD and PCH are quite similar in terms of development of pulmonary 
arterial intimal fibrosis and medial hypertrophy, as well as changes in pulmonary 
parenchyma[5].  PVOD and PCH are often included in PAH classifications because they 
show similar histological findings in the small pulmonary arteries[5]; clinical 
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presentation of PVOD, PCH, and PAH are often undistinguishable[21]; and all three 
diseases share similar risk factors, including scleroderma[51] and HIV infection[52, 53].  
Additionally, mutations in the BMPR2 gene have also been seen in patients with 
PVOD[54, 55]. 
 
1.1.5 Pulmonary hypertension due to left heart disease 
 
Left-heart disease may represent the most frequent cause of PH[56].   Ventricular or 
valvular diseases of the left side of the heart may cause an increase in left atrial pressure 
leading to an increased pulmonary artery pressure because of passive backwards 
transmission of the pressure[56].  In this situation, the pulmonary vascular resistance is 
normal or near normal, unlike in PAH.  In approximately 19% to 35% of patients with 
left heart disease, the increase in pulmonary artery pressure is out of proportion from 
what is expected by the increase in left arterial pressure, and there is an increase in 
pulmonary vascular resistance[56, 57].  Currently, no studies of patients with PH due to 
left heart disease using medications approved for PAH have been conducted; as  such, the 
efficacy and safety of PAH medications in this population remains unknown[5]. 
 
1.1.6 Pulmonary hypertension due to lung diseases and/or hypoxemia 
 
Alveolar hypoxia as a result of lung disease, impaired control of breathing, or residence 
at high altitude is the predominant cause of PH in this category, although the prevalence 
of PH in these conditions is unknown[5].  PH is generally modest with mean pulmonary 
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artery pressures from 25 – 35mmHg[58], however some patients can have much larger 
mean pulmonary artery pressures (35 – 50mmHg)[59].  Diseases including brochiectasis, 
in which recurrent infection and inflammation of the airways destroy and widen the large 
airways of the lung; cystic fibrosis, an autosomal recessive disorder that results in 
accumulation of mucus in the lungs[60]; and a newly identified syndrome characterized 
by emphysema in the upper portions of the lung and fibrosis in the lower portions of the 
lung have been shown to cause PH[61].  In those patients with the combined syndrome of 
fibrosis and emphysema, the prevalence of PAH is approximately 50%[61].  As with the 
left-heart related PH, PAH drugs have not been tested in this patient population[5]. 
 
1.1.7 Chronic thromboembolic pulmonary hypertension 
 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a frequent cause of PH 
with up to 4% of patients developing PH after an epsidoe of acute pulmonary 
embolism[62, 63].  Prognosis of CTEPH reflects the degree of associated right 
ventricular dysfunction and has predictable mortality related to the severity of the 
underlying PH[64].  Currently, the only cure is pulmonary thromboendarterectomy, 
removal of the blood clot (thrombus) from the occluded artery[65].  Those patients who 
are not surgical candidates may benefit from administration of PAH-specific 
medication[65, 66], but more studies are required. 
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 1.1.8 Pulmonary hypertension with unclear and/or multifactorial mechanisms  
 
The final PH group is composed of several subgroups of PH for which the cause is 
unclear or multifactorial. 
 
1.1.8.1 Subgroup 1 
 
Several hematological disorders including polycythemia vera, an abnormal increase in 
the number of red blood cells; essential thrombocytothemia, an over-production of 
platelets; and chronic myeloid leukemia can cause PH[67].  Chronic myeloproliferative 
disorders can cause PH by various mechansms, such as high cardiac output; auto or 
surgical asplenia, absence of normal spleen function; direct obstruction of pulmonary 
arteries by circulating megakaryocytes[68]; chronic thromboembolic pulmonary 
hypertension[69]; portopulmonary hypertension; and congestive heart failure[5].  
Splenectomy, either as the result of trauma or as a treatment for hematological disorders, 
can increase the risk of developing PH[70].  Portopulmonary hypertension is a 
complication of liver disease present in 0.25% to 4% of patients suffering from cirrhosis 
and in 4% - 6% of those referred for liver transplant[71]. 
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 1.1.8.2 Subgroup 2 
 
This subgroup includes systemic disorders that are associated with an increased risk of 
developing PH.  Sarcoidosis is a disease of unknown origin in which abnormal 
collections of granulomas form as nodules in multiple organs[72].  PH is increasingly 
recognized as a complication of sarcoidosis[73] with a reported prevalence of 1% - 
28%[74].  Severe PH is common in patients with end-stage pulmonary Langerhans cell 
histocytosis, an abnormal increase in the number of histiocytes[75].  
Lymphangioleiomyomatosis is a rare, multisystem disorder predicominantly affecting 
women that is characterized by lung destruction, lymphatic abnormalities, and abdominal 
tumors[76].  PH is an uncommon complication in patients with this disease[77, 78].  
Neurofibromatosis type 1, also known as von Recklinghausen’s disease, is an autosomal 
dominant disorder characterized by cutaneous fibromas and “café au lait” skin lesions 
and occasionally complicated by systemic vasculopathy.  The neurofibromatosis type 1 
gene modulates protein kinase B, which in turn regulates cell proliferation.  Several cases 
of PH have been reported in patients with von Recklinghausen’s disease[79-82]. 
 
1.1.8.3 Subgroup 3 
 
Subgroup 3 is composed of PH associated with metabolic disorders.  PH has been 
reported in a few cases of type Ia glycogen storage disease, a rare autosomal recessive 
disorder caused by a deficiency of glucose-6-phosphate[83-85].  Gaucher disease is a rare 
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disorder characterized by a deficiency of lysosomal β glucosidase resulting in an 
accumulation of glucocerebroside in reticuloendothelial cells.  In a study of 134 patients 
with Gaucher disease, PH was not common[86].  In addition, an association between 
thyroid disease, both hypothyroidism and hyperthyroidism, and PH has been reported in 
several studies[87, 88].  One study reported that more than 40% of patients with thyroid 
disease also had PH[89].  Another study of PAH patients showed that 49% had 
autoimmune thyroid disease suggesting a common immunogenetic susceptibility[90]. 
 
1.1.8.4 Subgroup 4 
 
Finally, subgroup 4 contains miscellaneous conditions associated with PH.  Tumor 
obstruction may cause PH if a tumor grows into the central pulmonary arteries.  
However, these cases are rare and occur principally due to pulmonary artery sarcomas 
and are usually rapidly fatal[91, 92].  Occlusion of the microvasculature by metastatic 
tumor emboli (mostly caused by gastric cancers) may be another cause of rapidly 
progressive PH[93].  Patients with mediastinal fibrosis, a late-stage complication of 
histoplasmosis characterized by invasive calcified fibrosis on lymph nodes that block 
major vessels and airways[94], may present with severe PH because of compression of 
both pulmonary arteries and veins[94, 95].  PH has been reported in patients with end-
stage renal disease (ESRD) maintained on long-term hemodialysis and may occur in up 
to 40% of patients in this population[96]. 
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1.2 Heart development and physiology 
 
1.2.1 Heart development 
 
The heart is the first organ to form and function in the embryo.  The vertebrate heart 
forms first from a population of myocardial precursor cells in the primitive streak termed 
the primary heart field, or first heart field[97, 98] (Figure 2). These cells migrate 
bilaterally into the anterior mesoderm and adopt a crescent shape;[99-101];  this structure 
is termed the cardiac crescent and is present at embryonic day (E) 7.5 in the mouse, 
which corresponds to week 2 of human gestation[102]. The cardiac crescent fuses at the 
midline to form the linear heart tube consisting of an inner endocardial layer and an outer  
myocardial layer[103] and is normally present at E8.0 in the mouse and gestational week 
3 in humans[102]. Rightward looping and differential growth along the outer curvatures 
of the heart tube ultimately generate the multichambered heart[101].  An additional 
source of cardiac precursors, the secondary heart field, are derived from the pharyngeal 
mesoderm located medially to the cardiac crescent and are progressively added to the 
developing heart to form the outflow tract, right ventricle, and atria[99, 100]. 
 
Committed progenitor ISL1+ cells are clustered in the right ventricular outflow tract and 
right and left atrium, all of which are derived from the secondary heart field.  These cells 
give rise to the endothelial cells, cardiomyocytes, and smooth muscle cells[104-106].  
Endothelial cells form the cardiac valves and the endocardium.  Cardiomyocytes form the  
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Figure 2: Heart Development in the Mouse 
 
a) Progenitor cells originate in the primitive streak (PS) and migrate to the anterior of the 
embryo. b) The progenitor cells migrate to under the head folds (HF) and form the 
cardiac crescent (CC). c) The heart tube forms through fusion of the cardiac crescent at 
the midline. d) Rightward looping begins the process of ventricle formation. e) By E10.5, 
the heart has well-defined ventricles.  f) In the fetal heart, ventricles are separated and 
connected to the aorta (AO) and the pulmonary trunk (PT) so that normal circulation can 
occur.  
 
Anterior (A)-posterior (P) and right (R)-left (L) axes are shown.  AA, aortic arch; AO, 
aorta; AVC, atrioventricular canal; CC, cardiac crescent; HF, head folds; IFT, inflow 
tract; IVC, inferior vena cava; LA, left atria; LV, left ventricle; OFT, outflow tract; PLA, 
primitive left atria; PRA, primitive right atria; PS, primitive streak; PT, pulmonary trunk; 
PV pulmonary vein; RA, right atria; RV, right ventricle; SVC, superior vena cava; Tr, 
trabeculae. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews  Genetics, M. 
Buckingham, S. Meilhac, and S. Zaffran, “Building the  Mammalian Heart from Two 
Sources of Myocardial Cells,” vol. 6: 826-835, copyright 2005. 
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ventricular and atrial myocytes as well as cells of the conduction system.  Smooth muscle 
cells form arteries and veins.[101] 
 
The transcription factors T-box 5 (Tbx5) and hand and neural crest derivatives expressed 
1 (Hand1) mark the primary heart field, whereas hand and neural crest derivatives 
expressed 2 (Hand2), ISL LIM homeobox 1 (Isl1), and fibroblast growth factor (Fgf10) 
are expressed in the secondary heart field[107, 108].  Natural killer 2 transcription factor 
related, locus 5 (Nkx2-5) is expressed in both heart fields[101].  Myocardial transcription 
factors are first detected in the cardiac crescent where myocardial differentiation is 
initiated; activation of key myocardial regulatory genes, such as Nkx2-5 and GATA 
binding protein 4 (Gata4), depends on positive signaling by bone morphogenetic proteins 
(BMPs) and fibroblast growth factors while wingless-type MMTV integration site family 
members (Wnts) exert a repressive effect[109].   
 
Mutations of Gata4 lead to cardiac bifida where the two halves of the cardiac crescent 
fail to converge at the midline[110-112].  In an Nkx2-5 knockout, there is loss of 
ventricular tissue and the absence of Hand1 expression at the cardiac crescent stage and 
later in the cardiac tube[113-115].  Hand1 mutants have a proliferation defect in the left 
ventricle (LV) and die from extra-embryonic defects[116-118].  Similarly, Tbx5 mutants 
show severe defects in the left ventricle and atria-inflow regions of the heart, although 
Hand1 is still detectable and the outflow tract and RV continue to grow normally[119].  
In contrast, Hand2 mutants show right-ventricular hypoplasia[120, 121] and extensive 
cell death in the pharyngeal arches where Hand2 is normally expressed[122]. 
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 Although fibroblast growth factors are necessary for proliferation of cells in the 
secondary heart field[123], Fgf10 mutant mice have no apparent early cardiac phenotype 
and the outflow tract seems to be normal[124, 125].  On the other hand, fibroblast growth 
factor 8 (Fgf8) knockout mice die at gastrulation, but an Fgf8 hypomorph dies later of 
cardiac failure that is due to malformation of the outflow region[126, 127].  T-box 
transcription factor 1 (Tbx1) mutant mice show a similar cardiac phenotype to the Fgf8 
hypomorph mice, although the neural crest defect in Tbx1 mutants is more severe[128-
131].  Targeted deletion of Tbx1 in the secondary heart field causes a proliferation 
defect[132].   
 
Isl1 may have several roles in the secondary heart field.  In its absence, migration of cells 
into the cardiac tube is not observed, proliferation is affected, and cells undergo 
apoptosis[107].  In a mutant embryo, the heart tube seems to have only two chambers and 
the outflow tract is absent.  Genetic markers show the presence of an atrial and 
ventricular myocardium and labeling with Hand1 and Tbx5 probes show the left 
ventricular identity of the anterior compartment.  Right ventricular markers are not 
expressed[100].  Myocyte enhancer factor 2C (Mef2c) Is regulated by Isl1 and 
Gata4[133].  Early expression of Mef2c is medial to the cardiac crescent and continues 
into the secondary heart field[133].  Mutants have a reduced outflow tract and the right 
ventricle does not develop[134]. 
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1.2.2 The fetal heart 
 
By the third week of gestation, blood begins forming and the primitive heart tube begins 
beating; active circulation begins by the end of the fourth week of gestation.  The right 
ventricle (RV) and pulmonary circulation begin to separate from the left ventricle (LV) 
and systemic circulation due to formation of the interventricular septum and formation of 
valves after the fifth week of gestation.  At birth, full septation is normally complete[135-
137].  In the fetus and embryo, the RV is the dominant chamber of the heart, accounting 
for approximately 60% of the total cardiac output; however, only about 15%-25% of the 
total cardiac output enters the lungs because the embryo receives oxygen from the 
placenta.  The remainder is shunted to either the systemic circulation via the foramen 
ovale and the LV or the pulmonary artery and aorta via the ductus arteriosis[138, 139].  
At birth, the increasing left atrial pressure closes off the formen ovale[140].  Soon after, 
the ductus arteriosis closes[139], the LV hypertrophies, and the RV involutes becoming 
thin walled[47].   
 
The fetal heart has different characteristics than the adult heart.  Unlike in the adult heart, 
the RV is as thick as the LV in the fetal heart[141].  A disproportionately smaller LV than 
RV, which is diagnosed by echocardiography, may be an indication of obstructive left-
sided heart disease[142]. The fetal/neonatal RV ejects blood at a higher pressure than 
systemic circulation.  A few days after birth, these pressures fall[143] and, by three 
weeks of age, the pulmonary artery pressure is usually lower than the systemic 
pressure[144].  Doppler echocardiography has shown that the RV output in human babies 
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is slightly larger than that of the LV at a gestational age of 38 weeks (60 ml/min 
compared to 40 ml/min)[145].  The two ventricles pump in parallel to the systemic 
circulation and the difference in pressure between the two ventricles is minimal[139]. 
 
1.2.3 The adult heart 
 
In adult humans, the right ventricle is the most anterior portion of the heart and is located 
directly behind the sternum[146].  The RV appears triangular when viewed from the side 
or has a crescent shape when viewed in a cross section; the entirety of the RV muscle lies 
between the tricuspid and pulmonary valves.  In contrast, the LV has an ellipsoid 
shape[141, 146].  The interventricular septum is concave towards the LV in the normal 
RV[141].  The free wall of the RV is normally 1-3mm thick compared to the 10mm thick 
LV free wall and accounts for approximately one-sixth of the total mass of the human 
heart – on average 26g/m2 compared to 87g/m2 of the LV[144, 146].  Table 3 
summarizes the characteristics of the normal RV and LV. 
 
Anatomically, the RV can be divided into three regions: the inflow tract, an apical region, 
and the outflow tract, which ends at the pulmonic valves.  The main pulmonary artery 
originates from the outflow tract[147] (Figure 3).  The pulmonary artery is a thin, elastic 
vessel that branches to supply the various pulmonary arteries, pulmonary arterioles, and 
alveolar capillaries.  Once blood travels through the alveolar capillaries and exchanges 
CO2 for O2, blood returns to the lungs through a system of pulmonary veins and branches 
to the left atrium.  From the left atrium, it goes to the left ventricle and is then pumped to  
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Table 3: Summary of normal adult RV and LV structure and function 
 
Characteristics RV LV 
shape [141, 146] triangular (side), 
crescent (cross-section)
ellipsoid 
mass index (g/m2) [146] 26 87 
free-wall thickness (mm) [144] 1-3 10 
ventricular pressure (mmHg) [148] 25/4 130/8 
PVR vs. SVR (dynes/s/cm5) [149] 123 2130 
contraction [144, 150] sequential concentric and twisting
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Figure 3: Pulmonary and systemic circulation 
 
The human circulatory system includes the heart, lungs, and blood vessels.  Blood leaves 
the right ventricle and travels through the pulmonary arteries to the lungs where CO2 is 
exchanged from O2.  Blood returns to the left atrium of the heart after passing through the 
pulmonary veins.  After the left atrium, blood pools in the left ventricle where it is 
pumped through the aorta to the systemic circulation and capillary beds where O2 is given 
to the tissues and CO2 removed from the tissues.  It then travels through the veins and 
venae cavae to the right atrium after which it returns to the right ventricle. 
 
Reprinted with permission from University of Amsterdam publications 
at http://www.biomedicalphysics.org. 
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the systemic circulation[149, 151, 152].  Almost the entire cardiac output is pumped by 
the thin-walled RV through the lung circulation while the oxygenated blood is collected 
by the four pulmonary veins and emptied into the LV[141].  The RV contracts in a 
sequential manner, starting with the inflow tract and moving towards the outflow tract in 
a wave-like manner.  In contrast, the LV has a concentric contraction along with a 
twisting motion[144, 153].   
 
Normally, the pulmonary circulation is a low-resistance, high-capacitance system 
allowing an increase of RV stroke volume by 3-4 fold without significantly increasing 
pulmonary pressure[154].  The alveolar membranes of the lung are thin and highly 
permeable.  As such, the pulmonary pressures must remain low to prevent pulmonary 
edema[155].  In humans, a normal mean pulmonary artery pressure is 14 mmHg with an 
upper limit of normal of 20.6 mmHg.  With exercise, the mean pulmonary artery pressure 
can have an upper limit of normal as high as 35 mmHg[154].  The average pressure of the 
RV is 25mmHg/4mmHg (systolic/diastolic) and the LV  is 130mmHg/8mmHg[148].  The 
function of the RV is often determined by measuring the so-called afterload, the 
pulmonary vascular resistance (PVR).  Pulmonary vascular resistance is defined by the 
ratio of the mean pressure drop from the main pulmonary artery to the left atrium divided 
by the cardiac output and is given in units of dynes/s/cm5.  It can also be measured in 
Wood units, which are defined as the mean pulmonary artery pressure minus the mean 
pulmonary capillary occlusive pressure (both in mmHg) divided by cardiac output 
(L/min).  One Wood unit is equivalent to 80 dynes/s/cm5[150].  In a normal human heart, 
pulmonary vascular resistance is approximately 1/20 that of the systemic vascular 
47 
resistance – 123 dynes/s/cm5 in the RV compared to 2130 dynes/s/cm5 in the systemic 
circulation[147]. 
 
1.3 The heart during progression of pulmonary arterial hypertension  
 
Pulmonary arterial hypertension develops as a consequence of lung vascular lesions that 
cause an increase in pulmonary vascular resistance against which the right ventricle must 
pump (Figure 4).  This increase in afterload is the first trigger for RV adaptation in 
PAH[48]. Based on the LaPlace relationship, an increase in intraluminal pressure will 
result in an increase in wall stress unless the thickness of the chamber wall is increased or 
the internal radius of the chamber is decreased.  Because an increase in wall stress would 
increase myocardial oxygen demand and impede myocardial perfusion, the RV adapts to 
the increasing afterload pressure through increased wall thickness, both by hypertrophy 
(increased muscle mass) and assuming a more rounded shape[48] (Table 4).  
Hypertrophy is largely the result of protein synthesis induced by stretch, which is sensed 
by integrins and stretch-activated ion channels in myocytes, fibroblasts, and endothelial 
cells of the heart[156].  Integrins are attached to the extracellular matrix (ECM) and the 
cytoskeleton allowing them to transduce mechanical stress to intracellular chemical 
signals that increase synthesis of contractile proteins and proteins for autocrine and 
paracrine signaling[157, 158].  Growth and proliferation of cardiomyocytes is paralleled 
by ECM synthesis and supporting capillary growth.  Angiogenesis, growth of new vessels 
from existing vessels, is part of this process and can be induced by angiopoietin-1 (Ang1) 
and vascular endothelial growth factor (VEGF) signaling[48]. 
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Figure 4: Changes in the Heart in PAH 
 
Schematic representation of the heart and lungs in a normal (left) and pulmonary 
hypertension (right) patient.  Pulmonary arteries constrict in pulmonary hypertension due 
to the formation of plexiform lesions causing an increase in pressure against which the 
right ventricle must pump.  Over time, this causes the right ventricle to hypertrophy. 
 
Reprinted with permission from Nationwide Children’s Hospital 
at http://www.nationwidechildrens.org. 
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Table 4: Summary of Changes in the RV and Circulation Associated with PAH 
 
Characteristics Normal PAH 
RV shape  triangular (side), 
crescent (cross-section) 
thickened and enlarged 
septum position concave towards right 
ventricle 
paradoxical shift 
towards left ventricle 
energy utilization [47, 159] varies from fatty acid to 
glycolysis as needed 
reliant on glucose 
metabolism 
RV mass index (g/m2)  
[146, 160] 
26 68 
RV free wall thickness (mm) 
[144, 160] 
1 – 3 5 – 7 
RV systolic pressure (mmHg) 
[148, 160] 
25 85 
mean pulmonary artery 
pressure, resting (mmHg)  
[1, 160] 
8 – 20 50 
PVR (dynes/s/cm5)  [149, 160] 123 240 
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 1.3.1 Adaptive vs. maladaptive hypertrophy 
 
Hypertrophy can be divided into two categories: adaptive, or pathological, and 
maladaptive, or physiological.  Examples of adaptive hypertrophy included athletes’ 
hearts and exercise-induced reversible cardiac enlargement[141].  Hypertrophy is induced 
in athletes’ hearts through aerobic interval training over long periods of time, which 
causes increased cardiac dimensions and mass as an adaptation to the increase in physical 
stress; they also show improved myocardial contractility[161-166].  This adaptation 
allows greater transport of blood and oxygen to the skeletal muscles in order to improve 
work capacity.[167]  Exercise increases secretion of insulin-like growth factor 1 (IGF-1) 
and growth hormones both systemically and locally in the heart[168-173].  
Overexpression of the IGF-1 receptor or an activated form of Akt leads to myocardial 
hypertrophy with enhanced cardiac function[170, 174].  While exercise training programs 
induce an improved work capacity and adaptive hypertrophy, pressure overload induces 
reduced contractile function and maladptive hypertrophy[175].  In maladptive 
hypertrophy, there can be a doubling of the heart weight, re-expression of fetal genes, and 
deactivation of the Akt/mTOR signaling cascade[175].  In contrast, adaptive hypertrophy 
does not reactivate the fetal gene program[176, 177].  Fetal gene re-expression is due to 
activation of the transcription factors nuclear factor of activated T-cells (Nfat) by 
calcineurin and myocyte enhancer factor 2 (Mef2) by calcium/calmodulin-dependent 
protein kinase (CaMK) or mitogen activated kinase-like protein (MAPK) [176] and 
increased protein degradation by the ubiquitin-proteosome system[178].  Molecular 
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markers have been found that distinguish between adaptive and maladaptive hypertrophy 
in the LV.  Gata4, cyclic-AMP response element binding protein (Creb), and signal 
transducer and activator of transcription 3 (Stat3) are markers of adaptive hypertrophy 
while phosphate and tensin homolog (Pten), nuclear factor of activated T-cells 3 (Nfat3), 
and Mef2 are markers of maladaptive hypertrophy[179]. 
 
While it is generally believed that sustained pressure overload is enough to induce 
maladptive hypertrophy and cardiace failure[48], recent studies[180] have shown that 
increased RV pressure overload alone is not sufficient to cause heart failure.  Rats with 
only pressure overload did not have heart failure or an increase in long-term mortality 
rates.  However, rats with increased RV pressure and angioproliferative pulmonary 
remodeling, as seen in human PAH, do have heart failure and increased rates of 
mortality[180].  Those rats with RV failure also have an increase in RV fibrosis, 
decreased capillary density, and oxidative stress[180]. 
 
1.3.2 Transition from hypertrophy to failure 
 
The mechanisms that underlie the transition from hypertrophy to failure in the RV 
associated with PAH have not been well characterized.  Similarly, it is not well 
understood why some patients with severe PAH rapidly progress to RV failure and others 
do not[141].  One hallmark of heart failure is the switch from alpha myosin heavy chain 
(MHC-α) to beta myosin heavy chain (MHC-β) in cardiomyocytes[48].  Normally, in the 
human RV approximately 25 – 34% of the MHC is in the form of MHC-α and the 
53 
remainder is MHC-β.  In PAH-associated RV failure, there is approximately 5% MHC-α 
and 95% MHC-β.[181]  MHC-β has lower ATP activity than MHC-α and the reduction 
in MHC-α causes a decrease in systolic function[182].  Additionally, neurohormonal 
overdrive, oxidative stress, inflammation, ischemia, and cell death may all contribute to 
the development of RV dilation and failure[48].  
 
1.3.2.1 Neurohormonal signaling 
 
Heart failure is associated with an activation of the renin-angiotensin system.  
Angiotensin II (ATII) is the most important factor involved in cardiac remodeling.  
Adrenergic overstimulation causes increased expression of several peptides including the 
natriuretic peptides atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP)[48].  While ATII, ANP, BNP, and aldosterone reach the heart via systemic 
circulation, they can also be produced locally by myocytes, endothelial cells, and 
fibroblasts in the heart to affect cardiomyocyte growth, proliferation, and survival[48]. 
 
1.3.2.2 Ischemia 
 
Myocardial ischemia occurs when blood flow to the heart muscle is decreased by 
obstruction of the arteries carrying blood to the heart muscle itself causing a decrease in 
the oxygen supply of the heart[183].  Exercise-related chest pain, often a symptom of 
myocardial ischemia, occurs frequently in patients with pulmonary hypertension despite 
normal coronary angiograms[184].  Systolic right coronary artery flow is reduced in 
54 
pulmonary hypertension[185] and can lead to RV ischemia[186] because of a mismatch 
between the number of capillaries and the size of the cardiomyocytes during development 
of cardiac hypertrophy and impairment of right coronary artery flow as a consequence of 
RV wall stress[187].  It has been suggested that the RV coronary circulation becomes 
more like that in the LV during PAH: greater oxygen extraction at rest and greater 
dependence on oxygen and an increase in coronary blood flow to meet the myocardial 
oxygen demand[188].    
 
1.3.2.3 Oxidative and nitrosative stress 
 
Excess reactive oxygen species (ROS) and reactive nitrogen species (RNS) induce 
contractile dysfunction through suppression of enzymes involved in excitation-
contraction coupling.  ROS and RNS also favor cardiac remodeling through induction of 
cell damage, apoptosis, and inflammation[48].  ATII, endothelin1, and other 
neurohormones can stimulate the formation of ROS to induce hypertrophic pathways 
within the cardiomyocyte[189].  Activation of ATII leads to ROS formation by 
upregulation of NAD(P)H oxidases[189].  Neutrophils are recruited to the pressure-
overloaded myocardium and may be a source of ROS because they have significant 
quantities of NAD(P)H oxidases[48].  Other sources of ROS production in heart failure 
are xanthine oxidase, cytochrome P450, and auto-oxidation of catecholamines[189-191].  
RNS in the heart can be hemoglobin dependent and constitutively expressed endothelial 
nitric oxide (NO) synthase (eNOS).  Desaturation of hemoglobin and uncoupling of 
eNOS can also contribute to ROS generation[192, 193].  Decreased expression of eNOs, 
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inhibition of eNOS activity, and inhibition of NO by superoxide anions can lead to 
reduced NO signaling[194].  NO signals through the guanylate cyclase/cyclic guanosine 
monophosphate (cGMP) pathway and acts as a vasodilator and growth inhibitor; 
decreased NO activity can cause endothelial cell dysfunction[194]. 
 
1.3.2.4 Energy utilization 
 
Otto Warburg proposed that a shift from oxidative phosphorylation to glycolysis and 
glucose metabolism was a hallmark of malignant cell transformation.  It has been 
observed that, in PAH, the Warburg effect occurs in lung vascular cells[195, 196].  Both 
cancer and lung vascular cells manifest excessive cell proliferation and impaired 
apoptosis.  While in PAH the lesion cells do not metastasize or disrupt vessel boundaries, 
lung vascular cells in PAH share a mitochondrial-metabolic abnormality with 
cancer[197].  Positron emission tomography (PET) studies have shown that there is an 
increase in glucose uptake in lung tissue of patients and animals with right ventricular 
hypertrophy[160].  Other studies have shown that there is an increased rate of glycolysis 
in right ventricular hypertrophy and that the switch from glucose oxidation to glycolysis 
is associated with impaired RV function in the form of reduced RV contractility and 
overall cardiac function[198].  This increase in glycolysis is in part due to increased 
expression in HIF-1α, which is known to be increased in animal models of PAH[180].  
HIF-1α activation causes an increase in transcription of glucose transporter 1 (Glut1), 
hexokinase, and lactate dehydrogenase kinase favoring glycolysis and inhibiting glucose 
oxidation by activating transcription of pyruvate dehydrogenase kinase genes[199].  
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Additionally, animal studies of PAH have shown that mitochrondrial function is 
abnormal due to hyperpolarization of mitochondrial memranes in RV myocytes[200]. 
 
1.3.2.5 Apoptosis of cardiac cells 
 
In the normal heart, apoptosis of cardiomyocytes is extremely rare: approximately one 
apoptotic cardiomyocyte per 104 – 105 cells[201].  In human heart failure, the apoptosis 
rate can increase to up to 1 in 400 cells[202, 203].  Apoptosis rates have been shown to 
be elevated to 14% in models of ischemia/reperfusion and lower than 1% in models of 
chronic pressure overload[204].  Even very low rates of apoptosis (approximately 1/5 that 
of human heart failure rates) have been shown to cause lethal dilated cardiomyopathy in 
mouse models[205].  Pressure load can induce apoptosis via activation of ATII, ROS, β-
adrenoreceptor agonists, and proinflammatory cytokines[206].  Ischemia is another 
strong activator of apoptosis in the heart[207].  Broad-spectrum caspase inhibitors have 
been used to block apoptosis after ischemia/reperfusion resulting in reduced infarct size 
and improved cardiac function[208, 209]. 
 
1.3.2.6 Inflammation and immune activation 
 
Patients with chronic heart failure have increased serum levels and myocyte expression of 
proinflmaatory cytokines: tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), and 
interleukin 6 (IL-6). Elevated levels correlate with disease severity reflected in clinical 
and hemodynamic parameters[210].  In left-heart failure studies, TNF- α can depress 
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myocardial contractility[211] and induce apoptosis of endothelial cells[212] and 
cardiomyocytes[213].  TNF- α is upregulated after trans-aortic contstriction, an 
experimental model of left-ventricular failure in rodents, and mediates cardiomyocte 
apoptosis, fibrotic remodeling through inflammatory cell influx, matrix metalloprotease 
(MMP) upregulation, and activation of IL-6, monocyte chemotactic protein 1, and 
macrophage inflammatory protein gamma[214].  IL-1 and IL-33 have been shown to be 
changed during the development of heart failure.  IL-1 has a negative inotropic effect on 
cardiomyocyctes[215] and enhances fetal gene expression[216].  IL-33 is produced by 
cardiac fibroblasts in response to mechanical strain[217]. 
 
In summary, pulmonary arterial hypertension consists of a group of diseases affecting 
lung circulation with a fatal outcome due to right heart failure.  As pulmonary 
hypertension progresses, there is a shift from adaptive to maladaptive hypertrophy, which 
can be characterized by pathways involving energy metabolism, inflammation, and 
apoptosis resulting in ischemia such that the right heart can no longer compensate for the 
increased strain. While there are some insights into the molecular pathways affected as 
the disease progresses, there has not been a systematic study of the gene expression 
changes of pulmonary hypertension or adaptive hypertrophy.  A better understanding of 
the molecular mechanisms of RVF will likely lead to the development of therapeutic 
strategies to prevent RVF.  Because RVF is entirely reversible after single-lung 
transplantation, other strategies need to be found that will reverse RVF even when the 
pulmonary artery pressure cannot be lowered by our present treatments. 
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Chapter 2: Materials and Methods 
 
 
2.1 Rat models 
 
2.1.1 Su5416 
 
Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g 
were injected subcutaneously with SU5416 suspended in 0.5% (w/v) 
carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 80, 
and 0.9% (v/v) benzyl alcohol in deionized water.  Rats were given a single injection of 
SU5416 (20 mg/kg) at the beginning of the 4-week experiment.  The animals were kept at 
the altitude of Richmond, VA (sea level) for another four weeks. 
 
2.1.2 Chronic hypoxia 
 
Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g 
were exposed to chronic hypoxia (simulated altitude of 5,000 m in a nitrogen dilution 
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chamber) for four weeks; thereafter the animals were kept at the altitude of Richmond, 
VA (sea level) for another two weeks. 
 
2.1.3 Su5416/hypoxia 
 
Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g 
were injected subcutaneously with SU5416 suspended in 0.5% (w/v) 
carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 80, 
and 0.9% (v/v) benzyl alcohol in deionized water.  Rats were given a single injection of 
SU5416 (20 mg/kg) at the beginning of the 6-week experiment.  The animals were then 
exposed to chronic hypoxia (simulated altitude of 5,000 m in a nitrogen dilution 
chamber) for four weeks; thereafter the animals were kept at the altitude of Richmond, 
VA (sea level) for another two weeks. 
 
2.1.4 Carvedilol only 
 
Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g 
were given carvedilol (15 mg/kg; Sigma-Aldrich, St. Louis, MO) dissolved in 20% 
dimethyl sulfoxide and water and administered once daily per oral gavage for 4 weeks. 
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 2.1.5 Su5416/hypoxia and carvedilol 
 
Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g 
were injected subcutaneously with SU5416 suspended in 0.5% (w/v) 
carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 80, 
and 0.9% (v/v) benzyl alcohol in deionized water.  Rats were given a single injection of 
SU5416 (20 mg/kg) at the beginning of the 6-week experiment.  The animals were then 
exposed to chronic hypoxia (simulated altitude of 5,000 m in a nitrogen dilution 
chamber) for four weeks.  Carvedilol (15 mg/kg; Sigma-Aldrich, St. Louis, MO) was 
dissolved in 20% dimethyl sulfoxide and water and administered once daily per oral 
gavage for 4 weeks, beginning after return to room air breathing. 
 
2.2 Isolation of total RNA with mortar and pestle 
 
Total RNA was isolated from approximately 30 mg of snap-frozen rat heart tissue using 
the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA).  Briefly, hearts were homogenized 
using a mortar and pestle under liquid nitrogen then mixed with Buffer RLT and β-
mercaptoethanol in a tissue homogenizer.  Samples were then transferred to an Eppendorf 
tube and spun at full speed for three minutes.  Supernatant was transferred to a new 2 ml 
tube and mixed with an equal volume of 100% ethanol, then placed in an RNeasy spin 
column.  Samples were washed once with buffer RWI and twice with buffer RPE before 
being eluted in 40 μL RNase-free water.  RNA concentration was determined using a 
61 
NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE) spectrophotometer.  
All samples had an A260/A280 ratio between 1.9 and 2.1 
  
2.3 Isolation of total RNA with FastPrep® lysing matrix 
 
Total RNA was isolated from approximately 30 mg of snap-frozen rat heart tissue using 
the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA).  Briefly, hearts were homogenized 
with Buffer RLT and β-mercaptoethanol in an MP FastPrep®-24 Lysing Matrix D tube 
(MP Biomedicals LLC, Solon, OH).  Samples were then transferred to an Eppendorf tube 
and spun at full speed for three minutes.  Supernatant was transferred to a new 2 ml tube 
and mixed with an equal volume of 100% ethanol, then placed in an RNeasy spin 
column.  Samples were washed once with buffer RWI and twice with buffer RPE before 
being eluted in 40 μL RNase-free water.  RNA concentration was determined using a 
NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE).  All samples had an 
A260/A280 ratio between 1.9 and 2.1 
 
2.4 Microarray hybridization 
 
The amplification and hybridization process is as follows.  500 ng of total RNA was 
amplified and labeled with Cyanine-5 and 500 ng of universal rat reference RNA 
(Stratagene, Santa Clara, CA) was amplified and labeled with Cyanine-3 using the 
Agilent QuickAmp Labeling kit (Agilent Technologies Inc., Santa Clara, CA) to produce 
labeled cRNA following the manufacturer’s protocol.  After amplification and labeling, 
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the dye incorporation was determined using a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE).  All ratios were greater than 8.0 pmole dye 
per μg cRNA per the manufacturer’s recommendation.  825 ng of sample and 825 ng of 
reference RNA were combined and incubated with an Agilent whole rat genome 4x44k 
microarray slide (Agilent Technologies Inc., Wilmington, DE) for 17 hours at 65°C.  
Following hybridization, slides were washed following the manufacturer’s protocol and 
scanned using an Axon GenePix 4200A scanner (Axon Instruments, Union City, CA) at a 
resolution of 5 μM.  The raw data will be generated using GenePix Pro 5.0 software 
(Axon Instruments, Union City, CA) and submitted to the Ramhorn Array Database 
(http://ramhorn.csbc.vcu.edu).  Ramhorn is a VCU-specific implementation of the 
Longhorn Array Database[218] maintained in the laboratory of Dr. Paul Fawcett. 
 
2.5 Microarray data analysis 
 
Microarray data were retrieved from Ramhorn after filtering the data using a set of spot-
quality metrics designed to ensure the reliability of the data.  Features were included in 
the dataset if they have a signal greater than or equal to 1.5 fold above background in 
both the red and green channels.  Those features with less than 50% good data across the 
set of arrays were eliminated.  Technical replicates were averaged together using a best-
effort averaging procedure.   
 
Statistical analysis of biological replicates was performed using the Significance Analysis 
of Microarrays (SAM) algorithm[219] with a two-class paired (for normal RV vs. normal 
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LV) or unpaired design (normal RV vs. failing RV) to identify differentially expressed 
genes.  Briefly, the SAM algorithm for a two-class comparison is as follows.  First, the 
relative difference in expression between two sets of samples is calculated for each gene; 
this is the observed relative difference.  To calculate the expected relative difference, data 
labels are permuted and the relative difference is calculated for each gene.  The expected 
relative difference for a gene will be the average relative difference across all 
permutations.  The observed relative difference is plotted against the expected relative 
difference.  Genes that fall outside of a threshold value, Δ, will be called significant.  Δ-
values were chosen to give an acceptable false discovery rate (FDR) of less than 5% and 
a 2-fold filter was applied.   
 
The gene list was clustered using hierarchical clustering methods in Cluster 3.0[220] and 
visualized in Java TreeView[221].  Based on literature search results and pathway 
analysis results obtained using Ingenuity Pathway Analysis (IPA, Ingenuity Systems, 
Redwood City, CA) and the PANTHER classification system[222, 223], genes were 
selected for confirmation by quantitive RT-PCR. 
 
For prediction analyses, raw expression data files were uploaded into R[224] and 
normalized using the marray package[225] by the Lowess normalization algorithm, then 
exported to BRB Array Tools.  Lowess intensity dependent normalization was used to 
adjust for differences in labeling intensities of the Cy3 and Cy5 dyes.  The adjusting 
factor varied over intensity levels[226].  Genes that were differentially expressed between 
the three classes were identified using an F test, using an α-level of 0.0001 for univariate 
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testing, and performing 1,000 permutations for multivariate analysis.  The class 
prediction model was developed using Diagonal Linear Discriminant Analysis[227], 
Nearest Neighbor Classification[228], and Nearest Centroid Classification.  The models 
incorporated genes that were previously deemed significant.  We estimated the prediction 
error of each model using leave-one-out cross-validation (LOOCV) as descried by Simon 
et al.[229].  For each LOOCV training set, the entire model building process was 
repeated, including the gene selection process.  We also evaluated whether the cross-
validated error rate estimate for a model was significantly less than one would expect 
from random prediction.  The class labels were randomly permuted and the entire 
LOOCV process was repeated.  The significance level is the proportion of the random 
permutations that gave a cross-validated error rate no greater than the cross-validated 
error rate obtained with the real data. 2,000 random permutations were used. 
 
2.6 Quantitative real-time polymerase chain reaction 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) to 
convert total RNA (1 μg) to cDNA and the Power SYBR® Green PCR Master Mix 
(Applied Biosystems, Carlsbad, CA) along with rat-specific primers (Table 5) 
(Invitrogen, Carlsbad, CA).  A dissociation profile was generated after each run to verify 
specificy of amplification.  All PCR assays were performed in triplicate and no template 
controls were included.  18S rRNA was used as a housekeeping gene.  Automated gene 
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expression analysis was performed using the Comparative Quantitation model of MxPro 
QPCR Software (Stratagene, Santa Clara, CA). 
 
2.7 Protein isolation 
 
Protein was isolated from approximately 40 mg of snap-frozen rat heart tissue using 
RIPA (radio-immunoprecipitation assay) buffer (Sigma-Aldrich, St. Louis, MO) and 
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) in an MP FastPrep®-24 
Lysing Matrix D tube (MP Biomedicals LLC, Solon, OH).  Protein concentration was 
measured using a standard colorimetric protein assay based on the method by Bradford 
(Bio-Rad, Hercules, CA).   A standard curve was generated by measuring the OD595 of 
the protein reagent mixed with bovine serum albumin (BSA) at concentrations of 2.5 
μg/mL, 5 μg/mL, 10 μg/mL, and 20 μg/mL.   
 
2.8 Western blot 
 
Proteins were separated by SDS-PAGE on Novex precast 4-12% Bis-Tris gels using the 
NuPAGE® system (Invitrogen, Carlsbad, CA).  Proteins were transferred to a PVDF 
membrane  (Biorad, Hercules, CA) in NuPAGE® transfer buffer (Invitrogen, Carlsbad, 
CA) for 1 hour at 50 volts.  The membrane was blocked for 45 minutes in TBS-T (20 
mM Tris-HCl pH 7.6, 137 mM NaCl, 0.1% Tween-20) containing 5% nonfat dry milk 
(Carnation, Wilkes-Barre, PA).  TBS-T was used for all wash steps.  The membranes 
were incubated overnight at 4°C in TBS-T containing 5% BSA with appropriate rat 
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antibodies (Table 6).  The membrane was washed in TBS-T and incubated with a 1/2000 
dilution of goat anti-rabbit IgG HRP secondary antibody (Cayman Chemical, Ann Arbor, 
Michigan).  Proteins were detected using Western Lightning™ Plus-ECL 
chemiluminescent substrate (PerkinElmer Inc., Waltham, MA). The ChemiDoc™ XRS+ 
Imaging System and Quantity One software (Bio-Rad, Hercules, CA) were used to 
capture and analyze digital images of chemiluminescent signals. 
 
2.9 Multiplex assay 
 
Levels of 23 cytokines (G-CSF, eotaxin, GM-CSF, IL-1α, leptin, MIP-1α, IL-4, IL-1β, 
IL-2, IL-6, IL-13, IL-10, IL-12p70, IFN, IL-5, IL-17, IL-18, MCP-1, IP-10, GRO/KC, 
VEGF, TNFα, RANTES) were measured in rat serum samples using the Milliplex® rat 
cytokine/chemokine magnetic bead panel kit (Millipore, Billerica, MA) following the 
manufacturer’s protocol.   Briefly, a standard curve at dilutions of 1:1, 1:4, 1:16, 1:64, 
1:256, 1:1,024, and 1: 4,096 of each analyte were prepared.  Serum samples were diluted 
1:4 using serum matrix.  Standards, quality control samples, and experimental samples 
were incubated overnight 4°C with antibody-immobilized magnetic beads.  Beads were 
washed twice with wash buffer, and then incubated with detection antibodies and 
streptavidin-phycoerythrin.  Beads were washed twice again before being resuspended in 
sheath fluid.  The plate was run on a Luminex 100 analyzer (Luminex Corporation, 
Austin, TX) and results were analyzed using BioPlex Manager Software 4.0 (BioRad, 
Hercules, CA).  
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Table 5: qRT-PCR Primers 
Name Sequence 5’ to 3’ Product size 
Ang-1 forward AGAAACTTCAGCATCTGGAGC 115bp 
Ang-1 reverse CGCATTCTGTTGTATCTGGG  
ANP forward CAAGGGCTTCTTCCTCTTCC 124bp 
ANP reverse TCTCCTCCAGGTGGTCTAGC  
Apelin forward GAATCTGAGTTTCTGCGTGC 108bp 
Apelin reverse CCTTCTTCTAGCCCTTTCCC  
BNP forward CAATCCACGATGCAGAAGC 84bp 
BNP reverse GCCTTGGTCCTTTGAGAGC  
CAPS1 forward CAAATGGCAGACCAAATAGC 107bp 
CAPS1 reverse CATGAGTAGGTTGACGGAGG  
CTGF forward AAATGCTGTGAGGAGTGGG 80bp 
CTGF reverse TTCCAGTCGGTAGGCAGC  
IGF1 forward GCTCTTCAGTTCGTGTGTGG 106bp 
IGF1 reverse CAACACTCATCCACAATGCC  
Irx2 forward CCAAGAAAGATGCCAGTGA 73bp 
Irx2 reverse GCTTGGCCCTCCTATAGG  
Klf5 forward CCAAATATCCAACCTGTCCG 161bp 
Klf5 reverse GCACTTGTAGGGCTTCTCG  
Nr2f2 forward CTCAAGGCCATAGTCCTGT 61bp 
Nr2f2 reverse CCACGTGGGCTACATC  
Rcan1 forward ACGGTGATGTCTTCAGCG 119bp 
Rcan1 reverse TGAAGTTTATTCGGACACGC  
VEGF forward CTGCAATGATGAAGCCCTGGAG 94bp 
VEGF reverse CTATGTGCTGGCTTTGGTGAGG  
Hexokinase2 forward GAGGTCAACTCCGGATGG 151bp 
Hexokinase2 reverse GAGGTCAACTCCGGATGG  
18s rRNA forward AGACGGACCAGAGCGAAAGC 309bp 
18s rRNA forward TGTCAATCCTGTCCGTGTCC  
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Table 6: Antibodies 
 
Name Company Product Number Species  
α-actinin Cell Signaling 3134 rabbit 
AKT Santa Cruz sc-8312 rabbit 
Ang-1 Santa Cruz sc-8357 rabbit 
Apelin Santa Cruz sc-33469 goat 
IGF-1 Santa Cruz sc-9013 rabbit 
p-AKT Santa Cruz sc-7985 rabbit 
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Chapter 3: Comparison of the Gene Expression Pattern between the Normal RV 
and the Normal LV 
 
 
3.1 Introduction 
 
Although we have concepts and data to explain mechanisms of left ventricular failure, 
there is little comparable knowledge of mechanisms of right ventricular failure.  Right 
heart failure has not been systematically investigated on the cellular and molecular level 
most likely because of the widely held opinion that the conditions which govern right 
ventricular failure and left ventricular failure are identical, or at least very similar.  As 
such, most concepts of right ventricular failure have been shaped by the studies of the left 
ventricle.  However, there exist both embryological and physiological differences 
between both ventricles that support a hypothesis that the gene expression patters differ 
between right and left ventricular failure.  We first sought to identify gene expression 
differences in the normal right ventricle (RV) and normal left ventricle (LV).  While 
differences in expression are known for individual genes, there has not been a systematic 
study of the gene expression differences of the two ventricles.  This study served as the 
basis for the studies of right ventricular failure associated with severe pulmonary arterial 
hypertension (PAH) in the rat that followed.   
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 The vertebrate heart forms from two populations of cardiac progenitor cells:  the primary 
heart field, or first heart field, and the secondary heart field, or anterior heart field.  The 
primary heart field originates in the anterior splanchnic mesoderm and gives rise to the 
cardiac crescent, left ventricle, and atria[99-101].  The secondary heart field is derived 
from the pharyngeal mesoderm, located medial to the cardiac crescent, and gives rise to 
the outflow tract and large portions of the right ventricle and atria[99, 230].  Progenitor 
cells from the cardiac crescent migrate medially and form the linear heart tube, which 
consists of an inner endocardial layer and an outer myocardial layer.  Right-ward looping 
and differential growth along the outer curvatures of the heart tube ultimately generate 
the multi-chambered heart[101].  Cells from the adjoining secondary heart field are 
progressively added to the developing heart forming additional structures, such as the 
right ventricle and atria[99, 100] (Figure 5). 
 
During these embryological processes, transcription factors are regionally expressed in 
the developing heart.  While some can be found in both the primary and secondary heart 
fields, others show specific expression patterns in just one of the developing heart fields.  
T-box 5 (Tbx5)  and the basic helix-loop-helix transcription factor heart and neural crest 
derivatives expressed-1 (Hand1) are both expressed in the primary heart field, while heart 
and neural crest derivatives expressed-2 (Hand2), islet-1 (Isl1), fibroblast growth factor-8 
(Fgf8), fibroblast growth factor-10 (Fgf10), paired-like homeodomain-2 (Pitx2), and 
Tbx5 are expressed in the secondary heart field[107, 108].   
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Figure 5: Overview of Heart Development 
The heart forms from two different heart fields, the primary heart field (shown in blue) 
and the secondary heart field (shown in purple).  a) The cardiac crescent is composed of 
cells from the primary heart field with cells from the secondary heart field located 
medially.  b) Cells from the cardiac crescent migrate medially and form the linear heart 
tube.  c) Rightward looping of the heard tube ultimately generates the multi-chambered 
heart (d). 
 
Reprinted from Cell, vol. 127, D.J. Garry and E.N. Olson, “A common progenitor at the 
heart of development,” 1101-1104, Copyright 2006, with permission from 
Elsevier. 
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Natural killer cell-associated antigen 2 transcription factor related, locus 5 (Nkx2-5) is 
expressed in both heart fields[101].   
 
Knockout mouse studies of these transcription factors reveal their importance during 
development of the heart.  Loss of Nkx2-5 was associated with a loss of ventricular tissue 
and the absence of Hand1 expression, both at the cardiac-crescent stage and later in the 
cardiac tube where it would normally mark the left ventricle[113-115].  Tbx5 mutant 
mice show severe defects in the atria-inflow region of the heart and left-ventricular 
hypoplasia; however, Hand1 and other left-ventricular markers are expressed.  Despite 
the abnormal development of the left ventricle, the outflow tract and right ventricle 
continue to develop normally[119].  Without expression of Hand1, formation of the left 
ventricle is disrupted due to a proliferation defect, and the mutants die from extra-
embryonic effects[116, 118, 231].  In contrast, Hand2 mutants show right-ventricular 
hypoplasia[120, 121]. Isl1 mutants have only two chambers in the heart tube.  Labeling 
with Hand1 and Tbx5 probes show that the left ventricle is present; however, markers of 
the right ventricle and outflow tract are not detected[100].  Chick embryo studies have 
shown that fibroblast growth factor signaling, including Fgf8 and Fgf10,  may be 
necessary for the proliferation of cells in the secondary heart field[123].  The 
transcription factor Pitx2 is expressed during the primitive heart tube stage and is 
responsible for the left/right specification of the chambers and the outflow tracts.  It is co-
expressed in the secondary, or anterior, heart field with Tbx1, which acts as an enhancer 
for Pitx2 and affects asymmetric cardiac morphogenesis[232, 233].  While each of these 
genes has been identified as playing a role in the development of the heart, there has not 
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been, to our knowledge, a global study of the gene expression differences between the 
normal LV and the normal RV.  
 
In addition to considering differences in embryological development between the 
ventricles, it is also necessary to consider the differences in physiology.  The normal 
pulmonary artery and right ventricular systolic pressure is 1/5 that of the systemic 
pressure.  Additionally, the thickness of the RV free wall is approximately 1/5 less than 
that of the LV free wall – 2 to 5 mm in the RV compared to 7 – 11mm in the LV[146, 
234].  The mass of the RV is 1/6 that of the LV[148].  While the LV has an ellipsoidal 
shape, the RV has a crescent shape in cross-section and appears triangular from the 
side[146, 234].  It has been reported that there are regional differences in the size of 
cardiomyocytes in adult rat hearts[235], and that cardiomyocytes respond differently to 
changes in hemodynamic load depending on the ventricle in which they are located[236].  
During the development of severe pulmonary hypertension (PH), the RV systolic 
pressure undergoes a 4-5 fold increase above normal[8, 237], whereas the LV systolic 
pressure in a widely studied model of chronic left ventricular failure, aortic stenosis, 
increases in pressure by only a few percent[202, 238, 239].    It is also known that α1-
adrenergic receptor agonists decrease the contractile force in the normal RV, whereas 
they increase the force in the corresponding LV[240].  Similarly, long-term infusion of 
norepinephrine led to LV hypertrophy, but the RV did not respond with 
hypertrophy[241].  Based on these physiological differences, we postulate that there is a 
difference in gene expression between the two ventricles. 
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Rationale: Based on the differences in embryology and physiology, there is sufficient 
reason to postulate that the normal RV and the normal LV have different gene expression 
profiles.  While many studies have examined the gene expression profile of the LV or the 
use the nonspecific term “ventricle”, none have looked at the differences between the RV 
and the LV.  In fact, many studies do not make the distinction between LV and RV and 
treat the ventricles as one muscle.  However, as explained above, the RV and LV neither 
respond in the same manner, nor do they arise from the same embryological background.  
It stands to reason that there is a difference in the normal gene expression patterns in the 
adult rat that ultimately lead to the differences in the ventricles during right ventricular 
failure. 
 
3.2 Microarray Analysis 
 
In order to more clearly determine the gene expression changes of the right ventricle 
during failure caused by PAH, our first goal was search for postulated differences in gene 
expression between the normal RV and the normal LV.  To this end, we adopted DNA 
microarray technology to elucidate the differences (Figure 6).  We used the Agilent 
Whole Rat Genome 4 x 44k chips, a commercially available microarray from Agilent 
Technologies, Inc.  Each array is comprised of probes that have been validated for 
sequence orientation, accuracy, and clustering assembly classification using the rat 
genome build m3[242].  In order to obtain an overview of the normal ventricle gene  
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Figure 6: Clustergram of normal RV and normal LV 
Normal RVs and LVs were isolated from the same animal and snap frozen on liquid 
nitrogen.  RNA was isolated from each ventricle and labeled with Cyanine-5 (red).  
Universal rat reference RNA from Stratagene was labeled with Cyanine-3 (green).  Genes 
were selected using the procedure in the text.  The left column shows expression in the 
LV and the middle column the RV. Genes colored red indicate higher expression than 
reference RNA, green indicates lower expression, and black indicates equal expression.  
The column to the right of the grey line is the difference between the RV and LV; in this 
case, red represents higher expression in the RV, and green represents higher expression 
in the LV.   
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expression, we performed a microarray analysis using paired samples, that is, the LV and 
the RV from six biological replicates (six rats). 
Our experimental design utilized a so-called “Type II” approach: each condition was 
hybridized against a pool of reference RNA from Strategene designed to provide a 
hybridization signal at each spot and to provide a consistent pool of RNA for each 
experiment.  As such, the expression of the RV and LV as shown is relative to the 
reference RNA pool and can be considered arbitrary; the important difference comes in 
the comparison between the two ventricles.  All data from the scanned arrays were 
uploaded to the Ramhorn Array Database, a VCU-specific installation of the Longhorn 
Array Database[218], for archiving and analysis.  To produce the clustergram shown in 
Figure 6, the basic analysis is as follows.  Microarray data were retrieved from the 
Ramhorn Array Database after filtering the data using a set of spot-quality metrics.  Spots 
were included in the dataset if they have a signal greater than or equal to 1.5 fold above 
background in both the red and green channels and greater than 50% good data across the 
set of arrays.  Technical replicates were averaged together.  To determine which genes 
had a statistically significant difference in their expression between the normal RV and 
normal LV, we used the Significance Analysis of Microarrays (SAM) algorithm[219] to 
perform a two-class paired analysis between the data from the normal RV and the normal 
LV.  The SAM analysis was conducted using 64 permutations of the replicate data, the 
maximum number of permutations given a two-class paired analysis and six biological 
replicates. Our approach to determining significance was to control the False Discovery 
Rate (FDR) of the analysis by choosing the lowest delta value resulting in a median FDR 
of 5% or less; for this analysis, a delta value of 0.92 was chosen giving a median FDR of 
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4.64%.  This results in reporting of genes with q-values (the multiple-comparison 
adjusted analog of the p-value used by SAM) < 0.05.  Of the 20,556 genes that passed 
filtering conditions, 335 were called significant.  The Stanford Unique Intentifiers 
(SUIDs) representing each significantly regulated gene were retrieved.  The expression of 
biological replicates was averaged for both the RV and LV arrays.  The Cluster 3.0 
program[220] was used to perform average-linkage hierarchical clustering and exported 
to the Java TreeView program[221] for visualization.  The resulting cluster shown in 
Figure 6 is comprised of the 355 genes passing the criteria listed above.  The major 
columns from left to right are: left ventricle average, right ventricle average, and the 
relative difference between the right ventricle average and the left ventricle average (red 
means higher expression in the RV than the LV and green means higher expression in the 
LV than the RV). 
 
Overall, the cluster shows a small number of genes that were differentially expressed.  Of 
the 355 genes with differential expression between the RV and LV, 332 had higher 
relative expression in the RV than the LV, while only 23 had higher relative expression in 
the LV than the RV.  The clustergram shows the expression in the LV in the first column 
and the RV expression in the middle column.  The third column represents the difference 
in expression between the RV and LV.  In focusing on the third column, smaller clusters 
become apparent, each with a different pattern of expression that corresponds to different 
biological functions and pathways.  The list of all biological processes associated with 
these genes that differ in expression was identified using the PANTHER classification 
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system and is given in Table 7[222, 223].  PANTHER was also used to assign the 
molecular functions of genes in each sub-cluster. 
 
 Cluster I This cluster has genes with higher relative expression in the RV 
than in the LV.  Genes in this cluster are involved in binding, catalytic activity, enzyme 
regulator activity, ion channel activity, receptor activity, structural molecule activity, 
transcription regulator activity, and transporter activity.   
 
In this cluster are several genes that control the Wnt signaling pathway, a signaling 
pathway that is active during the heart’s development in the secondary heart field to 
promote growth and diversification of precursor cells into the right ventricle and 
interventricular myocardium[243].  These genes include: FAT tumor suppressor homolog 
3 (Fat3), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily d, member 2 (Smarcd2), and transducer-like enhancer of split 3 (Tle3).  Thus, 
having higher expression of Wnt signaling pathways in the RV than the LV is consistent 
with the different embryological backgrounds of the two ventricles. 
 
In addition, genes involved in the IGF1/insulin signaling pathway can be found in this 
cluster: insulin-like growth factor 1 (Igf1) and insulin-like growth factor binding protein 3 
(Igfbp).  IGF1 signaling has been shown to cause cardiomyocyte growth[244] and control 
cell differentiation and apoptosis[245]. 
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Table 7: List of biological processes that are differentially expressed between the 
normal RV and normal LV.   
 
The biological processes were assigned by PANTHER for each gene and summarized 
here. 
 
Biological Process # of Genes 
Apoptosis 5 
Blood circulation and gas exchange 1 
Cell adhesion 3 
Cell cycle 8 
Cell proliferation and differentiation 10 
Developmental processes 25 
Homeostasis 4 
Immunity and defense 15 
Neuronal activities 5 
Oncogenesis 9 
Carbohydrate metabolism 3 
Lipid, fatty acid, and steroid metabolism 11 
Nucleoside, nucleotide, and nucleic acid metabolism 30 
Other metabolism 11 
Protein metabolism and modification 22 
Protein targeting and localization 1 
Cell structure and motility 7 
Intracellular protein traffic 5 
Transport 16 
Sensory perception 3 
Signal transduction 46 
Miscellaneous 2 
Unclassified or unknown 212 
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 Cluster II This cluster is composed of a single gene, heme binding protein 1 
(Hebp1), which has higher relative expression in the LV than in the RV.  Hebp1 is 
thought to play a role in heme utilization for hemoprotein synthesis[246].  In addition, it 
may play a role in the sequestration and extraction of porphyrins from cells[247]. 
 
 Cluster III Genes in this cluster have higher relative expression in the RV than 
in the LV.  These genes are involved in binding, catalytic activity, and encode structural 
molecules.  Of particular interest, protein phosphatase 3, catalytic subunit, alpha isoform 
(Ppp3ca), also known as calcineurin, is involved in several pathways, including the 
previously discussed Wnt signaling pathway and T-cell activation.  Activation of the 
Ca2+/calcineurin pathway increases Th2 cell development[248].  Additionally, inhibition 
of calcineurin was shown to be cardioprotective.  A decrease in calcineurin was 
associated with decreased cardiac hypertrophy and improved vascularization[249]. 
 
 Cluster IV In this cluster there are genes that have lower relative expression in 
the RV than in the LV.  These genes participate in cellular activities such as binding, 
catalysis, enzyme regulation, and transcription regulation.   Both cyclin D2 (Ccnd2) and 
growth arrest and DNA-damage inducible, alpha (Gadd45a) are involved in cell cycle 
regulation.  Gadd45a acts to repair damaged DNA, while Ccnd2 induces the transition 
from G1 to S in the cell cycle.  It has been shown that sirtuin (silent mating type 
information regulation 2 homolog) 1 (Sirt1) regulates both genes in the heart.  Increased 
levels of Sirt1 are associated with oxidative stress and cause induction of Gadd45a and 
repression of Ccnd2[250]. 
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  Cluster V Genes in this cluster have a higher relative expression in the RV 
than in the LV.  They have functions including: antioxidant activity, binding, catalytic 
activity, enzyme regulator activity, receptor activity, structural molecule activity, and 
transcription regulator activity.  In addition, two genes play roles in the endothelin 
signaling pathways: endothelin converting enzyme 1 (Ece1) and protein kinase N1 
(Pkn1).  Endothelin signaling is known to stimulate myocyte grown and affect the 
contractile properties of the heart.  It may also increases resistance to apoptosis[251]. 
Rho-associated coil-coil containing protein kinase 1 (Rock1) and von Willebrand factor 
(Vwf ) are members of the inflammation by chemokine and cytokine signaling pathway. 
 
 Cluster VI In this cluster, the genes have lower relative expression in the RV 
than the LV.  These genes participate in activities of catalysis, structural molecules, and 
transport..  While there are no significant pathways representative of these genes, several 
do act as signaling molecules, including homer homolog 2 (Homer2), regulator of 
calcineurin 1 (Rcan1), and natriuretic peptide precursor B (Nppb). 
 
3.3 Comparison of the gene expression pattern between the normal RV and LV 
by qRT-PCR 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate the 
microarray expression results of several genes from several different clusters: nuclear 
receptor subfamily 2, group F, member 2 (Nr2f2), Igf1, Iroquois homeobox 2 (Irx2), and 
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Nppb.  Igf1 and Nr2f2 were found in Cluster I, Irx2 in Cluster IV, and Nppb in Cluster 
VI.  The qRT-PCR results (Figure 7) were all consistent with the trends seen in the 
microarray data, giving us confidence in the technique and analysis of those data.  Nr2f2, 
also known as COUP-TFII (chicken ovalbumin upstream promoter-transcription factor 
2), is required for angiogenesis during heart development[252].  Nr2f2 is expressed two-
fold higher in the normal RV than the LV.  Igf1 was selected for its roles in 
cardiomyocyte growth and control of cell differentiation and apoptosis[244, 245].  Igf1 
was found to have levels in the normal RV 2.5 fold higher than those in the normal.   Irx2 
is a transcription factor expressed in the interventricular septum during heart 
development where it is thought to play a role in septum specification[253].  Irx2 was 
only found to be expressed in the normal LV and was expressed at high levels.  Nppb is 
the precursor to the protein BNP (brain natriuretic peptide), which is used clinically as a 
marker of heart failure.  Levels of Nppb were 7 fold higher in the LV than the RV.   
 
3.4 Discussion 
 
In this chapter, we identify the differences in gene expression between the normal RV 
and the normal LV.  These results are consistent with our understanding of the 
development and the normal physiology of the heart.  While it has been shown previously 
that chamber-specific gene expression occurs during formation of the LV and the 
RV[115, 117, 254], it is our understanding that these data represent the first systematic 
study of the differences in gene expression between the RV and the LV in the adult rat.   
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Figure 7: Comparison of expression levels of selected genes between the normal RV 
and normal LV by qRT-PCR  
 
 
Quantitative real-time PCR analysis of a) Nr2f2 (a, p<0.05 vs. LV), b) IGF1 (a, p<0.01 vs 
LV), c) Irx2 (a, p<0.05 vs RV), and d) BNP (a, p<0.005 vs RV) mRNA in rat normal left 
and right ventricles.  Data were normalized to expression of 18S rRNA and are shown as 
mean ± s.e.m. (n=3) 
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While the majority of the genes expressed in the normal rat heart shared gene expression 
profiles, a relatively small number of genes showed a significant difference in gene 
expression (Table 8).  While the set of differentially expressed genes between the normal 
LV and normal RV is small, they are enriched for genes and pathways that are known to 
play a role in the heart.  In the case of the transcription factor Irx2, the difference was 
categorical in that there was no expression in the normal RV.  Because Irx2 determines 
interventricular septum specification, absent free wall of the RV tissue expression of Irx2 
and high expression in the LV wall may serve as evidence that the interventricular 
septum is indeed part of the LV rather than the RV as is normally held.  For the majority 
of differentially expressed genes, the difference in expression was a matter of degree, 
exemplified by Nr2f2, Nppb, and Igf1.   
While previous studies investigating right ventricular failure have operated with concepts 
that were derived from the failing LV, these data make it clear that the RV and LV should 
be evaluated independently because of differences in gene expression patterns.  This 
notion is supported by the divergent response of the RV and LV to therapeutic agents in 
particular prostaglandin, which worsens left ventricular failure but improves right 
ventricular failure[240, 241].  We postulate that a set of gene expression changes 
associated with right ventricular failure can be identified and this study of the normal RV 
and the normal LV will serve as the basis for that work.  
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Table 8: Summary of genes with differential expression in the normal RV and 
normal LV 
 
Right Ventricle Left Ventricle 
Nr2f2 Irx2 
Igf1 Nppb 
calcineurin Hebp1 
Ece1  
Vwf  
Rock1  
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Chapter 4: Changes in Gene Expression in the RV during Hypertrophy and Failure 
 
 
4.1 Introduction 
 
 
Right ventricular failure (RVF) is increasingly recognized as an important clinical 
problem[255] and most patients with severe and progressive pulmonary arterial 
hypertension (PAH) die from right-heart failure.  Additionally, right ventricular failure is 
the worst prognostic indicator in patients with left ventricular failure[256, 257].  Acute 
right ventricular failure in PAH patients can arise due to the progression of the lung 
vascular disease or neurohormonal activation[154].   
 
During the progression of PAH, the mean pulmonary artery pressure (mPAP) increases 
progressively as the pulmonary vascular resistance (PVR) increases while the cardiac 
output (CO) remains the same (Figure 8).  The right ventricle (RV) usually adapts to the 
high pressure in the pulmonary artery with an increase in right ventricular wall thickness 
achieved through muscle hypertrophy[180].  This adaptation is also associated with an 
increased myocardial oxygen demand[48].  The increase in afterload, defined as the 
amount of pressure the RV must generated to move blood from the heart to the lungs, is  
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Figure 8: Progression of PAH 
 
As the pulmonary vascular resistance (PVR, purple line) increases, mean pulmonary 
artery pressure (PAP, green line) also increases.  Cardiac output (CO, blue line) remains 
constant initially.  As resting cardiac output decreases, patients begin to decline.  
Pulmonary artery pressure eventually decreases. 
 
 
 
Reprinted from Clinics in Chest Medicine, vol. 28(1), D.B. Taichman and J. Mandel, 
“Epidemiology of Pulmonary Hypertension,” 1-22, Copyright 2007, with permission 
from Elsevier  
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sensed by integrins and stretch-activated ion channels in cardiac cells to initiate protein 
synthesis for the adaptive hypertrophy[156].  Myocardial blood supply must keep up with 
the hypertrophy.  Angiogenesis, the growth of new vessels from existing vessels, is 
known to be initiated by vascular endothelial growth factor (VEGF), angiopoietin 1 
(Ang1), and other growth factors[48]. 
 
As the RV begins to fail and is no longer able to overcome the increased pulmonary 
vascular resistance, the mean pulmonary artery pressure and cardiac output fall [258] 
(Figure 8).  As RV end-diastolic volume and pressure increase, RV wall stress also 
increases, which leads to a reduction in RV stroke volume[154].  While it is often 
assumed that elevated mean pulmonary artery pressure and increased RV afterload is a 
sufficient cause of right ventricular failure associated with PAH, it has been shown in 
animal models of pulmonary hypertension that increased afterload alone does not cause 
the RV to fail[180].  In animal studies comparing models of elevated pulmonary 
afterload, achieved through pulmonary artery banding (PAB), with models of failure, the 
RV hypertrophies but does not fail after PAB[180]. 
 
While an increase in afterload is the first trigger for adaptation in the RV, development of 
RVF in PAH also arises from neurohormonal signaling, oxidative stress, inflammation, 
ischemia, and cell death[48].  Associated with the changes in pathology are a set of 
known changes in protein levels.  Levels of uric acid increase in hypoxic states and are 
correlated with functional decline in patients with PAH.[259]  Serum levels of BNP are 
also increased in PAH patients versus control and were inversely correlated with 
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functional status and survival rates[260].  Troponin levels are often elevated in patients 
with RVF due to myocardial stretch and ischemia[154].  Reactive oxygen species (ROS), 
reactive nitrogen species (RNS), and inflammatory responses further the development of 
right heart failure in PAH[48].  Excessive production of reactive oxygen and reactive 
nitrogen species induce contractile dysfunction and favor cardiac remodeling through 
induction of cell damage, apoptosis, and inflammation[48].  Patients with chronic heart 
failure have increased serum levels of tumor necrosis factor alpha (TNF-α), interleukin 1 
(IL-1), and interleukin 6 (IL-6)[210].  The switch from the α- to β-isotype of major thick 
filament protein myosin heavy chain (MHC) [MHC- α to MHC- β switch] in 
cardiomyocytes is a known hallmark of maladaptive cardiac growth and is known to be 
associated with right heart failure in PAH[181].  In addition, contractile dysfunction can 
be associated with mitochondrial defects, depletion of myocardial ATP, and 
modifications of myocardial energy metabolism and utilization[48].   
 
Rationale:  We have previously shown that the normal RV and normal LV have different 
gene expression profiles.  As such, we hypothesize that the failing RV cannot be 
examined in terms of known failing LV gene expression profiles.  We also hypothesize 
that the transition from adaptive hypertrophy to right ventricular failure in PAH is 
associated with a change in gene expression.  Using microarray techniology, we will 
characterize the gene expression of the failing RV and the RV with adaptive hypertrophy. 
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4.2 Animal models of hypertrophy and failure 
 
Pulmonary hypertension research began in Colorado in the 1950s and 1960s with studies 
of “brisket disease”, now known as pulmonary hypertension and heart failure, in cattle.  
In pioneering early PH studies, some cattle were kept at an altitude of 5,000 feet while 
others were kept at 10,000 feet and hemodynamic measurements were made of both 
groups.  Those cattle kept at the higher altitude developed pulmonary hypertension, while 
those kept at the lower altitude did not[261].  Later studeies comparing the response in 
sheep and cattle showed that sheep did not respond to the same extent as cattle to chronic 
high altitude hypoxia and that the hypoxic pulmonary vascular reponse is species 
dependent[262]. 
 
Roughly at the same time, the monocrotaline model of pulmonary hypertension was 
being developed.  Monocrotaline is a purified pyrollizidine alkaloid found in plants of the 
genus Crotalaria [263] that has been shown to cause hepatotoxicity, pneumotoxicity, and 
chronic pulmonary hypertension in humans[264-266].  Pathologically, injection of 
monocrotaline has been shown to cause endothelial cell damage [267, 268]; 
microvascular leak [269, 270]; arterial thickening; muscularization of small, normally 
nonvascular arteries; and thickening of the pulmonary artery trunk [271].  A progressive 
rise in pulmonary artery pressure and development of RVF also result from 
monocrotaline administration[272].  While the monocrotaline model produces a set of 
predictable pathological changes in the rat, it has come under criticism in recent years 
because it also causes myocarditis and pulmonary fibrosis making it difficult for 
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pulmonary hypertension researchers to correlate the data from this model with human 
idiopathic pulmonary arterial hypertension [273-276].  As such, it is likely not an 
appropriate model to for the study of RVF caused by PAH. 
 
A newer model of pulmonary hypertension is the SU5416/hypoxia model[277-279].  It 
requires administration of the selective vascular endothelial growth factor receptor 2 
(VEGFR2) tyrosine kinase inhibitor SU5416 (3-[2,4-dimethylpyrrol-5-yl)methylidenyl]-
indolin-2-one) [280] and exposure to chronic hypoxia (10% FiO2).  This model rests on 
two components: stress and death of lung vessel endothelial cells and chronic hypoxia.  
The SU5416/hypoxia model simulates human idiopathic PAH by inducing 
angioproliferative pulmonary lesions similar to those seen in human patients, severe 
pulmonary hypertension, and, ultimately, right ventricular failure [281].  The hearts show 
dilation and hypertrophy of the RV and paradoxical movement of the interventricular 
septum (Figure 9). When SU5416 is given alone, it causes mild pulmonary hypertension 
and pulmonary vascular remodeling, but neither irreversible PAH nor RVF[282].  
Exposure to chronic hypoxia alone for 4 weeks generates moderate pulmonary 
hypertension and RV hypertrophy, but not right ventricular failure[283].  While the 
Fulton index (RV/LV+S) increases with both chronic hypoxia and SU5416, the body 
weight of the animals does not change significantly with treatment (Figure 10). SU5416 
given alone does not cause a change in the body weight or in the Fulton index.  Because 
of the similarity to human disease, the SU5416/hypoxia model will be used for our 
studies 
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Figure 9: Maladaptive remodeling in rat models of right heart failure. 
 
a) The normal RV imaged by echocardiography has a crescent shape (arrow), an 
interventricular septum that is crescent shaped (dashed line) and a free wall that is 
difficult to identify by routine echocardiography.  b) in the RV failure model (SuHx), 
echocardiography shows RV hypertrophy (arrow), dilation, and paradoxical movement 
(towards the LV rather than the RV) of the interventricular septum (dashed line) c) 
freshly excised normal rat heart  d) freshly excised failing (SuHx) rat heart.  Arrow points 
to hypertrophied RV. 
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Figure 10: Body weight and Fulton index of animal models used in failure study 
 
a) Body weight in grams and b) RV hypertrophy expressed as Fulton index (RV/LV+S) 
of normal (control), SU5416 (SU5416) treated, hypoxia (hypoxia) treated, and 
SU5416/hypoxia (SuHx) treated rats (a, p<0.05 vs control). 
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4.3 Microarray analysis 
 
In order to identify differences in gene expression that occur during right ventricular 
failure associated with PAH, we used a microarray analysis similar to that employed in 
the comparison between the normal RV and normal LV.  Again, this was a “Type II” 
approach in which each hybridization was a combination of RNA from an animal model 
and a pool of commercially available reference RNA.  Total RNA was isolated from RV 
tissue from animals treated with SU5416 alone, chronic hypoxia alone, and SU5416 in 
combination with chronic hypoxia.  Because the normal RV was hybridized against the 
same pool of reference RNA, it can be used again in this analysis.  The expression of 
each RV treatment as shown is relative to the normal RV. 
 
Total RNA was isolated from the free wall of the RV from rats treated with SU5416 
(SU5416) only, rats exposed to chronic hypoxia for 4 weeks, and rats given a 
combination of SU5416 and chronic hypoxia.  RNA was converted to cDNA and 
fluorescently labeled with either Cyanine-3 (green) or Cyanine-5 (red) dye.  The two 
labeled cDNA samples were mixed together and hybridized to an Agilent Whole Rat 
Genome 4x44k microarray chip overnight.  Six biological replicates and three technical 
replicates per condition were hybridized.  Microarrays were washed and then scanned 
with an Axon GenePix 4200A scanner and GenePix Pro 5.0 software.  All data were 
uploaded into the Ramhorn Array Database (http://ramhorn.csbc.vcu.edu).  Microarray 
data were retrieved from the Ramhorn Array Database if they had a signal greater than or 
equal to 1.5 fold above background for both the red and green.  A gene was called “good” 
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and used for analysis if greater than 50% of all arrays for each condition used in the 
analysis passed the filtering conditions of expression greater than or equal to 1.5 fold 
above background expression.  Technical replicates were averaged together.   
 
To determine which genes had a stastically significant difference in their expression 
between conditions, we used the Significance Analysis of Microarrays (SAM) 
algorithm[219] to perform a two-class unpaired analysis with 1,000 permutations of 
replicate data.  To control the False Discovery Rate (FDR), the lowest delta value 
resulting in a median FDR of 5% or less was chosen to give genes with a q-value < 0.05.  
First, a pairwise comparison of each condition compared to normal was made.  In the 
comparison between the normal RV and the SU5416-only treated RV, 18,137 genes 
passed the filtering conditions.  Of these, 6,611 were called significant at a delta value of 
0.70 and a FDR of 4.83%.  When comparing the normal RV and the hypoxia-only RV, 
10,967 genes passed filtering conditions and 5,855 of these were significant using a delta 
value of 0.73 and a FDR of 4.79%.  Finally, in a comparison between the normal RV and 
the SU5416/hypoxia RV, 13,050 genes passed filtering conditions.  3,595 were called 
significant at a delta value of 0.80 corresponding to a FDR of 4.3%.  A venn diagram of 
the number of genes called significant between each condition and the overlap of those 
significant genes is shown in Figure 11.  493 genes were called significant in all of the 
pairwise conditions and there was also overlap in the genes called significant between 
sets of comparisons.  However, the majority of genes in each comparison were not shared 
in another condition and these differences most likely represent the genes causing 
changes in phenotype by the treatments. 
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Figure 11: Venn Diagram of Genes Called Significant in Pairwise Comparisons 
 
Pairwise comparisons were made between the normal RV and each condition, SU5416 
RV, hypoxia RV, and SU5416/hypoxia RV, using the Significance Analysis of 
Microarrays two-class unpaired comparison algorithm.  For each analysis a delta value 
was chosen such that the False Discovery Rate was 5% or less.  The number of genes 
called significant in each comparison is shown here as well as the number of significant 
genes shared between each pairwise comparison.  493 genes were called significant in all 
pairwise comparisons. 
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Normal vs Hypoxia Normal vs SU5416 
1,491 
genes 3,238 genes 3,696 genes 
493 
genes 
633 genes 921 genes 
1,548 genes 
Normal vs  
SU5416/hypoxia 
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To determine which genes had statistically significant difference in their expression 
between the normal RV, the failing (SU5416/hypoxia) RV, and the hypoxic RV, a series 
of two-class unpaired comparisons were made.  First, a two-class comparison between 
the normal RV and the SU5416/hypoxia RV was done to identify 3,595 called significant 
using the parameters listed previously.  Next, a two-class unpaired comparison was made 
between the SU5416/hypoxia RV and the hypoxia RV for those 3,595 genes called 
significant between the normal and failing RV.  Of the 3,595 genes, 1,980 were called 
significant between the SU5416/hypoxia RV and hypoxia RV at a delta value 0.74, which 
gives a FDR of 4.96%.  The Stanford Unique Indentifiers representing genes called 
signficant between both comparisons were compiled and data for all conditions – normal 
RV, SU5416 RV, Hypoxia RV, and SU5416/hypoxia RV – were retrieved from the 
Ramhorn Array Database and transformed by subtracting the average expression of the 
normal RV from each condition.  This gives the expression in each experimental 
condition relative to the normal RV and allows us to visualize the change in expression 
resulting from the treatment.  The Cluster 3.0 program[220] was used to perform 
average-linkage hierarchichal clustering of the whole dataset and exported to the Java 
TreeView program[221] for visualization.  The resulting cluster shown in Figure 12 is 
comprised of the 1,980 genes passing the filtering conditions above.  The major columns 
from left to right are: normal RV, SU5416 RV, Hypoxia RV, and SU5416/hypoxia RV.   
 
Overall, the cluster shows that an approximately equal number of genes were up-
regulated and down-regulated in the RV with SU5416/hypoxia treatment as compared to 
the normal RV.  Treatment with SU5416 had a clear pattern of expression in the; this  
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Figure 12: Clustergram of differentially expressed genes between the normal RV, 
hypertrophied RV, and failing RV 
 
Six biological replicates per condition were hybridized to Agilent Whole Rat Genome 
microarrays.  RV hypertrophy is generated by treating rats with SU5416 (samples labeled 
“SU5416”) or exposure to chronic hypoxia (samples labeled “Hypoxia”).  RV failure 
(samples labeled “SuHx”) is due to the treatment of rats with a combination of SU5416 
and chronic hypoxia.  Green indicates lower expression in a given condition than in the 
normal RV, red indicates higher expression in a condition than in the normal RV.  Black 
indicates that the expression in the condition is equal to expression in the normal RV.   
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pattern was not shared with the chronic hypoxia or SU5416/hypoxia treatment.  When 
contrasting RV hypertrophy caused by chronic hypoxia exposure and RV failure caused 
by SU5416/hypoxia treatment, there are distinct patterns of expression not shared by the 
two treatments. Of particular interest are clusters where overexpressed genes in chronic 
hypoxia are decreased in the failing RV.  These genes could indicate a pattern of adaptive 
hypertrophy gene expression.  Ingenuity Pathway Analysis (http://www.ingenuity.com) 
was used to identify the biological process associated with the genes that differ in 
expression between the normal RV and the failing RV and is shown in Table 9.  In 
focusing on cluster diagram, smaller clusters become apparent, each with a different 
pattern of expression that corresponds to different biological functions and pathways as 
determined by Ingenuity Pathway Analysis and the PANTHER Classification 
System[222, 223].   
 
 Subcluster I consists of genes that represent a “frank failure-activated” cluster; 
they have higher expression in the SU5416/hypoxia RV than the chronically hypoxic RV. 
The top five canonical pathways as defined by Ingenuity Pathway Analysis for genes in 
this cluster are listed in Table 10.  Integrin signaling is known to play a role in the heart’s 
adaptation to pressure overload by increasing synthesis of contractile proteins[157, 158].  
Expression of integrin-like kinase (ILK) is highest in the heart and is an essential for 
regulating cardiac growth, contractility, and repair[284].  Cardiac-specific expression of 
ILK induces hypertrophy suggesting that ILK is a regulator of hypertrophic signaling 
pathways[285].  Additionally, levels of α-skeletal mRNA have been shown to increase 
10-fold in a calf model of pulmonary hypertension induced by chronic hypoxia[286].  In  
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Table 9: Biological processes of genes differentially expressed between normal RV 
and SU5416/hypoxia RV  
 
Biological Process # of Genes 
Apoptosis 261 
Blood circulation and gas exchange 61 
Muscle contraction 142 
Cell adhesion 270 
Cell cycle 424 
Cell proliferation and differentiation 518 
Developmental processes 935 
Homeostasis 119 
Immunity and defense 731 
Neuronal activities 256 
Non-vertebrate process 8 
Oncogenesis 253 
Amino acid metabolism 116 
Carbohydrate metabolism 280 
Coenzyme and prosthetic group metabolism 97 
Lipid, fatty acid and steroid metabolism 417 
Nitrogen metabolism 12 
Nucleoside, nucleotide and nucleic acid metabolism 1173 
Other metabolism 206 
Phosphate metabolism 33 
Protein metabolism and modification 1240 
Sulfur metabolism 33 
Protein targeting and localization 105 
Cell structure and motility 505 
Intracellular protein traffic 400 
Transport 613 
Electron transport 149 
Sensory perception 149 
Signal transduction 1522 
Miscellaneous 19 
Unclassified or unknown 1369 
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Table 10: Top Five Canonical Pathways of Genes in Subcluster I 
 
Pathway Name p-value 
Integrin Signaling 1.56 x 10-6
Actin Cytoskeleton Signaling 4.11 x 10-6
ILK Signaling 6.40 x 10-6
Nrf2-mediated Oxidative Stress Response 8.35 x 10-6
IGF-1 Signaling 2.27 x 10-5
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the microarray dataset, expression of several actin genes were increased: actin alpha 1 
(Acta1) and actin gamma 1 (Actg1) were increased 3.5-fold in the SU5416/hypoxia RV 
over the hypoxic RV while actin beta (Actb) was increased 2-fold in the SU5416/hypoxia 
RV over the hypoxic RV.  Rho-kinase (Rock), a downstream effector of RhoA, plays a 
role in regulating rearrangement of the actin cytoskeleton[287] and has previously been 
shown to be increased in expression during pressure overload-induced cardiac 
hypertrophy[288].  Deletion of Rock1 was associated with reduced remodeling, including 
fibrosis, apoptosis, and chamber dilation[287].  RhoA was increased 2-fold in the 
SU5416/hypoxia RV compared to the hypoxic RV in the microarray dataset.  Based on 
these pathways and their involvement in heart disease and hypertrophy, it can be 
hypothesized that this cluster represents the damaged hearts’s attempt to compensate for 
the increased stress.  However, because these genes have higher expression in the 
SU5416/hypoxic RV than in the hypoxic RV, it is possible that this subcluster represents 
a maladaptive hypertrophy pattern reflecting damage. 
 
 Subcluster II is comprised of genes that reflect a “hypoxia activation cluster” 
and have increased expression in both the SU5416/hypoxia RV and the hypoxic RV.  The 
top five canonical pathways for genes in this subcluster as defined by Ingenuity Pathway 
Analysis are listed in Table 11.  There are several genes in this cluster that are members 
of the transforming growth factor beta (Tgf-β) signaling pathway: inhibin beta B (Inhba); 
mitogen-activated protein kinase 3 (Mapk3); and s100 calcium-binding protein A4.  Tgf-β 
has been shown to be induced by pressure overload[289] and injury[290] in the heart and 
increased Tgf-β1 expression has been identified in the myocardium during cardiac  
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Table 11: Top Five Canonical Pathways in Subluster II 
 
Pathway Name p-value 
IL-8 Signaling 5.73 x 10-7
Hepatic Fibrosis/Hepatic Stellate Cell Activation 2.24 x 10-5
Ovarian Cancer Signaling 6.30 x 10-5
Pancreatic Adenocarcinoma Signaling 9.05 x 10-5
Role of Tissue Factor in Cancer 9.71 x 10-5
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hypertrophy and failure[291-293].  Inhbb was increased by 3-fold in both the 
SU5416/hypoxia RV and hypoxic RV relative to normal. Mapk3 was increased 2-fold in 
the hypoxic RV and 1-fold in the SU5416/hypoxia RV compared to normal.  S100a4 was 
increased 1-fold in the hypoxic RV and 3-fold in the SU5416/hypoxia RV compared to 
the normal RV. Expression of interleukin-8 (IL-8) was increased in the serum of patients 
with PAH and patients with higher serum levels of IL-8 had lower 1-year and 5-year 
survival rates than patients with low IL-8 serum levels[294].  While IL-8 is a modulator 
of immune responses, IL-8 also plays a role in vascular remodeling and modulate smooth 
muscle and endothelial cell function[295-298].  This expression pattern is most likely an 
attempt to compensate for stress rather than a failure-specific pattern because genes are 
expressed almost equally in the hypoxic and SU5416/hypoxia RVs.    
 
 Subcluster III consists of genes that make up a “repression cluster” because they 
have decreased expression in both the hypoxic RV and the SU5416/hypoxia RV. The top 
five canonical pathways as defined by Ingenuity Pathway Analysis for genes in this 
subcluster are listed in Table 12.  The entire mitochondrial biogenesis pathway has been 
reported to be downregulated in heart failure[299] and the generation of reactive oxygen 
species (ROS) increases[300-303].  Mitochondria are the source of ROS and they are also 
damaged by the generated ROS[304].  This ROS damage is associated with 
mitochondrial dysfunction in failing hearts characterized by increased lipid peroxidation, 
decreased mitochondrial DNA (mtDNA) copy number, a decrease in mtDNA transcripts, 
and reduced oxidative capacity[305].  The decrease in oxidative capacity in the heart is 
caused by defects in the major electron transport chain (ETC) complexes[306]; this is  
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Table 12: Top Five Canonical Pathways in Subluster III  
Pathway Name p-value 
Oxidative Phosphorylation 3.25 x 10-9
Ubiquinone Biosynthesis 1.83 x 10-6
Mitochondrial Dysfunction 1.96 x 10-6
Purine Metabolism 2.06 x 10-5
Valie, Leucine, and Isoleucine Degradation 8.81 x 10-4
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reflected in our data in Figure 13.  Additionally, heart failure is characterized by a shift 
from fatty acid oxidation to glucose oxidation in both clinical[307-309] and 
experimental[310-312] studies. Furthermore, the ubiquitin proteasome system is involved 
in cell proliferation and adaptation to stress[313] and increased levels of ubiquitinated 
proteins are associated with depressed protseasomal activities.  Under normal conditions, 
the ubiquitin proteasome system protects cardiomyocytes by removing pro-apoptotic 
signaling molecules, but decreased ubiquiting-proteasome system activity allows pro-
apoptotic proteins to accumulate and trigger apoptosis[314].  
 
 Subcluster IV represents a “loss of hypoxic adaptation cluster;” genes in this 
cluster have increased expression in the hypoxic RV, but decreased expression in the 
SU5416/hypoxia RV.  Although the top five canonical pathways for genes in this cluster 
are listed in Table 13, none of the pathways has a p-value greater than 0.05.  As a result, 
we looked at specific genes within this subcluster. Of particular interest are the genes 
caspase 4 (Casp4) and transcription factor T-box 3 (Tbx3), both of which induce 
apoptosis signaling.  Casp4 induces apoptosis in response to ER-mediated stress[315, 
316] and is expressed 1.6-fold higher in the hypoxic RV than in the SU5416/hypoxia RV. 
Tbx3 causes inhibition of cell proliferation and induction of apoptosis[317] and has 2-fold 
higher expression in the hypoxic RV than the SU5416/hypoxia RV.  Patients with PAH 
have a decrease in proapoptic gene expression and an increase in antiapoptotic gene 
expression[318]. Additionally, treatment with dichloroacetate in a monocrotaline model 
of PAH results in induction of mitochondria-dependent aptoptosis and reversal of 
PAH[319].  This expression pattern could be interpreted as a failure of the  
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Figure 13: Mitochondrial dysfunction pathway in the failing RV  
 
Canonical pathway analysis indentified the pathways from the Ingenuity Pathway 
Analysis® library of canonical pathways that were most significant to the dataset. The p-
value for the mitochondrial dysfunction canonical pathway is 6.51 x 10-9. Genes are 
colored based on fold-change comparison between SU5416/hypoxia (failing) RV and 
hypoxia (hypertrophy) RV. Red correlates to relatively higher expression in the failing 
RV than the hypertrophied RV, and green correlates to relatively higher expression in the 
hypertrophied RV than the failing RV.  
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Table 13: Top Five Canonical Pathways in Subcluster IV 
 
Pathway Name p-value 
Purine Metabolism 0.0585
Oxidative Phosphorylation 0.0729
Relaxin Signaling 0.0826
Aldosterone Signaling in Epithelial Cells 0.0961
Endothelin-1 Signaling 0.1150
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SU5416/hypoxia heart to sustain stress to the same degree as the hypoxic heart, thus 
leading to failure. 
 
4.4 Prediction analysis 
 
In order to identify the postulated gene signature that could predict between the three 
conditions (normal, adaptive hypertrophy, and failing), prediction analyses were 
performed by applying a leave one-out cross-validation (LOOCV) approach on a dataset 
comprising six biological replicates in each class (normal RV, chronic hypoxia RV, and 
SU5416/hypoxia RV), including several technical replicates per class.  The LOOCV 
method takes into account the sample size and is suitable for small sample numbers[227, 
229].  Averaging the technical replicates in each class, four prediction algorithms were 
used: 1-nearest neighbor, 3-nearest neighbors, nearest centroid, and diagonal linear 
discriminant analysis[228].  We performed 2,000 permutations, which resulted in p < 
0.0005 for all prediction algorithms.  Thus, we found that 499 probes the provided a 
prediction accuracy of 100% on all four algorithms.  In addition, 450 of the 499 probes 
showed a 100% support of the LOOCV method.  These probes were clustered together 
(Figure 14) and are listed in Appendix A.  These 450 probes, corresponding to 405 
different genes, can now be used to predict to which class a new sample belongs and 
show a gene expression pattern that differentiates RV hypertrophy from right ventricular 
failure.   
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Figure 14: Prediction analysis cluster. 
 
 
Dendogram for clustering experiments using centered correlation and average linkage of 
the 450 probes that showed 100% agreement across LOOCV.  Red represents greater 
relative expression than reference RNA and green represents less relative expression than 
reference RNA. 
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A number of genes that demonstrated a fold-change difference in expression based on 
microarray analysis between RV hypertrophy and RV failure (Figure 12, Figure 14) 
were selected for qRT-PCR and their corresponding proteins selected for Western Blot 
(Figures 15 - 18).  These genes and proteins fell into one of five categories: signals 
shared between hypertrophy and failure, glycolytic enzymes, cell-growth promoting 
genes, angiogenesis, and cytoskeletal rearrangement. 
 
4.5 Shared signals between hypertrophy and failure 
 
As expected from previous reports, several genes, including natriuretic peptide prescursor 
a (Nppa), natriuretic peptide prescuror b (Nppb), and myosin heavy chain β (MHC-β), 
shared a gene expression pattern between hypoxia (hypertrophy) and SU5416/hypoxia 
(failure).  Nppa is the mRNA sequence precursor for atrial natriuretic peptide (ANP) and 
Nppb is the mRNA sequence encoding the precursor for brain natriuretic peptide, both of 
which are biomarkers of heart failure and increased plasma levels have been reported in 
patients with PAH[260].  Likewise, an increase in the expression of MHC- β is associated 
with hypertrophy and PAH-associated RV failure[48, 181].  Both NppA and NppB show 
increased expression in both hypoxia and SU5416/hypoxia and are not significantly 
different between hypoxia and SU5416/hypoxia[320].  Hypoxia-inducible factor 2, alpha 
(HIF-2α) is a transcription factor that, like hypoxia-inducible factor 1, alpha (HIF-1α), is 
activated in response to hypoxia.  HIF-2α recognizes the same DNA consensus sequence 
in the hypoxia response element (HRE) in promoters of target genes as HIF-1α[321].  
While both transcription factors recognize the same consensus sequence, they do not  
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Figure 15: Expression of genes shared between hypertrophy and failure. 
 
Quantitative real time PCR analysis of HIF-2α (a, p<0.01 vs SuHx; b, p<0.01 vs normal) 
mRNA in normal (normal), pulmonary artery banding (PAB), hypoxic (hypoxia), and 
SU5416/Hypoxia (SuHx) rat right ventricles. Data were normalized to expression of 18S 
rRNA and are shown as mean ± s.d. (n=3). 
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transactivate the same genes nor can they compensate for each other[322, 323].  HIF-2α 
is mainly expressed in endothelial cells, where it enhances transcription of endothelial-
specific genes related to angiogenesis and vessel maturation, such as vascular endothelial 
growth factor receptors 1 and 2 (Vegfr1 and Vegfr2), endothelium-specific receptor 
tyrosine kinase 2 (Tie2), and angiopoietin-1 (Ang1)[324-326].  In addition, HIF-2α 
maintains mitochondrial homeostasis by regulating the production of cellular factors to 
alleviate oxidative stress[327, 328].  The HIF-2α null phenotype shows increased 
oxidative stress because of decreased expression of genes encoding antioxidant enzymes, 
including Sod2[328].  HIF-2α can promote VEGF expression in some tumors that lack 
HIF-1α expression[329] and an activation mutant of HIF-2α dysregulates erythropoietin 
production in humans leading to PAH.[330]  As shown in Figure 15, HIF-2α expression 
increases 3.5 fold over normal in both the hypoxia and SU5416/hypoxia RVs, suggesting 
that HIF-2α may be important for adaptive hypertrophy.  While these data do not 
distinguish between hypertrophy and failure, they do show that the models produce the 
expected markers of hypertrophy and failure. 
 
4.6 Loss of cell-growth promoting genes 
 
Expression of growth factors, including insulin-like growth factor 1 (IGF-1), has been 
shown to increase in response to exercise[168-173] and overexpression of IGF-1 receptor 
or activated Akt leads to myocardial hypertrophy[170, 174].  In the hypoxic RV tissues, 
mRNA expression of Igf1 was increased 3-fold compared to normal; however, Igf1 was 
not increased in the SU5416/hypoxia RV compared to normal (Figure 16).  
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Figure 16: Expression of cell-growth promoting genes 
 
Quantitative real time PCR analysis of a) IGF-1 (a, p<0.05 vs normal; b, p<0.01 vs 
SuHx) and b) KLF-5 (a, p<0.01 vs normal; b, p<0.01 vs SuHx; c, p<0.05 vs SuHx) 
mRNA in normal (normal), pulmonary artery banding (PAB), hypoxic (hypoxia), and 
SU5416/Hypoxia (SuHx) rat right ventricles. Data were normalized to expression of 18S 
rRNA and are shown as mean ± s.d. (n=3). c) Western blot for expression of IGF-1 from 
these normal, hypoxia, and SU5416/hypoxia. d) Densitometry was performed using Quantity One 
1-D Analysis software (Bio-Rad) for normalized IGF-1 (a, p<0.001 vs Hx) 
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Importantly, the expression of IGF-1 protein was decreased in the SU5416/hypoxia RV 
in comparison to the normal and hypoxic RV.  Kruppel-like factor 5 (Klf5) has been 
identified as a factor that transactivates IGF-1 in cardiac fibroblasts; the secreted protein 
stimulates cardiomyocyte growth[244] and controls cell differentiation and 
apoptosis[245].  Klf5 expression also increased in the hypoxic RV (2 fold increase over 
normal), but not in the failing (SuHx) RV.  Together, these results suggest that in the 
failing RV cell growth is impaired. 
 
4.7 Impairment of angiogenic capillary maintenance 
 
HIF-1α also plays a role in the development of cardiac hypertrophy[331].  In addition, 
capillary rarefaction, the loss of capillaries, occurs in the failing RV[180].  While the 
expression of HIF-1α mRNA did not differ between RV hypertrophy and RV 
failure[180], downstream signaling molecules transcribed by HIF-1α were affected in the 
failing RV in comparison to the hypertrophied RV.  VEGF[320], Ang1, and apelin 
expression were reduced in the SU5416/hypoxia RV compared to the hypoxic RV tissue 
(Figure 17).  Similarly, apelin protein levels were also decreased in the SU5416/hypoxia 
RV when compared to the hypoxia RV (Figure 17).  Reduced apelin expression can 
impair capillary growth and maintenance[332], which is consistent with the results seen 
in the failing RV.  The combined effect of reduced expression of VEGF, Ang1, and apelin 
is that of a loss of capillary vessels and reduced angiogenesis.  Whereas HIF-1α gene 
expression cannot explain the decreased angiogenesis factor gene and protein expression, 
HIF-1α  protein stability may account for the impaired angiogenesis profile. 
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Figure 17: Expression of angiogenic capillary maintenance genes 
 
Quantitative real time PCR analysis of a) Angiopoietin-1 (a, p<0.05 vs normal; b, p<0.05 
vs SuHx) and b) apelin (a, p<0.01 vs normal; b, p<0.01 vs SuHx) mRNA in normal 
(normal), hypoxic (hypoxia), pulmonary artery banded (PAB), and SU5416/hypoxia 
(SuHx) rat right ventricles. Data were normalized to expression of 18S rRNA and are 
shown as mean ± s.d. (n=3). c) Representative Western blots for expression of 
angiopoietin-1, apelin and α-actinin from these groups.  Densitometry was performed using 
Quantity One 1-D Analysis software (Bio-Rad) for normalized d) Ang1 (no significant 
difference) and e) apelin (a, p<0.005 vs control; b, p<0.001 vs Hx). 
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4.8 Cytoskeletal rearrangement 
 
 
CTGF is an extracellular matrix-secreted protein that is induced by TGF-β[333, 334].  
Increased levels of CTGF are associated with cardiac fibrosis in a mouse model of 
cardiomyopathy[335].  CTGF can cause hypertrophy in cardiomyocytes and induce 
apoptosis via an activated caspase-3 pathway[336].  Induction of CTGF may be 
important in an initial beneficial adaptive response to cardiac stress; however, long-term 
activation of CTGF leads to dilation of ventricles and loss of cardiomyocytes[337].  As 
shown in Figure 18, expression of Ctgf increases 19-fold over normal in the hypoxic RV 
and then further increases in the SU5416/hypoxia RV – 46 fold over normal –  consistent 
with the theory that CTGF can have both a beneficial and detrimental role in the RV.  
Adducin 3 (Add3) encodes the γ subunit of the adducin protein, a heterodimeric 
cytoskeletal protein[338, 339].  Mutations in Adducin 1, encoding the α subunit of 
adducin, and Add3 have been associated with the development of hypertension[340].  
Adducin has been reported to positively regulate the intercellular junction of epithelial 
cells[341].  Overexpression of Add3 in cardiomyocytes blocks cell elongation and results 
in a more rounded structure[342].  While Add3 is expressed in the fetal heart, it is not 
typically expressed in the adult heart; microRNA (miR)-143 supresses expression of 
Add3[342].  Add3 is re-activated in the RV during development of pulmonary 
hypertension associated with RVF.  In hypoxic RV tissues, Add3 was increased by 8-fold 
over normal and increased 13-fold over normal in the SU5416/hypoxia tissues.  PAB, a 
model of increased afterload alone, did not increase levels of Add3 suggesting that this is 
an important adaptation to a hypoxic response.  Expression of miR-143 in the 
SU5416/hypoxia RV was approximately one-half that of the normal RV (Figure 19). 
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Figure 18: Expression of cytoskeletal rearrangement genes 
 
Quantitative real time PCR analysis of a) CTGF (a, p<0.05 vs normal; b, p<0.05 vs 
SuHx; c, p<0.01 vs normal) and b) Add3 (a, p<0.01 vs SuHx; b, p<0.001 vs normal; c, 
p<0.05 vs SuHx) mRNA in normal (normal), pulmonary artery banding (PAB), hypoxic 
(hypoxia), and SU5416/Hypoxia (SuHx) rat right ventricles. Data were normalized to 
expression of 18S rRNA and are shown as mean ± s.d. (n=3). 
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Figure 19: Expression of miR-143 expression in the RV   
 
Quantitative real-time PCR analysis of miR-143 (a, p<0.01 vs control) in normal 
(control), hypoxic (Hx), and Sugen/hypoxia (SuHx) rat right ventricle.  Data were 
normalized to expression of SNORA73A and are shown as mean ± s.d. (n=3).  
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4.9 Elevated expression of glycolytic enzymes 
 
We used the Ingenuity Pathway Analysis program (http://www.ingenuity.com) to further 
explore the microarray gene expression data with respect to the pathways involved in the 
different response to hypertrophy and failure.  Canonical pathways analysis identified the 
pathways from the Ingenuity Pathways Analysis library of canonical pathways that were 
most significant to the data set. Molecules from the dataset that had a fold-change greater 
than 2 between failing and hypertrophied RV were included in the analysis. The 
significance of the association between the data set and the canonical pathway was 
measured in 2 ways: 1) A ratio of the number of molecules from the data set that map to 
the pathway divided by the total number of molecules that map to the canonical pathway 
is displayed. 2) Fisher’s exact test was used to calculate a p-value determining the 
probability that the association between the genes in the dataset and the canonical 
pathway is explained by chance alone. The expression pattern of the 
glycolysis/gluconeogensis canonical pathway had a p-value of 0.009 (Figure 20) and 
seven different genes encoding glycolytic enzymes were found to be differentially 
expressed (Table 14).  Of particular interest, hexokinase 1 (Hk1) gene expression was 
five-fold greater in the SU5416/hypoxia RV compared to the hypertrophied RV, and 
phosphofructokinase (Pfkb) was increased 3-fold in expression between SU5416/hypoxia 
and hypoxia.  In contrast, alcohol dehydrogenase 7 (Adh7) was decreased two-fold in the 
SU5416/hypoxia RV compared to hypoxia RV.  Additionally, Ucp2, a marker of 
mitochondrial function, was increased 3-fold in SU5416/hypoxia RV compared to 
hypoxia RV supporting the concept of impaired metabolism and energy utilization.   
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Figure 20: Glycolysis and gluconeogenesis pathway in the failing RV 
 
Canonical pathway analysis indentified the pathways from the Ingenuity Pathway 
Analysis® library of canonical pathways that were most significant to the dataset. The p-
value for the glycolysis and gluconeogenesis canonical pathway is 0.00923. Genes are 
colored based on fold-change comparison between SU5416/hypoxia (failing) RV and 
hypoxia (hypertrophy) RV. Red correlates to relatively higher expression in the failing 
RV than the hypertrophied RV, and green correlates to relatively higher expression in the 
hypertrophied RV than the failing RV. Enzyme classification (EC) numbers reported by 
Ingenuity were converted to recommended names using the BRENDA enzyme 
database[343]; these names were then incorporated into the Ingenuity canonical pathway 
using the MyPathway® feature 
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Table 14: Expression of genes encoding glycolytic enzymes 
 
Hypertrophy fold change is given relative to the normal RV and failure fold change is 
given relative to the hypertrophied RV. Hexokinase 1 (Hk1) mRNA is clearly 
overexpressed in the failing RV when compared to the hypertrophied RV of the 
chronically hypoxic rats (Hx); likewise, phosphofructokinase (Pfkm) is overexpressed in 
the failing RV. 
 
 
 FOLD CHANGE
GENES HYPERTROPHY FAILURE 
Adh7  3.45 1.59 
HK1  -3.73 1.33 
PfkB  -1.48 2.31 
Ucp2 -1.25 1.86 
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These results are consistent with the observations that in tissues and cells from patients 
with PAH there is a shift from oxidative phosphorylation to glucose metabolism and 
glycolysis[195, 196].   
 
4.10 Cytokine production in plasma samples 
 
The levels of inflammatory cytokines were measured in rat serum using a multiplex 
ELISA kit.  Patients with chronic heart failure have increased serum levels of IL-1, IL-6, 
and TNF-α[210].  Similarly, patients with PAH have increased serum levels of IL-
8[294], IL-1β, IL-6, and TNF-α[344] in comparison to healthy controls.  Treatment with 
an IL-1 receptor agonist reduced right ventricular hypertrophy and PH in a rat 
monocrotaline model of PH[345].  Mice overexpressing IL-6 develop spontaneous 
pulmonary vascular remodeling and PH[346], while mice overexpressing TNF-α develop 
right ventricular hypertrophy and severe PH[347].  Additionally, levels of VEGF are 
significantly higher in the serum of patients with PAH than in control patients[348].  
These studies suggest that serum levels of these cytokines may be increased in the rat 
models of PH studied here.   
 
In fact, levels of IL-1β, IL-10, IL-13, IL-17, TNF-α, and VEGF were increased 
significantly in serum samples from the SU5416/hypoxia rats when compared with 
normal (Figure 21), whereas only VEGF and IL-13 were also significantly increased in 
the samples from hypoxia-only rats.  Levels of IL-6 were out-of-range for this assay (data 
not shown).  The increased levels of IL-1β, TNF-α, and VEGF are consistent with  
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Figure 21: Expression of cytokines in rat serum from normal, hypertrophy, and 
failing models 
 
Multiplex ELISA analysis of a) IL-1α, b) IL-1β, c) IL-2, d) IL-4, e) IL-5, f) IL-10, g) IL-
13, h) IL-17, i) IL-18, j) TNF-α, and k) VEGF protein in normal (normal), pulmonary 
artery banded (PAB), hypoxic (hypoxia), and SU5416/hypoxia (SuHx) rat serum samples 
(a, p<0.05 vs normal; b, p<0.01 vs normal). Data are shown as mean ± s.d. (n=3). 
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reported increases in serum levels of these cytokines in PAH patients. Although levels of 
IL-13 and IL-17 have not been investigated in the serum of patients with PH or animal 
models of PH, they do have previously characterized roles. IL-13 is upregulated in 
schistosomiasis-induced PH[349] and dysregulation of IL-13 signaling in PAH may play 
a role in vascular remodeling[350].  IL-17 is increased in lung samples from PAH 
patients[351].  Given these results, increased levels of IL-1β, IL-13, IL-17, TNF-α, and 
VEGF are to be expected in serum from SU5416/hypoxia rats. However, IL-10 is an anti-
inflammatory cytokine and is typically decreased in animal models of PH[349].  IL-10 
expression may be a compensatory mechanism and levels in the SU5416/hypoxia serum 
may not be high enough to exert and anti-inflammatory effect. 
 
4.11 Discussion 
 
Here, we identify changes in gene expression between the normal, hypertrophied, and 
failing RV in an attempt to understand the mechanisms leading to RV failure associated 
with PAH.  A major assumption underlying our experimental strategry has been that 
adaptive hypertrophy without failure exists.  The rat PAB and chronic hypoxia models 
both support this concept.  We induced hypertrophy in rats by exposing the animals to 
chronic hypoxia, and we induced right heart failure by combining chronic VEGF receptor 
blockade (SU5416) with chronic hypoxia[180, 283].  RV hypertrophy without failure was 
characterized by a normal cardiac output, while RV failure was characterized by a 
decrease in cardiac output and by RV dilation[180].  The gene expression pattern was 
analyzed by microarray analysis (Figure 12) and prediction analysis (Figure 14) to 
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identify genes that can distinguish between RV hypertrophy and RVF.  While some 
signals, such as ANP, BNP, and HIF-2α, are shared between hypertrophy and failure 
(Figure 15), it is also clear from Figure 12 that there are large differences in the overall 
gene expression patterns between hypertrophy and RV failure.  Through use of pathway 
analysis tools, we can characterize these changes in terms of several categories: loss of 
cell-growth promoting genes, changes in energy metabolism, impairment of 
angiogenesis, and cytoskeletal rearrangement. 
 
Several genes associated with cell growth are increased in expression in the hypoxic RV, 
but are decreased in the failing RV. Although Igf1 has been reported to increase in 
cardiomyopathy[352] and in myocardial biopsies from patients with LV failure[353], Igf1 
and its transcription factor Klf5[244] are both decreased in the failing rat RV.  Klf5 
transactivates Igf1 in cardiac fibroblasts to activate cardiomyocte growth[244] and Igf1 
controls cell differentiation and apoptosis[245].  That Klf5 and Igf1 are increased in the 
hypertrophied RV (chronic hypoxia model), but not in the failing RV, suggests an 
important loss of cell-growth promoting genes, which may be maladaptive. 
 
The changes in energy metabolism as the RV progresses from hypertrophy to failure are 
associated with a shift from fatty acid oxidation to glycolysis and downregulated 
expression of mitochondrial electron transport chain complexes.  A switch from fatty acid 
oxidation to glycolysis has been reported in left ventricular failure (LVF) [354] and has 
been hypothesized to occur in the transition from RV hypertrophy to RVF[198].  The 
increased expression of glycolytic enzymes and the mitochondrial uncoupling protein 
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Ucp2[355] in the failing RV suggests energy limitation and impaired energy utilization as 
described in LVF[356].  An increase in glycolytic enzymes and natriuretic peptides 
(including ANP and BNP)[357, 358] may be “attempts of the RV” to survive and 
maintain contractile function.  Furthermore, impairment of mitochondrial respiratory 
chain complexes is characteristic of damaged and dysfunctional mitochondria in failing 
hearts[305], mostly likely caused by increased generation of reactive oxygen 
species[300-303].  Figure 13 shows the decreased expression of genes encoding 
mitochondrial electron transport chain complexes; this combined with an increase in the 
expression of genes encoding glycolytic enzymes (Figure 20) indicates that there are 
indeed drastic changes in the energy generation and ultilization in the failing RV. 
 
Like the failing LV, the failing RV is characterized by capillary rarefaction[180], and 
here we show that the loss of expression of a number of angiogenic capillary 
maintenance.  VEGF signaling is important for the maintenance of normal cardiac 
function[359].  VEGF also induces expression of anti-hypertrophy signals, including 
regulator of calcineurin 1 (Rcan1) [360].  Apelin is induced by Ang1 and controls blood 
vessel diameter during angiogenesis[332].  Increases in apelin expression due to hypoxic 
stimuli have been linked to endothelial cell proliferation and angiogenesis[361, 362]. 
Additionally, increased apelin expression has been shown in the hypoxic RV[363] 
consistent with the results seen here.  Similarly, Ang1 promotes both cardiac myocyte 
survival[364] and endothelial cell survival[365].  Without expression of these genes, 
there is most likely an impairment of capillary growth and maintenance in the failing RV. 
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In addition to changes in capillary maintenance, the switch from RV hypertrophy to RVF 
is associated with changes in the cytoskeletal arrangement.  Integrins are activated to 
compensate from the pressure overload in the RV and induce expression of contractile 
proteins[157, 158].  ILK regulates cell hypertrophy signaling[285] and RhoA, via ROCK, 
regulates rearrangement of the cytoskeleton[287].  In addition, Add3, normally only 
expressed in the fetal tissue, is re-expressed in the failing RV and miR-143, expressed in 
the normal heart to suppress expression of Add3[342], is turned off (Figures 18 and 19).  
With increased expression of Add3, cardiomyocytes have a less elongated phenotype and 
hypertrophy[342], as is seen in the failing RV.  Finally, CTGF is typically seen as a 
hypertrophy signal, but long-term signaling leads to dilation of the ventricle and loss of 
cardiomyocytes[338].  These changes may be initially beneficial in the hypertrophied 
RV, but with long-term expression of these signals, the heart undergoes changes that are 
maladaptive and lead to RVF. 
 
Taken together, the data define a gene expression pattern that can robustly distinguish 
between adaptive RV hypertrophy and RV failure in a rat model of PAH.  To thoroughly 
assess the clinical importance of the gene expression set, it will be necessary to confirm 
the expression of these genes in human heart tissue.  However, this expression set also 
provides a basis for understanding the reversal of gene expression changes in the 
SU5416/hypoxia model of severe PAH using various therapeutic strategies. 
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Chapter 5: Reversibility of Right Ventricular Failure 
 
 
 
 
5.1 Introduction 
 
 
Although pulmonary arterial hypertension (PAH) is a disease originating in the lungs, 
most patients with PAH die from right-heart failure.  The three-year mortality rate for 
patients with PAH ranges from 20% for patients with heart disease to 80% for patients 
with PAH associated with scleroderma[366].  The response of the right ventricle (RV) 
typically determines the outcome of the disease[8, 367].  Current treatment for PAH 
includes the use of vasodilators, endothelin receptor blockers, and phosphodiesterase-5 
inhibitors[47, 48], but these do not specifically focus on reversing right ventricular failure 
(RVF). 
 
It is known from studies of post-lung transplant PAH patients that the RV is not 
irreversibly damaged by enlargement and hypertrophy[368].  In the 1980s, heart-lung 
transplant was the surgical treatment for PAH patients[369].  However, in the early 
1990s, this shifted towards lung transplant only[370].  A significant improvement in right 
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ventricular function occurs soon after lung transplantation – either single or double lung 
transplant[371-374].  Additionally, patients receiving living-donor lobar lung transplant 
have similar improvements within two months after transplantation[368].  After lung 
transplantation, the 1-, 3-, and 5-year survival rates for PAH patients have been reported 
as 77%,  62.6%, and 53.6%[375], with slightly higher rates for patients receiving a 
double-lung transplant than a single-lung transplant.[376]  Three years after transplant, 
89.6% of patients report no activity limitations[377].  These findings show that the right 
ventricular failure (RVF) associated with PAH is reversible and motivates the search for 
a non-surgical intervention that can reverse RVF.   
 
β-adrenergic receptor blockers are often used in the treatment of patients with left 
ventricular failure[378].  The β-adrenergic receptors are G-protein coupled receptors that 
activate c-AMP mediated protein kinase A[379, 380].  Long-term activation of the 
receptor leads to maladaptive cardiac remodeling and receptor down-regulation[381, 
382].  However, β-adrenergic receptors can also recruit β-arrestins to initiate a second 
wave of signaling that is independent of the G-protein signaling pathway[383, 384] and 
promote mitogenic and anti-apoptotic effects[385, 386].  Signaling through β-arrestins 
also transactivates epidermal growth factor receptor (EGFR) to promote cardioprotective 
signals in response to mechanical stress[387].   
 
The effects of β-blockers in left heart failure include: improved ventricular remodeling, 
preserved cardiac contractility, reduced oxidative stress, and reduced cardiac expression 
of proinflammatory cytokines[388, 389].  However, β-adrenergic receptor blockers are 
152 
not currently used as a treatment for PAH.  Reasons for this could be the potentially 
detrimental effects on hemodynamics and exercise capacity.  PAH patients increase 
cardiac output through increased heart rate because they have a decreased stroke volume 
and contractility problems prevent its increase[390].  A small group of patients with PAH 
due to portopulmonary hypertension was treated with propanalol, a non-specific β-
adrenergic receptor blocker, or atenolol, a β1-adrenergic receptor agonist.  Upon 
withdrawal of the adrenergic receptor blockers, patients had an improved exercise 
capacity[391] leading researchers to conclude that the adrenergic receptor blockers were 
not beneficial to the patients.  However, this study was limited due to small size – 10 
patients – and propanalol or atenalol are presently not used to treat left ventricular failure.   
 
Carvedilol, an α1/β1/β2-adrenergic receptor blocker that also has anti-oxidant 
properties[392], has been used to treat left-heart failure and to treat an animal model of 
PAH[360].  In post-myocardial infarction (MI) studies of the left ventricle, carvedilol 
treatment is associated with improved ventricular function, reduced left ventricular 
dilation, and there is improved survival in post-MI patients[393, 394].  Similarly, 
treatment with carvedilol of patients with chronic heart failure caused by ischemia has 
also improved survival when given in combination with conventional heart failure 
treatments[393, 395]. 
 
In animal studies of carvedilol treatment in the Su5416/hypoxia model of pulmonary 
hypertension, carvedilol had no effect on pulmonary vascular remodeling[360] and did 
not change the number of occluded small pulmonary vessels[277], but did have effects in 
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the heart.  While the amount of pressure overload was the same in both Su5416/hypoxia 
rats and Su5416/hypoxia rats treated with carvedilol, those that were given carvedilol 
treatment had decreased cardiac hypertrophy[360].  In addition, carvedilol treatment was 
associated with increased cardiac output, decreased RV dilation, increased stroke volume, 
decreased cardiomyocyte death, and decreased fibrosis[360].  Clinically, the 
SU5416/hypoxia + carvedilol rats have increased exercise capactity and increased 
survival when compared with the SU5416/hypoxia animals[360], suggesting that 
carvedilol treatment benefits the heart and reduces PAH symptoms.  A decrease in 
fibrosis was also reported with carvedilol treatment of pressure overload in the LV[396, 
397]. While some changes in gene expression have been reported in carvedilol-treated 
rats[360], a systematic study of the gene expression changes in the heart as a 
consequence of carvedilol treatment does not exist. 
 
Rationale: We have previously demonstrated the changes in gene expression associated 
with the development of right ventricular failure caused by PAH.  We hypothesize that 
right heart failure is reversible and that treatment of the failing RV with carvedilol will 
show a different gene expression profile than a non-treated failing RV.  Using microarray 
technology, quantitative real-time polymerase chain reaction (qRT-PCR), and multiplex 
enzyme-linked immunosorbent assays (ELISAs), we characterized the changes in gene 
expression due to the carvedilol treatment and reversal of RVF. 
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5.2 Physiological and gene expression changes with carvedilol treatment 
 
We first investigated the effects of carvedilol treatment on normal (control) rats.  There 
was no change in body weight in the carvedilol-treatment animals, and there was no 
significant difference in the Fulton index (RV/LV + S) between normal and carvedilol-
treated animals (Figure 22).  As previously reported by Bogaard et al., carvedilol 
treatment of normal rats had no effect on the resting hemodynamics of the heart, with the 
exception of a small change in heart rate[360]. 
 
We then examined the changes in gene expression in the RV of the carvedilol-treated 
animals in comparison to normal animals using quantitative real-time polymerase chain 
reaction (qRT-PCR).  Genes were selected based on their inclusion in previous analyses 
in Chapter 4 (Figure 23).  Although there was no significant difference in expression 
between normal and carvedilol-treated animals for the genes natriuretic peptide precursor 
A (Nppa, mRNA for the atrial natriuretic peptide [ANP]); natriuretic peptide precursor B 
(Nppb, mRNA for brain natriuretic peptide [BNP]); and connective tissue growth factor 
(Ctgf), there was a significant difference (p<0.05) for the remaining genes analyzed.  As 
previously discussed, insulin-like growth factor 1 (Igf1) and kruppel like factor 5 (Klf5) 
serve to promote cell growth in the heart; Igf1 expression was increased 2.8-fold and Klf5 
was increased almost 9-fold in the carvedilol treated control RV compared to the 
untreated normal RV.  Hypoxia-inducible factor 1α (HIF-1α), hypoxia-inducible factor 
2α (HIF-2α), vascular endothelial growth factor (VEGF), angiopoietin 1 (Ang1) and 
apelin are angiogenic and can increase capillary density in the heart.  Both  
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Figure 22: Body Weight and Fulton Index of Animal Models Used in Study 
a) Body weight in grams and b) Fulton index (RV/LV+S) (a, p<0.05 vs normal) of 
normal (control), SU5416 (SU5416) treated, hypoxia (hypoxia) treated, SU5416/hypoxia 
(SuHx) treated, carvedilol (carvedilol) treated, and SU5416/hypoxia + carvedilol (SuHx 
+ carv) treated rats.  Data are shown as mean mean ± s.d. (n=6). 
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Figure 23: Effects of Carvedilol on Gene Expression in the Normal Right Ventricle 
Quantitative real-time PCR analysis of Add3, Ang1, ANP, Apelin, BNP, CTGF, HIF-1α, 
HIF-2α, IGF-1, KLF5, MHC-α, MHC-β, and VEGF mRNA in normal and carvedilol rat 
right ventricles (a, p<0.05 vs normal; b, p<0.01 vs normal; c, p<0.005 vs normal). Data 
were normalized to expression of 18S rRNA and are shown as mean ± s.d. (n=3). 
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HIF-1α and HIF-2α were increased by over 4-fold in the carvedilol-treated RV 
compared to the normal RV, VEGF and apelin increased by approximately 3.5-fold, and 
Ang1 increased by 6-fold.  Adducin 3 (Add3), myosin heavy chain alpha (MHC-α), and 
myosin heavy chain beta (MHC-β) all function in cytoskeletal rearrangement.  Add3, 
MHC-α, and MHC-β were increased by 3.3-, 2.5-, and 4-fold respectively in the 
carvedilol-treated RV compared to the normal RV.   
 
 
5.3 Microarray analysis 
 
In order to identify differences in gene expression that occur during right ventricular 
failure associated with PAH, we used a microarray analysis similar to that employed in 
the comparison between the normal RV and normal LV and the models of adaptive 
hypertrophy and RVF.  Again, this was a “Type II” approach in which each hybridization 
was between RNA from an animal model and a pool of commercially available reference 
RNA.  Total RNA was isolated from RV tissue from animals subjected to the 
SU5416/hypoxia protocol for four weeks, then treated with carvedilol for four weeks.  
Because the SU5416/hypoxia RVs from previous studies in Chapter 4 were hybridized 
against the same pool of reference RNA, they can be used again in this analysis.   
 
Total RNA was isolated from the free wall of the RV from rats treated with a 
combination of SU5416 and chronic hypoxia for four weeks to establish RVF.  The 
animals were then treated with carvedilol for four weeks[360].  RNA was first converted 
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to cDNA and fluorescently labeled with either Cyanine-3 (green) or Cyanine-5 (red) dye 
and then the two samples were mixed together for overnight hybridization.  Six biological 
replicates per condition were hybridized to an Agilent Rat Whole Genome 4 x 44k 
microarray chip.  Microarrays were washed and scanned with an Axon GenePix 4200A 
Scanner and GenePix Pro 5.0 Software.  All data were uploaded into the Ramhorn Array 
Database (http://ramhorn.csbc.vcu.edu).  Microarray data were retrieved from the 
Ramhorn Array Database if they had a signal greater than or equal to 1.5 fold above 
background for both the red and green channels.  A gene was called “good” if greater 
than 50% of arrays for each condition (SU5416/hypoxia and SU5416/hypoxia + 
carvedilol) passed the filtering conditions of expression greater than or equal to 1.5 fold 
above the background expression.  Technical replicates were averaged together.   
 
To determine which genes had a statistically significant difference in their expression 
between the SU5416/hypoxia (failing) RV and the SU5416/hypoxia treated for four 
weeks with carvedilol (treated) RV, we used the Significance Analysis of Microarrays 
(SAM) algorithm[219] to perform a two-class unpaired analysis with 1,000 permutations 
of replicate data.  To control for the False Discovery Rate (FDR), the lowest delta value 
resulting in a median FDR of 5% or less was chosen.  For this analysis, a delta value of 
0.645 was selected corresponding to an FDR of 4.59%.  This results in reporting of genes 
with q-values < 0.05.  Of the genes passing initial filtering conditions, 4,714 were 
identified as significantly different in expression.  The Stanford Unique Indentifiers 
representing significantly regulated genes were compiled and data for the following 
conditions: normal RV, SU5416/Hypoxia RV, and SU5416/hypoxia + carvedilol RV 
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were retrieved from the Ramhorn Array Database.  The replicates for each condition were 
averaged and transformed by subtracting the average expression of the normal RV from 
each condition.  This gives the expression in each experimental condition relative to the 
normal RV and allows us to visualize the change in expression resulting from the 
treatment.  The Cluster 3.0 program[220] was used to perform average-linkage 
hierarchichal clustering by gene of the whole dataset, and clustered data was exported to 
the Java TreeView program[221] for visualization.   
 
The resulting cluster shown in Figure 24 is comprised of the 4,714 genes called 
significant by SAM between the SU5416/hypoxia RV and the SU5416/hypoxia + 
carvedilol RV.  The major columns from left to right are: normal RV, SU5416/Hypoxia 
RV, SU5416/hypoxia + carvedilol RV and the difference in SU5416/Hypoxia RV + 
carvedilol and SU5416/hypoxia RV (shown to the right of the grey line).  This final 
column allows us to focus in on the genes that are changing in the attempt to reverse right 
heart failure due to carvedilol treatment.  The subclusters seen in the figure are based on 
the Pearson correlation coefficient for similarity of genes in that cluster.  Using a 
threshold correlation value of 0.8 generates the four smaller clusters seen in Figure 24. 
 
 Subcluster 1 is comprised of genes that have increased expression in the 
SU5416/hypoxia and the SU5416/hypoxia + carvedilol RV and could represent a pattern 
of expression associated with increased hypertrophy in the heart.  The top five canonical 
pathways for genes in this cluster are listed in Table 15. Of these, the hepatic fibrosis and 
hepatic stellate cell activation pathway stood out because fibrosis is known to increase in  
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Figure 24: Microarray Cluster 
 
Six biological replicates per condition were hybridized to Agilent Whole Rat Genome 
microarrays.  Failing RV (samples labeled “SuHx”) is obtained by treating rats with a 
combination of SU5416 and chronic hypoxia.  Carvedilol treatment given after a 
combination of SU5416 and chronic hypoxia (samples labeled “SuHx + Carv) is an 
attempt to reverse right heart failure. Genes to the right of the grey line (column labeled 
“-“) show the difference in expression between the average SuHx + carvedilol RV and 
the average SuHx RV.  The small columns represent different animals treated with the 
same condition.  Each row represents a gene called significant by the SAM algorithm.  
Green indicates lower expression in a given condition than in the normal RV, red 
indicates higher expression in a condition than in the normal RV.  Black indicates that the 
expression in the condition is equal to expression in the normal RV.   
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Table 15: Top Five Canonical Pathways of Genes in Subcluster 1 
 
Pathway Name p-value 
Hepatic Fibrosis/Hepatic Stellate Cell Activation 6.01 x 10-8 
Calcium Signaling 1.09 x 10-5 
ILK Signaling 2.40 x 10-5 
VEGF Signaling 1.13 x 10-4 
Actin Cytoskeleton Signaling 1.13 x 10-4 
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PAH and in the SU5416/hypoxia model of PAH[291-293].  In the microarray data set, 
expression of transforming growth factor alpha (TGF-α) was increased 1.5-fold in the 
SU5416/hypoxia RV compared to the normal RV and 3-fold in the SU5416/hypoxia + 
carvedilol RV compared to the normal RV.  Similarly, transforming growth factor beta 2 
(TGF-β2) was increased 3-fold and 2.5-fold, respectively, in the SU5416/hypoxia RV 
and SU5416/hypoxia + carvedilol RV compared to the normal RV.  In addition, another 
of the pathways – Integrin-like kinase (ILK) signaling – has been implicated as a 
regulator of hypertrophic signaling pathways because cardiac-specific expression of ILK 
has been shown to induce hypertrophy[285].  ILK expression is highest in the heart and is 
essential for mediating repair, growth, and contractility in the heart[284].  Actin 
cytoskeleton rearrangement is mediated by rho-kinase (ROCK), a downstream mediator 
of RhoA[286].  Levels of ROCK have been reported to increase in expression during 
pressure overload-induced hypertrophy[288].  Deletion of Rock1 is assocated with 
reduced fibrosis, apoptosis, and chamber dilation in the heart[287].  RhoA was increased 
1.02-fold in the SU5416/hypoxia RV and 1.25-fold in the SU5416/hypoxia + carvedilol 
RV compared to normal.  Additionally, two actin molecules also showed increased 
expression: cardiac alpha actin 1 (Actc1) was increased 1.1-fold in the SU5416/hypoxia 
RV and 2-fold in the SU5416/hypoxia + carvedilol RV compared to normal and alpha 
actinin 2 (Actn2) was increased 1.8-fold in the SU5416/hypoxia RV and 2.1-fold in the 
SU5416/hypoxia + carvedilol RV compared to normal. Overall, genes in this cluster have 
increased levels of expression in the SU5416/hypoxia and SU5416/hypoxia + carvedilol 
RVs (Figure 24, subcluster 2) suggesting that these pathways are a mechanism of 
compensation for stress in the right ventricle. 
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 Subcluster 2 is made up of genes that might be characterized as having a 
“reversal of failure” expression pattern; these genes have increased expression in the 
carvedilol-treated SU5416/hypoxia RV when compared with the SU5416/hypoxia RV.  
The top five canonical pathways for these genes are listed in Table 16.  Of particular 
interest are the oxidative phosphorylation and mitochondrial dysfunction pathways.  The 
failing RV is known to be associated with a shift in energy metabolism towards glucose 
oxidation and away from fatty acid oxidation in clinical and experimental studies[307-
312].  In addition, mitochondrial biogenesis is downregulated in the failing heart[299] 
along with an increase in the generation of reactive oxygen species[300-303].  A decrease 
in the genes encoding proteins of the electron transport chain complexes is associated 
with a decrease in oxidative capacity[306].  These changes in metabolism were reflected 
in the failing RV in the SU5416/hypoxia RV (Chapter 4, Figure 13).  With carvedilol 
treatment after SU5416/hypoxia, there is an increase in expression of genes encoding 
mitochondrial enzymes (Figures 25 and 26).  Cytochrome c oxidase (Complex IV of the 
electron transport chain) is the last enzyme in the electron transport chain and catalyzes 
the oxidation of cytochrome c and reduction of oxygen to water.   Four subunits of 
cytochrome c oxidase are increased in the microarray dataset:  cytochrome c oxidase 
subunit I (Cox1), cytochrome c oxidase subunit II (Cox2), cytochrome c oxidase subunit 
VIa polypeptide 2 (Cox6a2), and cytochrome c oxidase subunit VIIIb (Cox8b).  Cox1 is 
increased 1.5-fold, Cox2 is increased 1.7-fold, Cox6a2 is increased 1.2-fold, and Cox8b is 
increased 1.6-fold in the SU5416/hypoxia + carvedilol RV compared to SU5416/hypoxia 
RV. We can conclude that these alterations in metabolism are beneficial to the heart and 
reflect the beginning of a return towards normal metabolism in the heart.   
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Table 16: Top Five Canonical Pathways of Genes in Subcluster 2 
 
Pathway Name p-value 
Oxidative Phosphorylation 1.86 x 10-3 
Mitochondrial Dysfunction 5.16 x 10-3 
Phospholipase C Signaling 1.07 x 10-3 
G Protein Signaling Mediated by Tubby 1.46 x 10-2 
Non-Small Cell Lung Cancer Signaling 1.88 x 10-2 
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Figure 25: Mitochondrial Dysfunction Genes in Subcluster 2 
 
Microarray gene expression of genes encoding proteins involved in mitochondrial 
dysfunction in subcluster 2.  The first three major columns on the left labeled “normal,” 
“SuHx”, and “SuHxCarv” denote expression in the normal, SU5416/hypoxia, and 
SU5416/hypoxia + carvedilol RVs.  Red coloration indicates increased expression 
compared to the average normal RV expression level while green indicates reduced 
expression.  The small columns represent different animals treated with the same 
condition.  The last major column on the right of the grey line labeled “-“ denotes the 
difference in expression between the SU5416/hypoxia + carvedilol and SU5416/hypoxia 
RVs.  Red coloration indicates increased expression in the SU5416/hypoxia RV with 
carvedilol treatment compared to an untreated SU5416/hypoxia RV, and green indicates 
reduced expression in the SU5416/hypoxia + carvedilol RV compared to the 
SU5416/hypoxia RV. 
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Figure 26: Mitochondrial Dysfunction Canonical Pathway  
 
Canonical pathway analysis indentified the pathways from the Ingenuity Pathway 
Analysis® library of canonical pathways that were most significant to the dataset. The p-
value for the mitochondrial dysfunction canonical pathway is 5.16 x 10-3. Genes are 
colored based on fold-change comparison between the SU5416/hypoxia + carvedilol 
(treated) RV and the SU5416/Hypoxia (failing) RV. Red correlates to relatively higher 
expression in the treated RV than the failing RV, and green correlates to relatively higher 
expression in the failing RV than the treated RV.  
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 Subcluster 3 contains genes that could represent a “reversal of failure” 
expression pattern; these genes have increased expression in the SU5416/hypoxia RV and 
decreased expression in the SU5416/hypoxia + carvedilol RV.  The top canonical 
pathways for genes in this cluster are shown in Table 17.  Two pathways, Regulation of 
eIF4 and p70S6k and eIF2 Signaling, will be discussed in more detail in section 5 of this 
chapter, while the protein ubiquitination pathway will be discussed further as part of 
subcluster 4.  One of the main biological functions of genes in this pathway is cardiac 
hypertrophy (Figure 27); a reduction in genes encoding cardiac hypertrophy functions is 
consistent with studies reporting that carvedilol reduces hypertrophy in the 
SU5416/hypoxia RV[360].  Of particular importance to pulmonary hypertension are the 
genes HIF-1α and angiopoietin-2 (Ang2).  Hypoxia-driven activation of HIFs plays a role 
in the pathogenesis of experimental PH[398, 399] by increasing angiogenesis[400] and 
the metabolic switch towards glycolysis[401].  HIF-1α, along with HIF-2α and VEGF, is 
found in plexiform lesions[10] and pulmonary artery smooth muscle cells[196] 
suggesting that HIF-dependent signaling contributes to proliferative activities in PAH.  In 
a HIF-1α heterozygous mouse there was impaired vascular remodeling, decreased RV 
hypertrophy, and decreased pulmonary artery pressure[399].  HIF-1α expression is 
decreased 2.1-fold in the SU5416/hypoxia + carvedilol RV in comparison to the 
SU5416/hypoxia RV.  Ang2 is also known to play a role in PAH.  Ang2 has pro-
angiogenic properties when expressed in high concentrations[402] or in combination with 
VEGF[403, 404]. Patients with idiopathic PAH had increased plasma levels of Ang2, and 
these levels correlated with cardiac index and pulmonary vascular resistance; increased 
Ang2 was an independent risk factor for mortality[405].  Ang2 expression is decreased  
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Table 17: Top Five Canonical Pathways in Subcluster 3 
 
Pathway Name p-value 
Protein Ubiquitination Pathway 1.13 x 10-9 
Estrogen Receptor Signaling 6.59 x 10-8 
Androgen Signaling 3.54 x 10-6 
Regulation of eIF4 and p70S6k Signaling 4.06 x 10-6 
eIF2 Signaling 5.61 x 10-6 
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Figure 27: Cardiac Hypertrophy Genes 
Microarray gene expression of genes involved in cardiac hypertrophy functions in 
subcluster 3.  The first three major columns on the left labeled “normal,” “SuHx”, and 
“SuHxCarv” denote expression in the normal, SU5416/hypoxia, and SU5416/hypoxia + 
carvedilol RVs.  Red coloration indicates increased expression compared to the average 
normal RV expression level while green indicates reduced expression.  The small 
columns represent different animals treated with the same condition.  The last major 
column on the right of the grey line labeled “-“ denotes the difference in expression 
between the SU5416/hypoxia + carvedilol and SU5416/hypoxia RVs.  Red coloration 
indicates increased expression in the SU5416/hypoxia RV with carvedilol treatment 
compared to an untreated SU5416/hypoxia RV, and green indicates reduced expression in 
the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia RV. 
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2.3-fold in the SU5416/hypoxia + carvedilol RV in comparison to the SU5416/hypoxia 
RV.  A reduction in these genes, as seen in the SU5416/hypoxia + carvedilol RV, could 
lead to reduced cardiac hypertrophy and improved myocardial function. 
 
 Subcluster 4 is composed of genes that have a “repression” expression pattern 
and have reduced expression in the SU5416/hypoxia RV and in the SU5416/hypoxia + 
carvedilol RV.  The top five canonical pathways for these genes are listed in Table 18, of 
which 2 are related: ubiquinone biosynthesis and the protein ubiquitination pathway. As 
previously discussed, the protein ubiquination system is cardioprotective because it 
removes pro-apoptotic signaling molecules from the cell[314].  Decreased expression of 
ubiquitination proteins leads to reduced proteasomal activities[313] and allows 
accumulation of pro-apoptotic proteins[314].  While carvedilol treatment of the 
SU5416/hypoxia RV does not change expression of these pathway genes compared to 
SU5416/hypoxia RV, they may not be essential for reversal of RV failure. 
  
5.4 Prediction analysis 
 
The prediction set generated in Chapter 4 was used to evaluate the SU5416/hypoxia + 
carvedilol data set.  The prediction set is made up of those 450 genes that had expression 
patterns that were most discriminatory between normal, hypertrophy, and failure in the 
RV.  By comparing the expression of carvedilol-treated failing RVs to the prediction set, 
we can determine which expression pattern carvedilol most resembles and see the effects 
that carvedilol had on this small subset of genes.   
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Table 18: Top Five Canonical Pathways in Subcluster 4 
 
Pathway Name p-value 
Ubiquinone Biosynthesis 4.03 x 10-11 
Pyruvate Metabolism 2.49 x 10-06 
Protein Ubiquitination Pathway 1.62 x 10-05 
Citrate Cycle 1.19 x 10-04 
AMPK Signaling 8.65 x 10-04 
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 This is a supervised learning method; the initial data set applies the knowledge 
represented by data label to create a class predictor that can classify samples in a new 
data set.  The previous data set, composed of the normal, hypoxia, and SU5416/hypoxia 
microarrays, acts as a training data set against which the SU5416/hypoxia + carvedilol 
data set – the prediction data set – is compared.   Using the 1-nearest neighbor, 3-nearest 
neighbors, nearest centroid, and linear discriminant analysis algorithms[228], each of the 
arrays in the SU5416/hypoxia + carvedilol data set was assigned a label of either 
“normal,” “hypertrophy,” or “failure” based on the similarity of the 450 genes in the 
training data set to the 450 genes in the prediction data set.   
 
As seen in Table 19, each of the SU5416/hypoxia + carvedilol arrays was classified as 
“failure” by all of the algorithms.  It is evident from Figure 28, that the expression of the 
genes in the SU5416/hypoxia + carvedilol set has a great deal of similarity to the failure 
gene set, but that there are also some genes with distinct expression patterns.  Although 
the SU5416/hypoxia + carvedilol data were classified as being most similar to failure 
(SU5416/hypoxia), it is important to remember that this is based on a small set of genes 
rather than the data set as a whole.   
 
However, there are some genes with a distinct gene expression pattern between the 
SU5416/hypoxia and SU5416/hypoxia + carvedilol RVs which may represent the genes 
that are responsible for reversal of failure.  Cox1, as previously discussed, was increased 
1.5-fold in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia RV  
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Table 19: Summary of Prediction Analysis Results 
Description of how the SU5416/hypoxia + carvedilol microarrays were classified by the 
prediction analysis set generated in Chapter 4. 
 
Array ID Number of 
genes in 
classifier 
1-Nearest 
Neighbor 
3-Nearest 
Neighbors 
Nearest 
Centroid 
Linear 
Discriminant 
Analysis 
237 435 Failure Failure Failure Failure 
238 435 Failure Failure Failure Failure 
239 435 Failure Failure Failure Failure 
526 435 Failure Failure Failure Failure 
527 435 Failure Failure Failure Failure 
604 435 Failure Failure Failure Failure 
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Figure 28: Prediction Analysis Results 
Dendogram for clustering experiments using centered correlation and average linkage of 
the 450 probes that showed 100% agreement across LOOCV.  The first three major 
columns on the left labeled “normal,” “SuHx”, and “SuHxCarv” denote expression in the 
normal, SU5416/hypoxia, and SU5416/hypoxia + carvedilol RVs.  Red coloration 
indicates increased expression compared to the average normal RV expression level 
while green indicates reduced expression.  The small columns represent different animals 
treated with the same condition.  Each row represents a gene from the prediction set.  The 
last major column on the right of the grey line labeled “-“ denotes the difference in 
expression between the SU5416/hypoxia + carvedilol and SU5416/hypoxia RVs.  Red 
coloration indicates increased expression in the SU5416/hypoxia RV with carvedilol 
treatment compared to an untreated SU5416/hypoxia RV, and green indicates reduced 
expression in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia 
RV. 
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demonstrating that there are effects of carvedilol on the complexes of the electron 
transport chain.  In addition, endothelin 2 (Edn2) was decreased 2.6-fold in the 
SU5416/hypoxia + carvedilol RV when compared to the SU5416/hypoxia RV; in several 
cancer cell lines, hypoxia triggers production of Edn2[406-408].  Edn2 has strong 
vasoconstricting activity[409] similar to endothelin 1, which has been implicated as a 
mediator of vascular tone and vascular remodeling in pulmonary hypertension[410].    
Similarly, expression of beta 5 tubulin (Tubb5) were decreased 2.9-fold in the 
SU5416/hypoxia + carvedilol RV in comparison to the SU5416/hypoxia RV.  Levels of 
β-tubulin increase in rat models of cardiac hypertrophy and pulmonary hypertension 
induced by monocrotaline[411], which has been associated with contractile 
dysfunction[412].  It may be that only a few differences in gene expression such as these 
can have a positive outcome on the function of the RV. 
  
5.5 Class comparison analysis 
 
Although the class prediction set classified all of the SU5416/hypoxia + carvedilol 
microarrays as “failure” because of similarities to the SU5416/hypoxia data set, there are 
a few significant changes in gene expression in that dataset.  In addition, the microarray 
analysis showed a large number of genes that were differentially expressed between the 
SU5416/hypoxia + carvedilol and SU5416/hypoxia microarrays.  As such, there is reason 
to believe that we can identify the genes that had the greatest difference in expression 
between the two data sets.  To do so, we employed a class comparison algorithm, which 
uses a T-test to compare the expression of each gene between the two classes in the data 
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set[413].  Those genes with a p-value below a given threshold value are called 
significant.  In addition, multivariate permutation testing can be used to control the false 
discovery rate[226, 414].  For each permutation in the multivariate permutation testing 
algorithm, the data labels are changed and the p-value is re-calculated for each gene.  The 
genes are then ordered by their p-value and the number of genes with a p-value below the 
threshold is recorded.  The process is repeated for all permutations.  For a given p-value, 
the number of genes selected via permutation testing is known and is the false discovery 
rate.  A threshold p-value is chosen to minimize the false discovery rate. 
 
When comparing the SU5416/hypoxia (failing) and SU5416/hypoxia + carvedilol 
(treatment) microarrays, a two-sample T-test was used to compare the two classes.  The 
p-value threshold was set at 0.001 to allow no more than 10 false-positive genes and a 
proportion of false-positive genes less than 5%.  Of the 43,379 probes in the data set, 489 
were selected as significant given the chosen test conditions.  The probability of selecting 
at least 489 probes by chance at the threshold p-value of 0.001 if there was no difference 
between the classes is 0.216%.  The list of these genes is given in Appendix 2 and the 
cluster showing their expression is shown in Figure 29.  Two clear subclusters are 
apparent in the cluster diagram and will be explained in more detail. 
 
 Subcluster 1 is composed of 282 probes that correspond to 275 different genes.  
The top five canonical pathways for genes in this cluster are given in Table 20.  Two of 
these pathways, regulation of eIF4 and p70S6k signaling and eIF2 signaling, are involved 
in common biological processes.  Eukaryotic initiation factor (eIF)-2 and 4 are both  
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Figure 29: Class Comparison between SU5416/hypoxia and SU5416/hypoxia + 
carvedilol 
 
Cluster for class comparison analysis between SU5416/hypoxia RV (failure) and 
SU5416/hypoxia + carvedilol RV (Tx = treatment) microarray data sets.  489 probes 
were called significant at an α<0.001 level and multivariate permutation testing gives a 
false discover rate less than 5%.  Red represents greater relative expression than reference 
RNA and green represents less relative expression than reference RNA. 
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Table 20: Top Five Canonical Pathways of Genes in Subcluster 1 of Multivariate 
Analysis 
 
Pathway Name p-value 
Regulation of eIF4 and p70S6k Signaling 1.98 x 10-4 
Glucocorticoid Receptor Signaling 2.61 x 10-4 
Ceramide Signaling 4.04 x 10-4 
EGF Signaling 4.94 x 10-4 
eIF2 Signaling 5.68 x 10-4 
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required for the initiation of translation.  eIF2 forms a complex with GTP and methionyl 
tRNA, which binds to the 40S ribosomal subunit to form the 43S preinitiation complex.  
The 43S preinitiation complex binds to mRNA.  Mammalian target of rapamycin 
(mTOR) phosphorylates eIF4e binding protein allowing eIF4e to separate from its 
binding protein and to bind to the mRNA and begin translation[415].  It is known that 
cardiac hypertrophy requires an increase in protein synthesis by individual 
cardiomyocytes[416], thus would require greater activity of the eIFs.  In a model of 
cardiac hypertrophy caused by chronic alcohol intake, eIF2 levels were increased[417].  
eIF4b has been shown to regulate translation of proliferative and pro-survival 
mRNAs[418].  Similarly, decreased expression of eIF4e leads to reduced rates of cell 
growth[419].  In the microarray dataset, several of the eIF genes were decreased in 
expression in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia 
RV: eIF2B3 was decreased 1.51-fold, eIF3F was decreased 2.19-fold, and eIF4G2 was 
decreased 2.46-fold, which should lead to decreased protein synthesis in the 
SU5416/hypoxia + carvedilol RV.  Another pathway, EGF Signaling, also plays a known 
role in the heart.  Transactivation of the epidermal growth-factor receptor (EGF-R) 
activates G protein-coupled receptors to mediate proliferation and mitogenic effects, 
including hypertension, vascular inflammation, tissue remodeling, and left ventricular 
hypertophy[380, 420-422].  Activation of EGF-R induces expression of interferon 
regulatory factor (IRF1) via phosphorylation of signal transducer and activator of 
transcription 1 and 3 (STAT1 and STAT3)[423]; in the microarray dataset, expression of 
Stat1 is decreased by 3.36-fold in the SU5416/hypoxia + carvedilol RV compared to the 
SU5416/hypoxia RV.  Another member of the EGF-R signaling pathway, mitogen-
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activated protein kinase 4 (Mapk4), was also decreased by 1.96-fold in the 
SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia RV in the microarray 
dataset.  Disruption of EGF signaling has been shown to be protective against cardiac 
hypertrophy[424, 425].  In addition, EGF-R signaling mediated the development of PAH 
in mice overexpressing transforming growth factor alpha (TGF-α)[426].  As shown in 
Figure 29, the eIF2-, eIF4-, and EGF signaling pathways are increased in the 
SU5416/hypoxia model when compared with the SU5416/hypoxia + carvedilol model.  
This suggests that these pathways have been affected by carvedilol to decrease 
hypertrophy and return the heart to a more normal state. 
 
 Subcluster 2 is made up of 207 probes that represent 192 different genes.  The 
top five canonical pathways for genes in this cluster are listed in Table 21.  Of these 
pathways, three – PPAR signaling, PPARα/RXRα activation, and Nrf2-mediated 
oxidative stress response – have common functions in the heart.  Peroxisome proliferator-
activator receptor (PPAR) alpha and gamma are both activated by PPAR coactivator-1 
alpha (PGC-1α) and signal through nuclear factor-like 2 (Nrf2).  Both PGC-1α and 
PPAR-α are preferentially expressed in tissues with high oxidative capacity, including 
the heart[427].  Through co-activation of PPAR-α and estrogen-related receptor alpha 
(ERRα), PGC-1α activates genes involved in the cellular uptake and mitochondrial 
activation of fatty acids[428].  As shown in gene knock-out studies, both ERRα and 
PPARα have been shown to play an important role in the functional adaptation of the 
heart to pressure overload[427, 429].  In PGC-1α knockout mice, there is a reduction of 
fatty acid oxidation and a reduction in expression of mitochondrial genes in the  
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Table 21: Top Five Canonical Pathways of Genes in Subcluster 2 of Multivariate 
Analysis  
 
Pathway Name p-value 
PPAR Signaling 2.59 x 10-5 
PPARα/RXRα Activation 5.75 x 10-4 
Agrin Interactions at Neuromuscular Junction 8.10 x 10-4 
NRF2-mediated Oxidative Stress Response 8.76 x 10-4 
Prostate Cancer Signaling 1.56 x 10-3 
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heart[430, 431].  It has been shown that levels of PGC-1α, PPAR-α, and ERR-α genes 
and protein are decreased in the SU5416/hypoxia RV and that this reduction in mRNA 
expression is correlated with RV function[432].  The reactive oxygen species created 
during oxidative stress increase levels of nuclear factor kappa B (NF-κB), which 
subsequently increases levels of pro-inflammatory cytokines such as IL-1, IL-6, and 
TNF-α[433].  Increased expression of NF-κB inhibitor alpha (NF-κBIA) suppresses the 
transcriptional activity of NF-κB; in the microarray data set, expression of NF-κBIA is 
increased 2.1-fold in the SU5416/hypoxia RV compared to the SU5416/hypoxia RV.  
Additionally, NF-κB activation prevents changes in expression of ATP-binding cassette 
subfamily C member 1 (Abcc1, also called multidrug-resistance associated protein 1 
(Mrp1)), which protects against oxidative stress[434, 435].  Further confirming this 
protective role, patients with COPD have decreased expression of Abcc1 compared with 
healthy patients[436].  In the SU5416/hypoxia + carvedilol RV, Abcc1 is expressed 1.4-
fold higher than that of the Su5416/hypoxia RV.  As shown in Figure 29, genes in these 
pathways are returning towards normal expression levels in the RV with carvedilol 
treatment, indicating that a change in energy metabolism and mitochondrial function is 
associated with the reversal of RVF. 
 
5.6 qRT-PCR and additional pathway analysis 
 
We next examined the changes in gene expression in RV tissue samples in rats treated 
with SU5416/hypoxia and carvedilol for genes previously examined by quantitative real-
time polymerase chain reaction (qRT-PCR) (Figure 30). Treatment of the  
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Figure 30: RT-PCR Results 
 
Quantitative real-time PCR analysis of a) Add3 (a, p<0.01 vs SuHx; b, p<0.01 vs normal; 
c, p<0.05 vs SuHx), b) Ang1 (a, p<0.05 vs normal; b, p<0.05 vs SuHx; c, p<0.01 vs 
normal), c) apelin (a, p<0.01 vs normal; b, p<0.01 vs SuHx; c, p<0.05 vs normal; d, 
p<0.05 vs SuHx), d) HIF-2α (a, p<0.01 vs SuHx; b, p<0.01 vs normal; c, p<0.05 vs 
normal; d, p<0.05 vs SuHx), e) IGF-1 (a, p<0.05 vs normal; b, p<0.05 vs SuHx; c, 
p<0.01 vs SuHx), and f) KLF5 (a, p<0.01 vs normal; b, p<0.01 vs SuHx; c, p<0.05 vs 
SuHx; d, p<0.05 vs normal) mRNA in normal and carvedilol rat right ventricles. Data 
were normalized to expression of 18S rRNA and are shown as mean ± s.d. (n=3). 
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SU5416/hypoxia RV with carvedilol was associated with a decrease in the expression of 
Add3 and HIF-2α; both genes returned towards normal levels of expression.  Similarly, 
expression of Ang1 and apelin also both returned towards normal RV expression levels 
and were increased in comparison to SU5416/hypoxia RV levels.  In contrast, levels of 
Aqp1, Nppb, and Klf5 increased above the SU5416/hypoxia RV levels, which were also 
increased in comparison to normal RV levels.  There was no significant effect on the 
expression of IGF-1 in the SU5416/hypoxia + carvedilol RV tissue. 
 
In addition, we examined the glycolysis/gluconeogenesis pathways (Figure 31) with 
respect to carvedilol treatment on the failing RV.  Genes that were up-regulated by 
SU5416/hypoxia treatment (Chapter 4, Figure 20) are now down regulated by carvedilol 
treatment.  In patients with PAH, there is a shift from oxidative phosphorylation to 
glycolysis in the heart[195, 196], which is associated with reduced RV contractility and 
impairment of cardiac function[198].  A reduction in expression of genes encoding 
glycolytic enzymes in the carvedilol-treated failing RV may be an indication that the 
heart is switching from glycolysis back to oxidative phosphorylation and may be 
consistent with some degree of myocardial metabolic recovery. 
 
5.7 Inflammatory genes 
 
On a molecular level, carvedilol treatment has been shown to affect inflammatory 
cytokines and apoptosis.  In post-MI rats that were treated with carvedilol, there was: 
preservation of myocardial contractility, reduced cardiac expression of IL-1β, and  
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Figure 31: Glycolysis and Gluconeogenesis Canonical Pathway 
Canonical pathway analysis identified the pathways from the Ingenuity Pathway 
Analysis® library of canonical pathways that were most significant to the dataset.  The p-
value for the glycolysis and gluconeogenesis canonical pathway is 0.00929.  Genes are 
colored based on fold-change comparison between Sugen/Hypoxia (failing) RV and 
Sugen/Hypoxia with carvedilol treatment (treated) RV.  Carvedilol was given to rats for 
four weeks at a dose of 15 mg/kg.  Red correlattes to relatively higher expression in the 
treated RV than the failing RV, and green correlates to relatively higher expression in the 
failing RV than the treated RV.  Enzyme classification (EC) numbers reported by 
Ingenuity were converted to recommended names using the BRENDA enzyme database 
(32); these names were then incorporated into the Ingenuity canonical pathway using the 
MyPathway® feature. 
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beneficial effects on ventricular remodeling; however, no effect on cardiac oxidative 
stress was seen[437].  Additionally, four weeks of treatment with carvedilol after MI 
reduced expression of the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and TGF-β 
while increasing levels of the anti-inflammatory cytokine IL-10[438].  Similarly, 
carvedilol as a treatment for myocarditis reduced expression of IL-1β and TNF-α and 
increased expression of IL-10[439].  Furthermore, carvedilol suppressed the activation of 
caspase3 via downregulation of TNF-α and inhibition of mitochondrial cytochrome c 
release, resulting in reduced endothelial cell apoptosis induced by congestive heart 
failure[440].  Because neither prazosin, an α1-adrenergic receptor blocker, or propanolol, 
a non-specific β-blocker, were able to induce the same effect but an antioxidant did, it is 
speculated that this effect is due to the antioxidant properties of carvedilol[440].  Finally, 
carvedilol has been shown to inhibit proliferation of pulmonary artery smooth muscle 
cells isolated from patients with idiopathic pulmonary arterial hypertension (PAH)[441]. 
 
We examined the effect of carvedilol on the production of cytokines using a multiplex 
ELISA.  As shown in Figure 32, there was no significant difference in the expression of 
cytokines between the normal rat and carvedilol-only treated normal rat serum samples.  
These signals activated by carvedilol may play a cardioprotective role and contribute to 
the beneficial effects seen with carvedilol treatment in the right ventricular failure animal 
models.  Whether carvedilol also affects the expression of the above-mentioned genes in 
the normal and carvedilol-treated LV will be investigated. 
 
198 
Figure 32: Effects of carvedilol on cytokine production in serum samples 
 
Multiplex ELISA analysis of IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, IL-18, 
TNF-α, and VEGF protein in normal and carvedilol rat serum samples (no significant 
difference). Data are shown as mean ± s.d. (n=3). 
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In addition, we analyzed the expression of cytokines in the serum taken from different rat 
models (Figure 33).  Of the previously analyzed cytokines (Chapter 4, Figure 21), only 
IL-1β and VEGF had increased expression in the SU5416/hypoxia + carvedilol samples 
when compared to normal rat serum samples.  Additionally, there was no significant 
difference in cytokine expression in serum samples between the SU5416/hypoxia 
samples and the SU5416/hypoxia + carvedilol samples.  It is possible that there is a 
change in cytokine levels in the tissues of the heart that is not reflected in the serum 
samples. 
 
To determine if there were effects on the expression of cytokines in the RV, the 
microarray data were analyzed with respect to inflammatory genes (Figure 34).  Several 
genes were affected by carvedilol in the manner expected based on previously published 
literature results.  VEGF forms B and C were decreased by 1.5-fold and 1.3-fold 
respectively in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia 
RV.  IL-18 also decreased by 1.4-fold and IL-10 increased 1.2-fold, consistent with 
previously published literature that shows IL-10 decreases with carvedilol treatment[438, 
439].  VEGF-A did have a different expression in the two conditions.  However, other 
pro-inflammatory cytokines were increased in expression with carvedilol treatment in the 
SU5416/hypoxia RV compared to the SU5416/hypoxia RV, including IL-1α (1.6-fold 
increase), IL-1β (1.3-fold increase), IL-2 (6.5-fold increase), IL-4 (1.8-fold increase), IL-
5 (1.4-fold increase), IL-6 (1.6-fold increase), IL-13 (2-fold increase), and TNF-α (1.5-
fold increase).  However, unlike the cytokine assay that measures protein levels, the  
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Figure 33: Expression of cytokines in rat serum from normal, failing, and 
carvedilol-treated models 
 
Multiplex ELISA analysis of a) IL-1α, b) IL-1β, c) IL-2, d) IL-4, e) IL-5, f) IL-10, g) IL-
13, h) IL-17, i) IL-18, j) TNF-α, and k) VEGF protein in normal (normal), pulmonary 
artery banded (PAB), hypoxic (hypoxia), SU5416/hypoxia (SuHx), carvedilol (Carv), and 
SU5416/hypoxia + carvedilol (SuHx + Carv) rat serum samples (a, p<0.05 vs normal; b, 
p<0.01 vs normal). Data are shown as mean ± s.d. (n=3). 
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Figure 34: Clustergram of inflammatory genes  
 
Microarray gene expression of inflammatory genes in microarray dataset.  The first three 
major columns on the left labeled “normal,” “SuHx”, and “SuHxC” denote expression in 
the normal, SU5416/hypoxia, and SU5416/hypoxia + carvedilol RVs.  Red coloration 
indicates increased expression compared to the average normal RV expression level 
while green indicates reduced expression.  The small columns represent different animals 
treated with the same condition.  The last major column on the right of the grey line 
labeled “-“ denotes the difference in expression between the SU5416/hypoxia + 
carvedilol and SU5416/hypoxia RVs.  Red coloration indicates increased expression in 
the SU5416/hypoxia RV with carvedilol treatment compared to an untreated 
SU5416/hypoxia RV, and green indicates reduced expression in the SU5416/hypoxia + 
carvedilol RV compared to the SU5416/hypoxia RV. 
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microarray only measures mRNA expression and the actual protein levels of these 
cytokines in the RV may be different due to post-translational mRNA modifications.   
 
5.8 Discussion 
 
Carvedilol, an α1/β1/β2-specific adrenergic receptor blocker, has been shown to improve 
the hemodynamics in the failing RV of the SU5416/hypoxia model, as well as reduce RV 
hypertrophy and dilation, myocardial fibrosis, and increase RV capillarization.  Animals 
given carvedilol treatment after development of PAH from SU5416/hypoxia had an 
increased exercise capacity and survival rate. Here, we test whether the partial reversal of 
the RV failure in the SU5416/hypoxia model by carvedilol was also associated with a 
change of the RV-associated gene expression pattern.  The gene expression pattern was 
analyzed by microarray analysis (Figure 24), prediction analysis (Figure 28), and class 
comparison analysis (Figure 29) to identify those signals that reverse failure.   
 
Although the prediction analysis classified the SU5416/hypoxia + carvedilol predictor set 
as being most similar to the expression of the failing RV, it is clear from the class 
comparison analysis in Figure 28 that there are distinct changes in gene expression 
between the failing and treated RVs, including genes involved in endothelin signaling 
and genes encoding mitochondrial electron transport chain complexes.  Carvedilol 
treatment is associated with a reduction in translation initiation and epidermal growth 
factor receptor signaling, both of which are involved in the cardiac response to 
hypertrophy.  A reduction in EGF signaling leads to reduced cardiac hypertrophy[424, 
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425]; similarly, a reduction in translation will also lead to a decrease in hypertrophy[416].  
Treatment with carvedilol also increased expression of genes involved in PPAR and 
Nrf2-mediated signaling.  These signaling pathways are activated while the heart 
compensates for increased pressure afterload[427, 429].  Additionally, the mitochondrial 
dysfunction pathway (Figure 26) and glycolysis/gluconeogenesis pathway (Figure 31) 
have been affected by carvedilol treatment.  In both, there is a higher expression of genes 
in the failing (SU5416/hypoxia) RV than in the treated (SU5416/hypoxia + carvedilol) 
RV.  As it is known that PAH causes a shift from oxidative phosphorylation to glucose 
metabolism and glycolysis[195, 196], this may be a return towards normal metabolism in 
the RV. 
 
Treatment of the failing RV with carvedilol also changed the expression of the genes that 
were previously examined.  While some, including Ang1, Add3, apelin, and HIF-2a, 
returned towards normal RV expression levels with carvedilol treatment, others, 
including Aqp1, BNP, and Klf5, increased further above normal RV and SU5416/hypoxia 
RV levels with carvedilol treatment.  There was no change in Igf1 expression in the 
SU5416/hypoxia + carvedilol RV.  Although there is a change in some of the genes 
analyzed, it is unclear whether they are responsible for the functional improvement seen 
in the heart or whether they are a consequence of the RV functional improvement. 
 
Carvedilol has been reported to decrease expression of pro-inflammatory cytokines and 
increase expression of anti-inflammatory cytokines[438, 439].   Microarray analysis 
(Figure 13) reflected these results in the expression of IL-18, which decreased with 
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carvedilol treatment, and increased expression of IL-10.  However, an increase in mRNA 
expression of IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, and TNF-α was also found and 
is not consistent with literature results.  There may be differences in protein levels in the 
RV that are not reflected in the mRNA results.  In the serum, there were no significant 
differences in the expression of cytokines between the SU5416/hypoxia and 
SU5416/hypoxia + carvedilol samples.  As such, the reported anti-inflammatory effects 
of carvedilol may not play a role in the reversal of RVF.  
 
In the SU5416/hypoxia model of PAH, carvedilol treatment has improved RV function 
and reversed maladaptive RV remodeling.  On a gene expression level, carvedilol 
affected key signaling pathways, including mitochondrial dysfunction, oxidative stress, 
and glycolysis.  These changes in energy utilization should be studied further to examine 
the extent of metabolic remodeling caused by carvedilol treatment.  In addition, further 
characterization of the signaling pathway activated by carvedilol in the heart to change 
gene expression should be undertaken.  Silencing RNA (siRNA) has been used against β-
arrestin to characterize the signaling pathway[442]; such a strategy could be employed to 
effectively knock-out β-arrestin in the carvedilol-treated rat model and compare the 
resulting RVF in the normal and knock-out rats.  Finally, these results indicate the 
promise in using carvedilol to treat PAH in human patients.  A Phase I/Phase II clinical 
trial on the safety and efficacy of carvedilol in PAH was started at Virginia 
Commonwealth University in 2011 (NCT00964678).  Based on the results of these and 
additional trials, carvedilol may become a standard treatment for PAH patients.
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Chapter 6: Discussion and Future Directions 
 
 
6.1 Introduction 
 
Pulmonary arterial hypertension (PAH) is associated with changes in gene expression in 
the right ventricle (RV) of the heart corresponding to physiological changes such as 
hypertrophy, capillary rarefaction, and reduced contractility.  Identifying a therapeutic 
intervention that targets these changes in the RV has been a challenge for researchers.  
We show that carvedilol, a β-adrenergic receptor blocker, reduces hypertrophy, induces 
angiogenesis, and increases contractility; these physiological changes are associated with 
a change in gene expression.  Here, we provide a brief overview of PAH before focusing 
more in-depth on the three aims of this study and its implications on future research 
directions.   
 
PAH is a disease of the lung vessels in which vascular changes increase the pulmonary 
vascular resistance (PVR) which, in turn, leads to increase afterload in the right ventricle 
(RV) of the heart.  Patients are diagnosed with PH if they have a mean pulmonary artery 
pressure of greater than 25 mmHg at rest or greater than 30 mmHg during exercise; a 
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normal mean pulmonary artery pressure is 8 – 20 mmHg at rest[1].  The mean pulmonary 
artery pressure increases in PAH patients as the PVR increases.  The RV can adapt to the 
increase in pressure by hypertrophying – an increase in RV wall thickness through 
increased muscle mass and a more rounded shape[180].  The RV begins to fail as PH 
progresses, which is usually associated with RV dilation, a decrease in cardiac 
output[258], and a reduction in RV stroke volume[154].  Right ventricular failure (RVF) 
is the leading cause of death in patients with PH[255].  The estimated mean life span after 
diagnosis of PAH prior to the period of drug treatment is 2.8 years[8] with a 1-, 2-, and 3-
year survival rate of 77%, 69%, and 35%[9]. 
 
Three classes of drugs are current standards of treatment for PH: prostanoids 
(prostacyclin and analogues like iloprost), endothelin receptor blocks (bosentan or 
ambristentan), and phosphodiesterase-5 inhibitors (sildenafil)[47, 48].  These drugs act as 
pulmonary vasodilators and there had been the hope that they would also reverse 
pulmonary vascular remodeling[47, 48].  However, they can have negative effects on the 
heart by increasing RV contractility, which causes an increase in oxygen[48].  While 
these treatments for PH focus on controlling symptoms and inducing pulmonary 
vasodilation, they do not address the aspect of RVF associated with PH.  RVF is known 
to be reversible from studies of patients that have undergone lung transplant[368].  After 
lung transplant, a significant improvement in both pulmonary artery pressure and right 
ventricular function occur[374].  In addition, the 1-, 3-, and 5-year survival rates for PH 
patients after lung transplant increase to 77%, 62.6%, and 53.6%[375].  These studies 
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demonstrate that PH-associated RVF is reversible and motivate the search for 
pharmacological interventions that can reverse RVF. 
 
In order to investigate the effectiveness of drugs on reversing right ventricular failure, it 
was necessary to first understand the changes in the RV that occur with hypertrophy and 
failure associated with PAH.  The studies here aimed to address these questions in the 
following ways: 1) identifying the differences in gene expression between the normal 
right ventricle and normal left ventricle, 2) identifying changes in gene expression 
between the normal, hypertrophied, and failing right ventricle in animal models of 
pulmonary hypertension, and 3) identifying changes in gene expression in the failing 
right ventricle after treatment with carvedilol, an α1/β1/β2-adrenergic receptor blocker. 
 
6.2 Identifying differences in gene expression between the normal LV and RV 
 
Given that there are differences in embryology and physiology between the normal RV 
and normal LV, we identified a small, but significant, number of genes that were 
differentially expressed between the normal RV and normal LV using DNA microarray 
technology.  These genes were indentified using the Significance Analysis of Micorarrays 
(SAM) two-class paired analysis[219]; 335 genes with identified as having significantly 
different patterns of expression between the normal RV and normal LV from the total 
20,556 genes.  These genes were clustered together using average-linkage hierarchical 
clustering[220] and pathway analysis using the PANTHER classification system[222, 
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223] and Ingenuity Pathway Analysis (http://www.ingenuity.com) identified molecular 
functions and differentially expressed pathways. 
 
Differentially expressed genes are associated with known cardiac functions.  The Wnt 
signaling pathway is active during development in the secondary heart field and helps 
promote growth and diversification of precursor cells in the RV[243].  Genes in this 
pathway had higher expression in the normal RV than the normal LV.  Additionally, 
genes in the IGF-1/insulin signaling pathway are more highly expressed in the normal 
RV than the normal LV.  Activation of this pathway leads to cardiomyocyte growth[244] 
and can control cell differentiation and apoptosis[245].  In contrast, genes involved in 
cell-cycle regulation and DNA damage repair were more highly expressed in the normal 
LV than the normal RV. 
 
From cluster and pathway analysis, several genes were selected for follow-up by 
quantitative real-time polymerase chain reaction (qRT-PCR): Nr2f2, Igf1, Irx2, and Nppb.  
Nr2f2, also known as COUP-TFII (chicken ovalbumin upstream promoter-transcription 
factor 2) is required during development for angiogenesis[252].  Igf1, as previously 
mentioned, controls cardiomyocyte growth, differentiation,  and apoptosis[244, 245].  
Irx2 is expressed during development in the interventricular septum and is thought to 
play a role in septum specification[253].  Nppb is the precursor to BNP, which is 
commonly used as a clinical marker of heart failure.  These genes may provide insight 
into gene expression changes that occur during heart failure.  
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This study sought to identify differences in gene expression between the normal RV and 
normal LV.  These data support the concept that the RV and LV should be evaluated 
independently rather than using the LV as the basis for studies of the RV.  This study also 
serves as the basis for studies of changes in gene expression in the RV caused by 
hypertrophy and right ventricular failure associated with PH.  Another unanswered 
question is whether the interventricular septum is part of the right or left ventricle.  
Microarray studies similar to those used above can answer this question both for the 
normal, unstressed heart and for the heart in PAH where the interventricular septum is 
shifted into the LV cavity impairing LV filling. 
 
6.3 Identifying changes in gene expression between the normal, hypertrophied, 
and failing RV in animal models of PAH 
 
Given that the normal RV and normal LV have different gene expression profiles, it can 
be hypothesized that RVF cannot a priori be described by known patterns of gene 
expression in the failing LV.  In addition, we hypothesize that the transition from 
adaptive hypertrophy to RVF associated with the development of PAH will be associated 
with a change in gene expression.  Using DNA microarray technology, the gene 
expression patterns associated with the normal RV, hypertrophied RV, and failing RV 
were examined in a rat model.  Hypertrophy was induced by exposure to chronic 
hypoxia[283] while failure was induced by a combination of chronic hypoxia and 
administration of a vascular endothelial growth factor receptor (VEGFR) blocker 
SU5416[281].  Echocardiography and hemodynamic studies showed that the RV was 
fully functional in the chronically hypoxic and pulmonary hypertension rats, but that the 
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RV failed (had decreased cardiac output) in the SU5416/hypoxia rats.  The SAM two-
class unpaired analysis[219] was used to identify 3,595 genes with significantly different 
expression between the normal RV and the failing RV.  In addition, a prediction set of 
450 probes corresponding to 405 different genes that distinguish between the normal RV, 
hypertrophied RV, and failing RV was developed using four algorithms and leave one-
out cross-validation[226-229].  These genes were analyzed with cluster analysis[220], the 
PANTHER classification system[222, 223], and Ingenuity Pathway Analysis 
(http://www.ingenuity.com) to identify biological functions and pathways associated with 
the differences in gene expression as the RV transitions from hypertrophy to failure. 
  
There were several genes with shared expression patterns between the failing RV and the 
hypertrophied RV, including ANP, BNP, and hypoxia-inducible factor 2, alpha (HIF-2α).  
Increased expression of ANP and BNP can be expected from previously described 
reports[48, 181] as they are markers of heart stress and failure.  HIF-2α expression is 
increased in response to hypoxia signaling[321] and enhances transcription of 
endothelial-specific genes related to angiogenesis and vessel maturation[324, 325].  
Because these genes have increased expression in both the hypertrophied and failing 
RVs, it suggests that they are important to the adaptation to hypertrophy, but may not 
play a role in the transition to RVF.  Several themes with different expression patterns 
between the failing RV and the hypertrophied RV became apparent in the analysis steps: 
elevated expression of glycolytic enzymes, loss of cell-growth promoting genes, impaired 
angiogenic capillary maintenance, and cytoskeletal rearrangement.   
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A switch from fatty acid oxidation to glycolysis has been reported in studies of left 
ventricular failure[354] and has been hypothesized to occur in the failing RV associated 
with PAH[198].  The increased expression of genes encoding glycolytic enzymes in the 
failing RV in this study suggests a shift in energy metabolism that has been described in 
left ventricular failure.  In addition, the data show a downregulation of genes encoding 
mitochondrial electron transport chain complexes, which is known to be a characteristic 
of damaged and dysfunctional mitochondria in the failing heart[305].  These findings 
indicated that there are drastic changes in energy utilization as the RV transitions from 
hypertrophy to failure. 
 
The studies described here as well as previous studies suggest that there is a shift from 
fatty acid oxidation to glycolysis in the failing RV.  However, these are based on 
expression of mRNA of genes involved in the glycolytic and mitochondrial dysfunction 
pathways rather than studies of respiration in intact cardiac mitochondria.  Single 
populations of cardiac mitochondria can be isolated from the normal and failing 
RVs[443].  Oxygen consumption by these intact mitochondria can be measured to 
determine the ADP/O ratio[444-446].  A lower ADP/O ratio indicates more oxygen used 
per unit of ADP provided in the assay and is an indication of impaired mitochondrial 
efficiency.  We would expect to find that the failing RV from the SU5416/hypoxia rat has 
a lower ADP/O2 ratio than the normal rat based on our microarray results showing 
increased mitochondrial dysfunction and decreased expression of genes encoding 
mitochondrial electron transport chain subunits in the SU5416/hypoxia RV on the mRNA 
level.   
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 Several genes, including Igf1 and Kruppel-like factor 5 (Klf5), had an increased 
expression in the hypertrophied RV, but a decrease in expression in the failing RV.  Igf1 
is transactivated by Klf5 in cardiac fibroblasts and secreted to activated cardiomyocyte 
growth[244] and control cell differentiation and apoptosis[245].  Although increased 
expression of Igf1 has been reported in cardiomyopathy[352] and in myocardial biopsies 
from failing hearts[353], we did not find an increase in Igf1 expression in the failing rat 
RV.  This suggests that cell-growth promoting genes are important in triggering a 
response to hypertrophy, and that a reduction in the expression of cell-growth promoting 
genes may characterize RV failure. 
 
Based on these results, increasing expression of IGF-1 may prove to be beneficial to the 
failing heart.  Mecasermin is a recombinant human insulin-like growth factor I (rhIGF-1) 
approved by the United States Food and Drug Administration in the fall of 2005 for use 
in treating severe primary IGF-1 deficiency[447].  Patients with growth hormone and 
IGF-1 deficiency have increased cardiac mortality[448], and studies are ongoing to see 
whether rhIGF-1 has a beneficial effect on heart failure in humans[449].  rhIGF-1 may 
also prove beneficial in the treatment of pulmonary hypertension because of the role of 
IGF-1 in adaptive, or beneficial, hypertrophy that is lost in the failing heart.  We could 
induce PAH using the SU5416/hypoxia model as described in our studies here and then 
treat with mecasermin.  After mecasermin treatment, hemodynamic measurements would 
be taken and the gene expression profile analyzed using microarrays and analysis 
techniques similar to those described here.  We would expect to see a gene expression 
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profile more closely resembling the hypertrophied RV.  However, mecasermin may need 
to be administered in combination with an existing therapy for PAH, such as sildenafil, to 
improve the hemodynamic performance in the heart.  Future studies may also address the 
aspects of combination therapy of rhIGF-1 and another treatment. 
 
This study sought to identify differences in RV gene expression between normal, 
hypertrophy, and failure.  A set of genes that were descriptive of those changes and a set 
of genes that could predict those differences was identified and analyzed for common 
themes among the differences in gene expression.  Our data show that there is a 
difference in expression between the hypertrophied and failing RV and the key pathways 
that may govern the transition from hypertrophy to failure associated with PAH.  This 
data set also provides a basis for evaluating any changes in gene expression in the RV as 
a result of a pharmacological intervention, a treatment goal for PAH. 
 
One possible pharmacological intervention for PAH is dexamethasone, an anti-
inflammatory and immunosuppressive glucocorticoid used to treat inflammatory and 
autoimmune disorders[450].  Dexamethasone inhibits secretion of T-helper 1 (Th1) cells 
and enhances production of T-helper 2 (Th2) cytokines both in vitro and in vivo[451-
453].  Small groups of patients with PAH due to connective tissue disorders including 
scleroderma, systemic lupus erythematosus (SLE), and mixed connective tissue diseases 
have been treated with a combination of immunosuppressant drugs and glucocorticoids 
resulting in an improvement of PAH symptoms[454].  Additionally, dexamethasone was 
used to prevent development of PAH in a rat monocrotaline model; these rats had 
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significantly decreased pulmonary artery pressure and RV hypertrophy compared to the 
monocrotaline-induced PAH rats[455].  While the prevention of PAH shows promising 
results, treatment with dexamethasone after development of PAH would be the most 
clinically relevant study.  PAH could be induced using the SU5416/hypoxia model as 
described in our studies here followed by treatment with dexamethasone.  Following 
several weeks of dexamethasone treatment, hemodynamic measurements would be taken 
and the gene expression profile analyzed using microarrays and analysis techniques 
similar to those described here.  We would expect to see a decrease in RV hypertrophy 
compared to the untreated SU5416/hypoxia RV and a gene expression profile more 
closely resembling the normal or hypertrophied RV. 
 
6.4 Identifying changes in gene expression in the failing RV after treatment with 
carvedilol 
 
Treatment for PAH is currently focused on the use of vasodilators, endothelin-receptor 
blockers, and phosphodiesterase-5 inhibitors[47, 48], but none of these drugs have effects 
on reversing RVF.  One possible pharmacological intervention is the use of β-adrenergic 
receptor blockers, which are often used in treatment of patients with left ventricular 
failure[378].  In recent animal studies, carvedilol, an α1/β1/β2-adrenergic receptor 
blocker[360], was tested as a treatment for PAH.  Carvedilol had no effect on the 
pulmonary vascular remodeling in these animals, but did reduce RV hypertrophy and 
reverse the capillary rarefaction; increase cardiac output and stroke volume; and decrease 
fibrosis and cardiomyocyte apoptosis[360].   
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Although some changes in gene expression due to carvedilol treatment have been 
reported[360], a systematic study of the gene expression changes in the RV as a result of 
carvedilol treatment of a failing RV had not been done.  Carvedilol was given to rats for 
four weeks after SU5416/chronic hypoxia treatment and the carvedilol-treated RV was 
compared to the untreated failing RV using DNA microarrays.  Although the previously 
described prediction set classified the carvedilol-treated data set as being similar to the 
failing RV, other methods were used to identify genes that were different between the 
failing and carvedilol treated RV.  A two-class unpaired SAM analysis[219] identified 
4,714 genes that were differentially expressed between the failing RV and the carvedilol-
treated RV.  Additionally, a class comparison analysis[226, 413, 414] identified 489 
genes that were significantly different between the failing and carvedilol-treated RV at a 
p-value < 0.001.  The genes from these two analyses were analyzed with clustering 
algorithms[220], the PANTHER classification system[222, 223], and Ingenuity Pathway 
Analysis (http://www.ingenuity.com).  
 
Previously discussed results demonstrate that the failing RV was characterized by a shift 
from fatty acid oxidation to glycolysis[197] and a decrease in expression of genes 
encoding mitochondrial electron transport chain complexes[198, 305].  With carvedilol 
treatment, there was an increase in the expression of mitochondrial electron transport 
chain genes and a decrease in expression of glycolytic enzymes, suggesting that there was 
a return towards normal myocardial metabolism in the heart after treatment with 
carvedilol.  In addition, there was an increase in expression in genes in the peroxisome 
proliferator-acitvator receptor (PPAR) and nuclear factor-like 2 (Nrf2) signaling 
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pathways.  PPAR-α is activated by PPAR coactivator-1, alpha (PGC-1α) and signals via 
Nrf2.  PGC-1α and PPAR-α are preferentially expressed in the heart[427] and activate 
genes involved in the cellular uptake and mitochondrial activation of fatty acids[428].  
PPAR-α plays an important role in the functional adaptation in the heart to pressure 
overload[427, 429].  An increase in the expression of genes in these signaling pathways 
in the carvedilol-treated RV suggests that a change in energy metabolism and 
mitochondrial function is important in reversing RVF.  Targeting mitochondrial function 
pharmacologically may be an important aspect of clinical treatment for PAH. 
 
In addition, signaling for fibrosis and integrin-like kinase (ILK) were increased in both 
the SU5416/hypoxia RV and the SU5416/hypoxia + carvedilol RV.  TGF-β-mediated 
cardiac fibrosis can be induced by increased pressure afterload[289] and injury[214].  
Similarly, increased pressure or afterload induces expression of rho-kinase (ROCK), 
which induces cardiac hypertrophy[288].  These pathways may be involved in 
mechanisms of cardiac compensation.  Conversely, the SU5416/hypoxia RV and 
SU5416/hypoxia + carvedilol RV also show the same expression pattern for 
downregulated pathways, including protein ubiquitination and ERK/MAPK signaling.  
Without protein ubquitination pathway, pro-apoptotic proteins accumulate in the 
RV[314].  ERK signaling induces adaptive hypertrophic responses, such as 
cardiomyocyte growth and cytoskeletal rearrangement[456-458].  ERK signaling can also 
prevent myocardial damage, as is evident from studies of pre-ischemic conditioning[459].  
Although these pathways may be maladaptive, changes in expression may or may not be 
required for “beneficial effects” of carvedilol on the overall function of the RV. 
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 Carvedilol treatment of the failing RV also affected the expression of genes that were 
previously examined.  mRNA expression of Ang1, Add3, apelin, and HIF-2α returned 
towards normal expression levels in the carvedilol-treated RV.  However, Aqp1, BNP, 
and Klf5 increased in expression further above normal RV and failing RV levels with 
carvedilol treatment.  However, carvedilol had no apparent effect on changing serum 
cytokine levels from those observed in the SU5416/hypoxia animals, although there was 
a significant increase in the expression of IL-1β and VEGF from normal serum levels. 
 
Although our data demonstrate that carvedilol changes gene expression in the failing RV, 
they are not descriptive of the mechanism by which carvedilol acts.  Carvedilol acts as an 
α1/β1/β2-adrenergic receptor blocker, but also has antioxidant properties.  Whether 
carvedilol-induced gene expression changes occur mainly via adrenergic receptor activity 
or via antioxidant activity in the failing heart has yet to be examined.  In addition, the 
adrenergic receptors may signal either through G protein-coupled receptors to promote 
anti-apoptotic and mitogenic effects[383-386] or via β-arrestin to promote 
cardioprotective signals in response to mechanical stress[387].  The role of these two 
signaling pathways could be elucidated in future research by using siRNA to β-arrestin in 
the rat or by using β-arrestin knockout mice.  We have demonstrated here that carvedilol 
treatment of normal rats is associated with increased mRNA expression of angiogeneic 
and growth factor genes.  If these are a consequence of β-arrestin signaling rather than 
signaling through G-protein coupled receptors, there should be no increase in mRNA 
expression of those genes in animals lacking β-arrestin. 
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 The data described here characterize a set of expressed genes that distinguishes between 
the normal RV and failing RV and between a failing RV and a carvedilol-treated RV.  
While changes in specific genes and pathways have been characterized, these changes are 
by no means a complete list of all of the genes associated with failure and recovery from 
RVF.  In addition, it is unclear whether the genes and pathways described after carvedilol 
treatment are directly responsible for the functional improvement seen in the RV or are a 
consequence of functional RV improvement.  Further examination of the present data set 
as well as time course studies to characterize the transition phase from compensated 
hypertrophy to RVF are necessary to more rigorously describe the mechanisms governing 
failure and recovery. 
 
Although these data describe differences in the gene expression pattern between the 
normal, hypertrophies, failing, and treated RV, they are derived from an animal model of 
pulmonary hypertension (PH).  As such, the same changes may or may not be present in 
other animal models of PH or in human heart tissue samples.  These data may serve as 
the basis and reference for comparison to other animal models and to heart tissue samples 
from patients with PAH.  Correlating these data with human sample data will be 
important for developing therapeutic strategies for human PAH. 
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Appendix A: Probes identified by prediction analysis with 100% across LOOCV 
# of 
Probes Gene Name Description 
1 40060 Rattus norvegicus septin 4 (Sept4), mRNA [NM_001011893] 
1 A_44_P105213 Unknown 
1 A_44_P314231 Unknown 
1 A_44_P384688 Unknown 
1 A_44_P431358 Unknown 
1 A_44_P459484 Unknown 
1 A_44_P546267 Unknown 
1 A_44_P575763 Unknown 
1 A_44_P704947 Unknown 
1 A_44_P729183 Unknown 
1 A_44_P921710 Unknown 
1 A_44_P944159 Unknown 
1 AA900990 
AA900990 UI-R-E0-dj-f-04-0-UI.s1 UI-R-E0 Rattus norvegicus cDNA 
clone UI-R-E0-dj-f-04-0-UI 3' similar to gi [AA900990] 
1 AA963280 
AA963280 UI-R-E1-gh-h-04-0-UI.s1 UI-R-E1 Rattus norvegicus cDNA 
clone UI-R-E1-gh-h-04-0-UI 3', mRNA sequence [AA963280] 
1 Aars 
PREDICTED: Rattus norvegicus alanyl-tRNA synthetase (Aars), 
mRNA [XM_214690] 
1 Abtb2 
Rattus norvegicus ankyrin repeat and BTB (POZ) domain containing 2 
(Abtb2), mRNA [NM_134403] 
2 Acaa1 
Rattus norvegicus acetyl-Coenzyme A acyltransferase 1 (Acaa1), 
mRNA [NM_012489] 
1 Actn4 Rattus norvegicus actinin alpha 4 (Actn4), mRNA [NM_031675] 
1 Add2 Rattus norvegicus adducin 2 (beta) (Add2), mRNA [NM_012491] 
1 Afg3l1_predicted 
PREDICTED: Rattus norvegicus AFG3(ATPase family gene 3)-like 1 
(yeast) (predicted) (Afg3l1_predicted), mRNA [XM_341714] 
1 AI010816 
EST205267 Normalized rat muscle, Bento Soares Rattus sp. cDNA 
clone RMUAS84 3' end, mRNA sequence [AI010816] 
1 AI043579 
UI-R-C1-jt-e-10-0-UI.s1 UI-R-C1 Rattus norvegicus cDNA clone UI-R-
C1-jt-e-10-0-UI 3', mRNA sequence [AI043579] 
1 AI045508 
AI045508 UI-R-C1-kj-g-08-0-UI.s1 UI-R-C1 Rattus norvegicus cDNA 
clone UI-R-C1-kj-g-08-0-UI 3', mRNA sequence [AI045508] 
1 AI229412 
AI229412 EST226107 Normalized rat embryo, Bento Soares Rattus sp. 
cDNA clone REMCG02 3' end, mRNA sequence [AI229412] 
1 Akap2 
Rattus norvegicus A kinase (PRKA) anchor protein 2 (Akap2), mRNA 
[NM_001011974] 
1 Akt1 
Rattus norvegicus thymoma viral proto-oncogene 1 (Akt1), mRNA 
[NM_033230] 
1 Aldoa Rattus norvegicus aldolase A (Aldoa), mRNA [NM_012495] 
1 Aldoal1 
Rattus norvegicus aldolase A-like 1 (Aldoal1), mRNA 
[NM_001013943] 
1 Anp32b 
Rattus norvegicus acidic nuclear phosphoprotein 32 family, member B 
(Anp32b), mRNA [NM_131911] 
1 Anxa5 Rattus norvegicus annexin A5 (Anxa5), mRNA [NM_013132] 
10 Aqp1 Rattus norvegicus aquaporin 1 (Aqp1), mRNA [NM_012778] 
1 Arhgap21_predicted 
PREDICTED: Rattus norvegicus Rho GTPase activating protein 21 
(predicted) (Arhgap21_predicted), mRNA [XM_225628] 
251 
1 Arpc1b 
Rattus norvegicus actin related protein 2/3 complex, subunit 1B 
(Arpc1b), mRNA [NM_019289] 
1 Atox1 
Rattus norvegicus ATX1 (antioxidant protein 1) homolog 1 (yeast) 
(Atox1), mRNA [NM_053359] 
1 Atp2b2 
Rattus norvegicus ATPase, Ca++ transporting, plasma membrane 2 
(Atp2b2), mRNA [NM_012508] 
1 AW141147 
AW141147 EST291183 Normalized rat brain, Bento Soares Rattus sp. 
cDNA clone RGIBE08 5' end similar to C-1, putative transcription 
factor, mRNA sequence [AW141147] 
1 AW142959 
AW142959 EST293251 Normalized rat kidney, Bento Soares Rattus sp. 
cDNA clone RGIBA46 5' end, mRNA sequence [AW142959] 
1 AW143194 
AW143194 EST293490 Normalized rat brain, Bento Soares Rattus sp. 
cDNA clone RGIBF39 5' end, mRNA sequence [AW143194] 
1 AW143900 
AW143900 EST294196 Normalized rat embryo, Bento Soares Rattus 
sp. cDNA clone RGICC51 5' end, mRNA sequence [AW143900] 
1 AW144158 
AW144158 EST294454 Normalized rat ovary, Bento Soares Rattus sp. 
cDNA clone RGICK08 5' end, mRNA sequence [AW144158] 
1 AW144236 
AW144236 EST294532 Normalized rat ovary, Bento Soares Rattus sp. 
cDNA clone RGICN59 5' end, mRNA sequence [AW144236] 
1 AW253396 
AW253396 UI-R-BJ0-aen-d-08-0-UI.s1 UI-R-BJ0 Rattus norvegicus 
cDNA clone UI-R-BJ0-aen-d-08-0-UI 3', mRNA sequence 
[AW253396] 
1 AW433572 
AW433572 UI-R-BJ0p-aez-g-10-0-UI.s1 UI-R-BJ0p Rattus norvegicus 
cDNA clone UI-R-BJ0p-aez-g-10-0-UI 3', mRNA sequence 
[AW433572] 
1 AW529005 
AW529005 UI-R-BT1-aka-a-11-0-UI.s1 UI-R-BT1 Rattus norvegicus 
cDNA clone UI-R-BT1-aka-a-11-0-UI 3', mRNA sequence 
[AW529005] 
1 AW915016 
AW915016 EST346320 Normalized rat ovary, Bento Soares Rattus sp. 
cDNA clone RGIBN51 5' end, mRNA sequence [AW915016] 
1 AW915635 
AW915635 EST346939 Normalized rat embryo, Bento Soares Rattus 
sp. cDNA clone RGICY71 5' end, mRNA sequence [AW915635] 
1 AW916021 
AW916021 EST347325 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIDF02 5' end, mRNA 
sequence [AW916021] 
1 AW917132 
EST348436 Rat gene index, normalized rat, norvegicus, Bento Soares 
Rattus norvegicus cDNA clone RGIDZ63 5' end, mRNA sequence 
[AW917132] 
1 AW917894 
AW917894 EST349198 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIEJ82 5' end, mRNA 
sequence [AW917894] 
1 AW918202 
AW918202 EST349506 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIEN76 5' end, mRNA 
sequence [AW918202] 
1 AW918729 
AW918729 EST350033 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIEX24 5' end, mRNA 
sequence [AW918729] 
1 AW919096 
AW919096 EST350400 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIFC69 5' end, mRNA 
sequence [AW919096] 
1 AW919109 
AW919109 EST350413 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIFC89 5' end, mRNA 
sequence [AW919109] 
252 
1 AW920343 
AW920343 EST351647 Rat gene index, normalized rat, norvegicus, 
Bento Soares Rattus norvegicus cDNA clone RGIGU32 5' end, mRNA 
sequence [AW920343] 
1 Bat1a 
Rattus norvegicus HLA-B-associated transcript 1A (Bat1a), mRNA 
[NM_133300] 
1 Bat3 
Rattus norvegicus HLA-B-associated transcript 3 (Bat3), transcript 
variant 2, mRNA [NM_053609] 
1 Bcam 
Rattus norvegicus basal cell adhesion molecule (Bcam), mRNA 
[NM_031752] 
1 BF395647 
BF395647 UI-R-CM0-bjp-e-07-0-UI.s1 UI-R-CM0 Rattus norvegicus 
cDNA clone UI-R-CM0-bjp-e-07-0-UI 3', mRNA sequence [BF395647] 
1 BF404842 
BF404842 UI-R-CA1-bic-d-02-0-UI.s1 UI-R-CA1 Rattus norvegicus 
cDNA clone UI-R-CA1-bic-d-02-0-UI 3', mRNA sequence [BF404842] 
1 BF563221 
BF563221 UI-R-BO1-ajh-a-06-0-UI.r1 UI-R-BO1 Rattus norvegicus 
cDNA clone UI-R-BO1-ajh-a-06-0-UI 5', mRNA sequence [BF563221] 
1 BG376818 
UI-R-CA1-blh-e-03-0-UI.s1 UI-R-CA1 Rattus norvegicus cDNA clone 
UI-R-CA1-blh-e-03-0-UI 3', mRNA sequence [BG376818] 
1 BI274747 
BI274747 UI-R-CX0-bxd-e-07-0-UI.s1 UI-R-CX0 Rattus norvegicus 
cDNA clone UI-R-CX0-bxd-e-07-0-UI 3', mRNA sequence [BI274747] 
1 BI294916 
BI294916 UI-R-DK0-ced-f-05-0-UI.s1 UI-R-DK0 Rattus norvegicus 
cDNA clone UI-R-DK0-ced-f-05-0-UI 3', mRNA sequence [BI294916] 
1 BM389289 
BM389289 UI-R-DZ0-cko-f-18-0-UI.s1 NCI_CGAP_DZ0 Rattus 
norvegicus cDNA clone IMAGE:7338356 3', mRNA sequence 
[BM389289] 
1 BM986517 
BM986517 EST594111 Rat gene index, normalized rat, norvegicus 
Rattus norvegicus cDNA clone RGOAC85 3' end similar to 
diphosphoinositol polyphosphate phosphohydrolase, mRNA sequence 
[BM986517] 
1 BQ210430 
UI-R-DY1-coi-g-14-0-UI.s1 UI-R-DY1 Rattus norvegicus cDNA clone 
UI-R-DY1-coi-g-14-0-UI 3', mRNA sequence [BQ210430] 
1 Bsg Rattus norvegicus basigin (Bsg), mRNA [NM_012783] 
2 Bst2 
Rattus norvegicus bone marrow stromal cell antigen 2 (Bst2), mRNA 
[NM_198134] 
1 C1r 
C1r protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q4G030] 
[ENSRNOT00000015897] 
1 Casp4 
Rattus norvegicus caspase 4, apoptosis-related cysteine peptidase 
(Casp4), mRNA [NM_053736] 
1 CB606450 
CB606450 AMGNNUC:TRXP1-00001-B1-A trxp1 (10556) Rattus 
norvegicus cDNA clone trxp1-00001-b1 5', mRNA sequence 
[CB606450] 
1 CB615257 
AMGNNUC:SRCS1-00113-G5-A srcs1 (10883) Rattus norvegicus 
cDNA clone srcs1-00113-g5 5', mRNA sequence [CB615257] 
1 CB759117 
AMGNNUC:SRPG2-00040-D8-A srpg2 (10238) Rattus norvegicus 
cDNA clone srpg2-00040-d8 5', mRNA sequence [CB759117] 
1 Ccnd2 Rattus norvegicus cyclin D2 (Ccnd2), mRNA [NM_022267] 
1 Cd63 Rattus norvegicus CD63 antigen (Cd63), mRNA [NM_017125] 
1 Cdc42ep2 
Rattus norvegicus CDC42 effector protein (Rho GTPase binding) 2 
(Cdc42ep2), mRNA [NM_001009689] 
4 Cdkn1a 
Rattus norvegicus cyclin-dependent kinase inhibitor 1A (Cdkn1a), 
mRNA [NM_080782] 
1 Cebpd 
Rattus norvegicus CCAAT/enhancer binding protein (C/EBP), delta 
(Cebpd), mRNA [NM_013154] 
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1 CF107866 
Shultzomica01117 Rat lung airway and parenchyma cDNA libraries 
Rattus norvegicus cDNA clone NA9257 5', mRNA sequence 
[CF107866] 
1 CF111029 
Shultzomica04280 Rat lung airway and parenchyma cDNA libraries 
Rattus norvegicus cDNA clone Contig3797 5', mRNA sequence 
[CF111029] 
1 CF111207 
Shultzomica04458 Rat lung airway and parenchyma cDNA libraries 
Rattus norvegicus cDNA clone Contig3944 5', mRNA sequence 
[CF111207] 
1 Chrac1_predicted 
PREDICTED: Rattus norvegicus chromatin accessibility complex 1 
(predicted) (Chrac1_predicted), mRNA [XM_235400] 
1 Cilp_predicted 
PREDICTED: Rattus norvegicus cartilage intermediate layer protein, 
nucleotide pyrophosphohydrolase (predicted) (Cilp_predicted), mRNA 
[XM_236348] 
1 Ciz1_predicted 
PREDICTED: Rattus norvegicus CDKN1A interacting zinc finger 
protein 1 (predicted) (Ciz1_predicted), mRNA [XM_216034] 
1 Col4a2_predicted 
PREDICTED: Rattus norvegicus procollagen, type IV, alpha 2 
(predicted) (Col4a2_predicted), mRNA [XM_225043] 
1 COX1 
Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Cytochrome c oxidase 
polypeptide I). [Source:Uniprot/SWISSPROT;Acc:P05503] 
[ENSRNOT00000050156] 
1 CR469283 
CR469283 Rat pBluescript Lion Rattus norvegicus cDNA clone 
LIONp463E09157 3', mRNA sequence [CR469283] 
1 Creld1 
Rattus norvegicus cysteine-rich with EGF-like domains 1 (Creld1), 
mRNA [NM_001024783] 
1 Crim1_predicted 
PREDICTED: Rattus norvegicus cysteine-rich motor neuron 1 
(predicted) (Crim1_predicted), mRNA [XM_233798] 
1 Cst3 Rattus norvegicus cystatin C (Cst3), mRNA [NM_012837] 
1 Cstb Rattus norvegicus cystatin B (Cstb), mRNA [NM_012838] 
10 Ctgf 
Rattus norvegicus connective tissue growth factor (Ctgf), mRNA 
[NM_022266] 
1 CV102701 
AGENCOURT_31523961 NIH_MGC_270 Rattus norvegicus cDNA 
clone IMAGE:7446235 5', mRNA sequence [CV102701] 
6 Cyp1a1 
Rattus norvegicus cytochrome P450, family 1, subfamily a, polypeptide 
1 (Cyp1a1), mRNA [NM_012540] 
1 Cyp27a1 
Rattus norvegicus cytochrome P450, family 27, subfamily a, 
polypeptide 1 (Cyp27a1), mRNA [NM_178847] 
1 Dbnl Rattus norvegicus drebrin-like (Dbnl), mRNA [NM_031352] 
1 Dctn1 Rattus norvegicus dynactin 1 (Dctn1), mRNA [NM_024130] 
1 Dhrs4 
Rattus norvegicus dehydrogenase/reductase (SDR family) member 4 
(Dhrs4), mRNA [NM_153315] 
1 Dlx1 
PREDICTED: Rattus norvegicus distal-less homeobox 1 (Dlx1), mRNA 
[XM_230987] 
1 Dnajb5_predicted 
BF558851 UI-R-A1-dv-f-06-0-UI.r1 UI-R-A1 Rattus norvegicus cDNA 
clone UI-R-A1-dv-f-06-0-UI 5', mRNA sequence [BF558851] 
1 Dst_predicted 
PREDICTED: Rattus norvegicus dystonin (predicted) (Dst_predicted), 
mRNA [XM_237042] 
1 DV718416 
RVL9000 Wackym-Soares normalized rat vestibular cDNA library 
Rattus norvegicus cDNA 5', mRNA sequence [DV718416] 
1 DV722942 
RVL14623 Wackym-Soares normalized rat vestibular cDNA library 
Rattus norvegicus cDNA 5', mRNA sequence [DV722942] 
1 DV728620 
RVL21285 Wackym-Soares normalized rat vestibular cDNA library 
Rattus norvegicus cDNA 5', mRNA sequence [DV728620] 
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1 Dvl1 
Rattus norvegicus dishevelled, dsh homolog 1 (Drosophila) (Dvl1), 
mRNA [NM_031820] 
1 Edg2 
Rattus norvegicus endothelial differentiation, lysophosphatidic acid G-
protein-coupled receptor, 2 (Edg2), mRNA [NM_053936] 
1 Edn2 Rattus norvegicus endothelin 2 (Edn2), mRNA [NM_012549] 
1 Eef2 
Rattus norvegicus eukaryotic translation elongation factor 2 (Eef2), 
mRNA [NM_017245] 
1 Eef2k 
Rattus norvegicus eukaryotic elongation factor-2 kinase (Eef2k), mRNA 
[NM_012947] 
1 Egln3 
Rattus norvegicus EGL nine homolog 3 (C. elegans) (Egln3), mRNA 
[NM_019371] 
6 Eif4b 
Rattus norvegicus eukaryotic translation initiation factor 4B (Eif4b), 
mRNA [NM_001008324] 
1 Eif4g3_predicted 
PREDICTED: Rattus norvegicus eukaryotic translation initiation factor 
4 gamma, 3 (predicted) (Eif4g3_predicted), mRNA [XM_216563] 
1 Eml2 
Rattus norvegicus echinoderm microtubule associated protein like 2 
(Eml2), mRNA [NM_138921] 
1 Enah 
Rattus norvegicus enabled homolog (Drosophila) (Enah), mRNA 
[NM_001012150] 
1 Eno1 Rattus norvegicus enolase 1, alpha (Eno1), mRNA [NM_012554] 
1 ENSRNOT00000000707 
Myristoylated alanine-rich C-kinase substrate (MARCKS) (Protein 
kinase C substrate 80 kDa protein). 
[Source:Uniprot/SWISSPROT;Acc:P30009] [ENSRNOT00000000707] 
1 ENSRNOT00000005432 Unknown 
1 ENSRNOT00000007351 
PREDICTED: Rattus norvegicus similar to Small nuclear 
ribonucleoprotein F (snRNP-F) (Sm protein F) (Sm-F) (SmF) 
(LOC680737), mRNA [XM_001058626] 
1 ENSRNOT00000008057 
PREDICTED: Rattus norvegicus similar to small unique nuclear 
receptor co-repressor (predicted) (RGD1560600_predicted), mRNA 
[XM_214099] 
1 ENSRNOT00000009344 
PREDICTED: Rattus norvegicus similar to Calsequestrin-1 precursor 
(Calsequestrin, skeletal muscle isoform) (LOC686019), mRNA 
[XM_001063867] 
1 ENSRNOT00000013672 
PREDICTED: Rattus norvegicus similar to proline arginine rich coiled 
coil 1, transcript variant 5 (LOC681287), mRNA [XM_001058826] 
1 ENSRNOT00000015113 
LOC501069 protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q5U4E6] [ENSRNOT00000015113] 
1 ENSRNOT00000017043 
PREDICTED: Rattus norvegicus similar to mKIAA1604 protein 
(predicted) (RGD1565385_predicted), mRNA [XM_342453] 
2 ENSRNOT00000017422 
Mago-nashi-like proliferation-associated protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q27W02] 
[ENSRNOT00000017422] 
1 ENSRNOT00000023601 
Memory related protein-1 (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q78E25] [ENSRNOT00000023601] 
1 ENSRNOT00000023696 
E3 ubiquitin-protein ligase MIB2 (EC 6.3.2.-) (Mind bomb homolog 2) 
(RBSC-skeletrophin/dystrophin-like polypeptide). 
[Source:Uniprot/SWISSPROT;Acc:Q68LP1] 
[ENSRNOT00000023696] 
1 ENSRNOT00000028121 Unknown 
1 ENSRNOT00000029141 
similar to Fructose-bisphosphate aldolase A (Muscle-type aldolase) 
(Aldolase 1) (LOC290761), mRNA 
[Source:RefSeq_dna;Acc:XR_007988] [ENSRNOT00000029141] 
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1 ENSRNOT00000037887 
Alpha-mannosidase 2 (EC 3.2.1.114) (Alpha-mannosidase II) 
(Mannosyl- oligosaccharide 1,3-1,6-alpha-mannosidase) (MAN II) 
(Golgi alpha- mannosidase II) (Mannosidase alpha class 2A member 1) 
(Fragment). [Source:Uniprot/SWISSPROT;Acc:P28494]... 
1 ENSRNOT00000040029 
PREDICTED: Rattus norvegicus eukaryotic translation initiation factor 
4 gamma, 1 (Eif4g1), mRNA [XM_213569] 
1 ENSRNOT00000041388 Unknown 
1 ENSRNOT00000041594 Unknown 
1 ENSRNOT00000048684 
similar to RIKEN cDNA 5031410I06 (LOC686886), mRNA 
[Source:RefSeq_dna;Acc:XR_009064] [ENSRNOT00000048684] 
1 ENSRNOT00000051257 
PREDICTED: Rattus norvegicus dysferlin (predicted) (Dysf_predicted), 
mRNA [XM_232123] 
1 ENSRNOT00000055469 
similar to nemo like kinase (LOC365949), mRNA 
[Source:RefSeq_dna;Acc:XR_009210] [ENSRNOT00000055469] 
1 ENSRNOT00000056257 
LOC360570 protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q3B8R3] [ENSRNOT00000056257] 
1 ENSRNOT00000057386 
Col4a1 protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q5FWY9] 
[ENSRNOT00000057386] 
1 ENSRNOT00000058206 
TSC22 domain family protein 1 (Transforming growth factor beta-1- 
induced transcript 4 protein) (Regulatory protein TSC-22) (TGFB- 
stimulated clone 22 homolog). 
[Source:Uniprot/SWISSPROT;Acc:P62501] [ENSRNOT00000058206] 
1 Fads3 Rattus norvegicus fatty acid desaturase 3 (Fads3), mRNA [NM_173137] 
3 Fdps 
Rattus norvegicus farensyl diphosphate synthase (Fdps), mRNA 
[NM_031840] 
2 Fhl1 
Rattus norvegicus four and a half LIM domains 1 (Fhl1), transcript 
variant 2, mRNA [NM_145669] 
1 Fkbp5 
Rattus norvegicus FK506 binding protein 5 (Fkbp5), mRNA 
[NM_001012174] 
1 Fkrp 
Rattus norvegicus fukutin related protein (Fkrp), mRNA 
[NM_001025678] 
1 Fliih 
Rattus norvegicus flightless I homolog (Drosophila) (Fliih), mRNA 
[NM_001008279] 
1 Fln29 
Fln29 protein. [Source:Uniprot/SPTREMBL;Acc:Q5M806] 
[ENSRNOT00000033984] 
1 Flnc_predicted 
PREDICTED: Rattus norvegicus filamin C, gamma (actin binding 
protein 280) (predicted) (Flnc_predicted), mRNA [XM_342653] 
1 Flot1 Rattus norvegicus flotillin 1 (Flot1), mRNA [NM_022701] 
1 Ftl1 Rattus norvegicus ferritin light chain 1 (Ftl1), mRNA [NM_022500] 
1 Fts Rattus norvegicus fused toes (Fts), mRNA [NM_001011926] 
1 Gadd45a 
Rattus norvegicus growth arrest and DNA-damage-inducible 45 alpha 
(Gadd45a), mRNA [NM_024127] 
2 Gas6 
Rattus norvegicus growth arrest specific 6 (Gas6), mRNA 
[NM_057100] 
1 Gata4 
Rattus norvegicus GATA binding protein 4 (Gata4), mRNA 
[NM_144730] 
1 Gcdh_predicted 
Rattus norvegicus similar to glutaryl-CoA dehydrogenase precursor 
(LOC364975), mRNA [XM_344744] 
1 Gchfr 
Rattus norvegicus GTP cyclohydrolase I feedback regulator (Gchfr), 
mRNA [NM_133595] 
1 Gdnf 
Rattus norvegicus glial cell line derived neurotrophic factor (Gdnf), 
mRNA [NM_019139] 
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1 Gng11 
Rattus norvegicus guanine nucleotide binding protein (G protein), 
gamma 11 (Gng11), mRNA [NM_022396] 
1 Gnpda2_predicted 
PREDICTED: Rattus norvegicus glucosamine-6-phosphate deaminase 2 
(predicted) (Gnpda2_predicted), mRNA [XM_214029] 
1 Gorasp1 
Rattus norvegicus golgi reassembly stacking protein 1 (Gorasp1), 
mRNA [NM_019385] 
1 Gpc1 Rattus norvegicus glypican 1 (Gpc1), mRNA [NM_030828] 
1 Gpsm1 
Rattus norvegicus G-protein signalling modulator 1 (AGS3-like, C. 
elegans) (Gpsm1), mRNA [NM_144745] 
1 Gyg1 Rattus norvegicus glycogenin 1 (Gyg1), mRNA [NM_031043] 
1 Gzmc Rattus norvegicus granzyme C (Gzmc), mRNA [NM_134332] 
1 H2-T18 
Rattus norvegicus histocompatibility 2, T region locus 18 (H2-T18), 
mRNA [NM_001002821] 
3 Hcrt Rattus norvegicus hypocretin (Hcrt), mRNA [NM_013179] 
1 Hdac5 
Rattus norvegicus histone deacetylase 5, mRNA (cDNA clone 
IMAGE:7301599), partial cds. [BC086431] 
1 Hip1 
HIP1 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8VHU1] 
[ENSRNOT00000001967] 
1 Hipk2_predicted 
Rattus norvegicus similar to nuclear body associated kinase 1a 
(LOC362342), mRNA [XM_342662] 
1 Hk1 Rattus norvegicus hexokinase 1 (Hk1), mRNA [NM_012734] 
1 Hmgb1 
Rattus norvegicus high mobility group box 1 (Hmgb1), mRNA 
[NM_012963] 
1 Hps6 
Rattus norvegicus Hermansky-Pudlak syndrome 6 (Hps6), mRNA 
[NM_181432] 
1 Hrmt1l2 
Rattus norvegicus heterogeneous nuclear ribonucleoproteins 
methyltransferase-like 2 (S. cerevisiae) (Hrmt1l2), mRNA 
[NM_024363] 
1 Hspa12b_predicted 
PREDICTED: Rattus norvegicus heat shock protein 70kDa 12B 
(predicted) (Hspa12b_predicted), mRNA [XM_230610] 
1 Hspa5bp1 
Rattus norvegicus heat shock 70kDa protein 5 binding protein 1 
(Hspa5bp1), mRNA [NM_178021] 
1 Hspb3 
Rattus norvegicus heat shock 27kDa protein 3 (Hspb3), mRNA 
[NM_031750] 
1 Hspca 
Rattus norvegicus heat shock protein 1, alpha (Hspca), mRNA 
[NM_175761] 
1 Hspcb 
Rattus norvegicus heat shock 90kDa protein 1, beta (Hspcb), mRNA 
[NM_001004082] 
1 Hspd1 
Rattus norvegicus heat shock protein 1 (chaperonin) (Hspd1), mRNA 
[NM_022229] 
1 Idh3B 
Rattus norvegicus isocitrate dehydrogenase 3 (NAD+) beta (Idh3B), 
mRNA [NM_053581] 
1 Ilvbl_predicted 
PREDICTED: Rattus norvegicus ilvB (bacterial acetolactate synthase)-
like (predicted) (Ilvbl_predicted), mRNA [XM_343174] 
1 Inha Rattus norvegicus inhibin alpha (Inha), mRNA [NM_012590] 
1 Inpp5a_predicted 
Rattus norvegicus similar to Type I inositol-1,4,5-trisphosphate 5-
phosphatase (5PTASE) (LOC365382), mRNA [XM_344971] 
2 Ipo13 Rattus norvegicus importin 13 (Ipo13), mRNA [NM_053778] 
4 Itgb1 
Rattus norvegicus integrin beta 1 (fibronectin receptor beta) (Itgb1), 
mRNA [NM_017022] 
1 Josd3 
Rattus norvegicus Josephin domain containing 3 (Josd3), mRNA 
[NM_001014207] 
1 Ka15 Rattus norvegicus type I keratin KA15 (Ka15), mRNA 
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[NM_001004022] 
1 Ke2 
Rattus norvegicus MHC class II region expressed gene KE2 (Ke2), 
mRNA [NM_212506] 
1 Kif3b_predicted 
PREDICTED: Rattus norvegicus kinesin family member 3B (predicted) 
(Kif3b_predicted), mRNA [XM_215883] 
1 Klf9 Rattus norvegicus Kruppel-like factor 9 (Klf9), mRNA [NM_057211] 
1 Krt1-18 
Rattus norvegicus keratin complex 1, acidic, gene 18 (Krt1-18), mRNA 
[NM_053976] 
1 Lamb2 Rattus norvegicus laminin, beta 2 (Lamb2), mRNA [NM_012974] 
1 Ldhd 
Rattus norvegicus lactate dehydrogenase D (Ldhd), mRNA 
[NM_001008893] 
1 LOC288526 
LOC288526 protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q496Y9] [ENSRNOT00000037829] 
1 LOC289517 
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phospho-
D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) 
(LOC289517), mRNA [XR_008796] 
1 LOC290721 
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phospho-
D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) 
(LOC290721), mRNA [XR_005691] 
1 LOC291205 
PREDICTED: Rattus norvegicus similar to 60 kDa heat shock protein, 
mitochondrial precursor (Hsp60) (60 kDa chaperonin) (CPN60) (Heat 
shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) (HSP-65) 
(LOC291205), mRNA [XR_007380] 
1 LOC294154 
Rattus norvegicus similar to chromosome 6 open reading frame 106 
isoform a (LOC294154), mRNA [NM_001039607] 
1 LOC297826 
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phospho-
D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) 
(LOC297826), mRNA [XM_001066983] 
1 LOC298606 
Rattus norvegicus similar to RIKEN cDNA 1810012H11 (LOC298606), 
mRNA [NM_001013936] 
1 LOC308950 
PREDICTED: Rattus norvegicus similar to heat shock protein 1 
(chaperonin) (LOC308950), mRNA [XR_009038] 
1 LOC309169 Rattus norvegicus tangerin (LOC309169), mRNA [NM_001025117] 
1 LOC361399 
Rattus norvegicus similar to autoantigen (LOC361399), mRNA 
[NM_001033068] 
1 LOC364556 Rattus norvegicus Ab1-351 mRNA, complete cds. [AY325145] 
1 LOC365354 
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phospho-
D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) 
(LOC365354), mRNA [XR_009200] 
1 LOC365511 
PREDICTED: Rattus norvegicus similar to zinc finger protein 296 
(LOC365511), mRNA [XM_345065] 
1 LOC499022 
Quaking protein. [Source:Uniprot/SWISSPROT;Acc:Q91XU1] 
[ENSRNOT00000023304] 
1 LOC499778 
PREDICTED: Rattus norvegicus similar to 60S ribosomal protein L7a 
(LOC499778), mRNA [XR_006491] 
1 LOC499779 
Rattus norvegicus similar to RIKEN cDNA 2900010J23, mRNA 
(cDNA clone MGC:105672 IMAGE:7304460), complete cds. 
[BC082799] 
1 LOC499856 
Rattus norvegicus hypothetical protein LOC499856 (LOC499856), 
mRNA [NM_001025042] 
1 LOC679923 
PREDICTED: Rattus norvegicus similar to voltage-dependent anion 
channel 1 (LOC679923), mRNA [XM_001054981] 
1 LOC680319 
PREDICTED: Rattus norvegicus hypothetical protein LOC680319 
(LOC680319), mRNA [XM_001056630] 
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1 LOC686892 
Muscleblind-like protein BLES04 (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q8CIQ0] [ENSRNOT00000014315] 
1 LOC690516 
PREDICTED: Rattus norvegicus similar to Smad ubiquitination 
regulatory factor 1 isoform 2 (LOC690516), mRNA [XM_001074660] 
1 Maoa 
Amine oxidase [flavin-containing] A (EC 1.4.3.4) (Monoamine oxidase 
type A) (MAO-A). [Source:Uniprot/SWISSPROT;Acc:P21396] 
[ENSRNOT00000003910] 
1 Mapk12 
Rattus norvegicus mitogen-activated protein kinase 12 (Mapk12), 
mRNA [NM_021746] 
1 Mapk14 
Rattus norvegicus p38 mitogen activated protein kinase mRNA, 
complete cds. [U73142] 
1 Mbd3_predicted 
PREDICTED: Rattus norvegicus methyl-CpG binding domain protein 3 
(predicted) (Mbd3_predicted), mRNA [XM_343162] 
1 MGC109491 
Rattus norvegicus similar to 1110007F12Rik protein (MGC109491), 
mRNA [NM_001009709] 
1 MGC116197 
Rattus norvegicus similar to RIKEN cDNA 1700001E04 
(MGC116197), mRNA [NM_001025755] 
1 MGC94736 
Rattus norvegicus similar to hypothetical protein MGC35097 
(MGC94736), mRNA [NM_001007685] 
1 Msc_predicted 
RVL633 Wackym-Soares normalized rat vestibular cDNA library 
Rattus norvegicus cDNA 5', mRNA sequence [CX569607] 
1 Mtch1 
Rattus norvegicus mitochondrial carrier homolog 1 (C. elegans), mRNA 
(cDNA clone IMAGE:7377090), partial cds. [BC098813] 
1 Mvp Rattus norvegicus major vault protein (Mvp), mRNA [NM_022715] 
1 Myd116 
Rattus norvegicus myeloid differentiation primary response gene 116 
(Myd116), mRNA [NM_133546] 
1 Myh14 
Putative myosin IIC (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q9EPH4] [ENSRNOT00000027132] 
1 Nck1_predicted 
PREDICTED: Rattus norvegicus non-catalytic region of tyrosine kinase 
adaptor protein 1 (predicted) (Nck1_predicted), mRNA [XM_217246] 
1 Ncl Rattus norvegicus nucleolin (Ncl), mRNA [NM_012749] 
1 Neu1 Rattus norvegicus neuraminidase 1 (Neu1), mRNA [NM_031522] 
1 Nppb 
Rattus norvegicus natriuretic peptide precursor type B (Nppb), mRNA 
[NM_031545] 
1 Nrxn1 Rattus norvegicus neurexin 1 (Nrxn1), mRNA [NM_021767] 
1 Ogt 
Rattus norvegicus O-linked N-acetylglucosamine (GlcNAc) transferase 
(UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl 
transferase) (Ogt), mRNA [NM_017107] 
1 Olr1273_predicted 
Rattus norvegicus olfactory receptor 1273 (predicted) 
(Olr1273_predicted), mRNA [NM_001000458] 
1 Olr1583_predicted 
Rattus norvegicus olfactory receptor 1583 (predicted) 
(Olr1583_predicted), mRNA [NM_001000080] 
1 Olr3_predicted 
Rattus norvegicus olfactory receptor 3 (predicted) (Olr3_predicted), 
mRNA [NM_001000110] 
1 Olr53_predicted 
Rattus norvegicus olfactory receptor 53 (predicted) (Olr53_predicted), 
mRNA [NM_001001008] 
1 Olr778_predicted 
Rattus norvegicus olfactory receptor 778 (predicted) 
(Olr778_predicted), mRNA [NM_001000607] 
1 Ostf1 
Rattus norvegicus osteoclast stimulating factor 1 (Ostf1), mRNA 
[NM_148892] 
1 Oxnad1_predicted 
PREDICTED: Rattus norvegicus oxidoreductase NAD-binding domain 
containing 1 (predicted) (Oxnad1_predicted), mRNA [XM_224623] 
1 Pabpc4 Pabpc4 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q5I0G7] 
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[ENSRNOT00000056592] 
1 Paf1 
Rattus norvegicus Paf1, RNA polymerase II associated factor, homolog 
(S. cerevisiae) (Paf1), mRNA [NM_001024898] 
1 Pbk_predicted 
Rattus norvegicus PDZ binding kinase (predicted) (Pbk_predicted), 
mRNA [NM_001079937] 
1 Pbxip1 
Rattus norvegicus pre-B-cell leukemia transcription factor interacting 
protein 1, mRNA (cDNA clone IMAGE:7097507) [BC085776] 
1 Pcbp2 
Rattus norvegicus poly(rC) binding protein 2 (Pcbp2), mRNA 
[NM_001013223] 
1 Pcbp3 
Rattus norvegicus poly(rC) binding protein 3 (Pcbp3), mRNA 
[NM_001011945] 
1 Pcgf1 
Rattus norvegicus polycomb group ring finger 1 (Pcgf1), mRNA 
[NM_001007000] 
1 Pdzrn3_predicted 
PDZ domain-containing RING finger protein 3 (Semaphorin 
cytoplasmic domain-associated protein 3) (Protein SEMACAP3). 
[Source:Uniprot/SWISSPROT;Acc:P68907] [ENSRNOT00000008032] 
1 Pex14 
Rattus norvegicus peroxisomal biogenesis factor 14 (Pex14), mRNA 
[NM_172063] 
1 Pik3r2 
Rattus norvegicus phosphatidylinositol 3-kinase, regulatory subunit, 
polypeptide 2 (Pik3r2), mRNA [NM_022185] 
3 Plat 
Rattus norvegicus plasminogen activator, tissue (Plat), mRNA 
[NM_013151] 
1 Plekha3 
Rattus norvegicus pleckstrin homology domain-containing, family A 
(phosphoinositide binding specific) member 3 (Plekha3), mRNA 
[NM_001013077] 
1 Pnpla2_predicted 
PREDICTED: Rattus norvegicus patatin-like phospholipase domain 
containing 2 (predicted) (Pnpla2_predicted), mRNA [XM_341960] 
1 Pop7_predicted 
PREDICTED: Rattus norvegicus processing of precursor 7, 
ribonuclease P family, (S. cerevisiae) (predicted) (Pop7_predicted), 
mRNA [XM_213733] 
1 Por 
Rattus norvegicus P450 (cytochrome) oxidoreductase (Por), mRNA 
[NM_031576] 
1 Postn_predicted 
PREDICTED: Rattus norvegicus periostin, osteoblast specific factor 
(predicted) (Postn_predicted), mRNA [XM_342245] 
1 Pou2f3 
POU domain, class 2, transcription factor 3 (Octamer-binding 
transcription factor 11) (Oct-11) (Transcription factor Skn-1). 
[Source:Uniprot/SWISSPROT;Acc:P42571] [ENSRNOT00000012170] 
1 Ppargc1b 
Rattus norvegicus peroxisome proliferative activated receptor, gamma, 
coactivator 1 beta (Ppargc1b), mRNA [NM_176075] 
1 Ppfia4 
PREDICTED: Rattus norvegicus protein tyrosine phosphatase, receptor 
type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4 
(Ppfia4), mRNA [XM_573454] 
1 Ppp1r9b 
Rattus norvegicus protein phosphatase 1, regulatory subunit 9B 
(Ppp1r9b), mRNA [NM_053474] 
1 Prkaa2 
Rattus norvegicus protein kinase, AMP-activated, alpha 2 catalytic 
subunit (Prkaa2), mRNA [NM_023991] 
1 Prpf38a_predicted 
PREDICTED: Rattus norvegicus PRP38 pre-mRNA processing factor 
38 (yeast) domain containing A (predicted) (Prpf38a_predicted), mRNA 
[XM_216475] 
1 Prss15 Rattus norvegicus protease, serine, 15 (Prss15), mRNA [NM_133404] 
1 Psap Rattus norvegicus prosaposin (Psap), mRNA [NM_013013] 
1 Psme4 
Rattus norvegicus proteasome (prosome, macropain) activator subunit 4, 
mRNA (cDNA clone IMAGE:7128175), complete cds. [BC090326] 
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1 Rab15 
RATRAB15X Sprague-Dawley (clone LRB9) RAB15 mRNA, 
complete cds [M83679] 
1 Rab6ip1_predicted 
PREDICTED: Rattus norvegicus Rab6 interacting protein 1 (predicted) 
(Rab6ip1_predicted), mRNA [XM_219270] 
1 Rad23b 
Rattus norvegicus RAD23b homolog (S. cerevisiae) (Rad23b), mRNA 
[NM_001025275] 
1 Raly 
Rattus norvegicus hnRNP-associated with lethal yellow (Raly), mRNA 
[NM_001011958] 
1 Rasl10b_predicted 
PREDICTED: Rattus norvegicus RAS-like, family 10, member B 
(predicted) (Rasl10b_predicted), mRNA [XM_220782] 
1 Rcsd1_predicted 
PREDICTED: Rattus norvegicus RCSD domain containing 1 
(predicted) (Rcsd1_predicted), mRNA [XM_341147] 
1 RGD1304827 
Rattus norvegicus hypothetical LOC316091 (RGD1304827), mRNA 
[NM_001009437] 
1 RGD1306959_predicted 
PREDICTED: Rattus norvegicus similar to C11orf17 protein (predicted) 
(RGD1306959_predicted), mRNA [XM_341902] 
1 RGD1307395 
PREDICTED: Rattus norvegicus similar to SR rich protein 
(RGD1307395), mRNA [XM_001060221] 
1 RGD1307401 
Rattus norvegicus similar to RIKEN cDNA 2310005P05 
(RGD1307401), mRNA [NM_001014088] 
1 RGD1307772 
RGD1307772 protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q4FZU8] [ENSRNOT00000023710] 
1 RGD1307973_predicted 
PREDICTED: Rattus norvegicus similar to 2900002H16Rik protein 
(predicted) (RGD1307973_predicted), mRNA [XM_222150] 
1 RGD1309054_predicted 
PREDICTED: Rattus norvegicus similar to FKSG26 protein (predicted) 
(RGD1309054_predicted), mRNA [XM_214707] 
1 RGD1309410_predicted 
PREDICTED: Rattus norvegicus LOC363020 (predicted) 
(RGD1309410_predicted), mRNA [XM_347094] 
1 RGD1309471 
Rattus norvegicus similar to hypothetical protein MGC6696 
(RGD1309471), mRNA [NM_001034829] 
1 RGD1309906 
Rattus norvegicus similar to RIKEN cDNA 2310004I24 gene 
(RGD1309906), mRNA [NM_001009246] 
1 RGD1310147_predicted 
PREDICTED: Rattus norvegicus similar to TBC1 domain family, 
member 8; BUB2-like protein 1; vascular Rab-GAP [XM_340793] 
1 RGD1310470 
RGD1310470 protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q5BJL1] [ENSRNOT00000003001] 
1 RGD1311267 
Rattus norvegicus similar to RIKEN cDNA 4931426K16 gene 
(RGD1311267), mRNA [NM_001039024] 
1 RGD1311307 
Rattus norvegicus similar to 1300014I06Rik protein (RGD1311307), 
mRNA [NM_001025719] 
1 RGD1311849_predicted 
PREDICTED: Rattus norvegicus similar to mKIAA1797 protein 
(predicted) (RGD1311849_predicted), mRNA [XM_233144] 
1 RGD1311939_predicted 
PREDICTED: Rattus norvegicus similar to AI115348 protein 
(predicted) (RGD1311939_predicted), mRNA [XM_233838] 
1 RGD1560731_predicted Unknown 
1 RGD1561232_predicted 
PREDICTED: Rattus norvegicus similar to Keratin, type II cytoskeletal 
8 (Cytokeratin 8) (Cytokeratin endo A) (predicted) 
(RGD1561232_predicted), mRNA [XM_001070211] 
1 RGD1561296_predicted 
PREDICTED: Rattus norvegicus similar to cDNA sequence BC022133 
(predicted) (RGD1561296_predicted), mRNA [XM_575607] 
1 RGD1562658_predicted 
PREDICTED: Rattus norvegicus similar to RIKEN cDNA 1700009P17 
(predicted) (RGD1562658_predicted), mRNA [XM_573504] 
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1 RGD1562755_predicted 
PREDICTED: Rattus norvegicus similar to 60S ribosomal protein L23a 
(predicted) (RGD1562755_predicted), mRNA [XM_223453] 
1 RGD1562778_predicted 
Rattus norvegicus similar to tripartite motif protein 50 (predicted) 
(RGD1562778_predicted), mRNA [NM_001077675] 
1 RGD1562936_predicted 
PREDICTED: Rattus norvegicus similar to Heat shock protein HSP 90-
beta (HSP 84) (predicted) (RGD1562936_predicted), mRNA 
[XR_007989] 
1 RGD1563344_predicted 
PREDICTED: Rattus norvegicus similar to OTU domain containing 1 
(predicted) (RGD1563344_predicted), mRNA [XM_574086] 
1 RGD1563524_predicted 
PREDICTED: Rattus norvegicus similar to 60 kDa heat shock protein, 
mitochondrial precursor (Hsp60) (predicted) (RGD1563524_predicted), 
mRNA [XM_229115] 
1 RGD1563532_predicted 
PREDICTED: Rattus norvegicus similar to ankyrin repeat domain 25 
(predicted) (RGD1563532_predicted), mRNA [XM_001077488] 
1 RGD1563990_predicted 
Rattus norvegicus similar to 8430411H09Rik protein (LOC300146), 
mRNA [XM_217014] 
1 RGD1564981_predicted 
PREDICTED: Rattus norvegicus similar to Nonspecific lipid-transfer 
protein, mitochondrial precursor (NSL-TP) (predicted) 
(RGD1564981_predicted), mRNA [XR_008599] 
1 RGD1565022_predicted 
PREDICTED: Rattus norvegicus similar to calmodulin regulated 
spectrin-associated protein 1 (predicted) (RGD1565022_predicted), 
mRNA [XM_216007] 
1 RGD1565350_predicted 
PREDICTED: Rattus norvegicus similar to Shb protein (predicted) 
(RGD1565350_predicted), mRNA [XR_008772] 
1 RGD1565584_predicted 
BG673264 DRNBRC09 Rat DRG Library Rattus norvegicus cDNA 
clone DRNBRC09 5', mRNA sequence [BG673264] 
1 RGD1565602_predicted 
PREDICTED: Rattus norvegicus similar to PLU1 (predicted) 
(RGD1565602_predicted), mRNA [XM_239761] 
1 RGD1566014_predicted 
PREDICTED: Rattus norvegicus similar to Factor VIII associated 
protein (predicted) (RGD1566014_predicted), mRNA [XM_577058] 
1 Rnaseh1 
Rattus norvegicus ribonuclease H1 (Rnaseh1), mRNA 
[NM_001013097] 
2 Rnd1 
Rattus norvegicus Rho family GTPase 1 (Rnd1), mRNA 
[NM_001013222] 
1 Rnf3_predicted 
PREDICTED: Rattus norvegicus ring finger protein 3 (predicted) 
(Rnf3_predicted), mRNA [XM_223729] 
1 Rpa3_predicted 
PREDICTED: Rattus norvegicus replication protein A3 (predicted) 
(Rpa3_predicted), mRNA [XM_216097] 
1 Rpl4 Rattus norvegicus ribosomal protein L4 (Rpl4), mRNA [NM_022510] 
1 Rps25 
UI-R-FS0-cqo-a-09-0-UI.s1 UI-R-FS0 Rattus norvegicus cDNA clone 
UI-R-FS0-cqo-a-09-0-UI 3', mRNA sequence [CA508544] 
1 Rrad 
Rattus norvegicus Ras-related associated with diabetes (Rrad), mRNA 
[NM_053338] 
1 Rsn 
Rattus norvegicus restin (Reed-Steinberg cell-expressed intermediate 
filament-associated protein) (Rsn), mRNA [NM_031745] 
1 RT1-A2 
Rattus norvegicus RT1 class Ia, locus A2 (RT1-A2), mRNA 
[NM_001008829] 
1 RT1-CE1 
Rattus norvegicus RT1 class I, CE1 (RT1-CE1), mRNA 
[NM_001008832] 
1 RT1-CE16 
Rattus norvegicus RT1 class I, CE16 (RT1-CE16), mRNA 
[NM_001008839] 
1 RT1-CE2 
Rattus norvegicus RT1 class I, CE2 (RT1-CE2), mRNA 
[NM_001008840] 
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1 RT1-CE3 
Rattus norvegicus RT1 class I, CE3 (RT1-CE3), mRNA 
[NM_001008841] 
1 RT1-CE4 
Rattus norvegicus RT1 class I, CE4 (RT1-CE4), mRNA 
[NM_001008842] 
1 RT1-CE7 
Rattus norvegicus RT1 class I, CE7 (RT1-CE7), mRNA 
[NM_001008845] 
1 RT1-Cl 
Rattus norvegicus RT1 class Ib, locus Cl (RT1-Cl), mRNA 
[NM_206848] 
1 RT1-Db1 
Rattus norvegicus RT1 class II, locus Db1 (RT1-Db1), mRNA 
[NM_001008884] 
1 S63519 
S63519 Rattus sp. membrane protein-73 mRNA, partial cds; 
mitochondrial gene for mitochondrial product [S63519] 
1 Scly 
Rattus norvegicus selenocysteine lyase (Scly), mRNA 
[NM_001007755] 
1 Serbp1 
Rattus norvegicus Serpine1 mRNA binding protein 1 (Serbp1), mRNA 
[NM_145086] 
1 Serping1 
Rattus norvegicus serine (or cysteine) peptidase inhibitor, clade G, 
member 1 (Serping1), mRNA [NM_199093] 
1 Sfrs14_predicted 
Rattus norvegicus similar to arginine/serine-rich 14 splicing factor 
(LOC361126), mRNA [XM_341413] 
1 Sgcg 
Rattus norvegicus sarcoglycan, gamma (dystrophin-associated 
glycoprotein) (Sgcg), mRNA [NM_001006993] 
1 Slc12a7 
PREDICTED: Rattus norvegicus solute carrier family 12 (potassium 
[XM_001071999] 
1 Slc25a5 
Rattus norvegicus solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 5 (Slc25a5), mRNA 
[NM_057102] 
1 Spag7_predicted 
PREDICTED: Rattus norvegicus sperm associated antigen 7 (predicted) 
(Spag7_predicted), mRNA [XM_220574] 
1 Spg7 
Rattus norvegicus spastic paraplegia 7 homolog (human) (Spg7), 
mRNA [NM_181388] 
1 Spink5_predicted 
PREDICTED: Rattus norvegicus serine protease inhibitor, Kazal type 5 
(predicted) (Spink5_predicted), mRNA [XM_001056195] 
1 Spsb4_predicted PREDICTED: Rattus norvegicus splA [XM_236555] 
1 Srp68_predicted 
Rattus norvegicus similar to signal recognition particle 68kDa 
(LOC363707), mRNA [XM_343986] 
1 Stat3 
Rattus norvegicus signal transducer and activator of transcription 3 
(Stat3), mRNA [NM_012747] 
1 Taf9 
Rattus norvegicus TAF9 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor (Taf9), transcript variant 2, mRNA 
[NM_184048] 
1 Tagln2 Rattus norvegicus transgelin 2 (Tagln2), mRNA [NM_001013127] 
1 TC583295 Unknown 
1 TC584984 Unknown 
1 TC587305 Unknown 
1 TC588650 
Q3UE36_MOUSE (Q3UE36) Bone marrow macrophage cDNA, 
RIKEN full-length enriched library, clone:G530015L18 
product:TFIIIC2 subunit homolog, partial (3%) [TC588650] 
1 TC590435 Unknown 
1 TC595486 
Q2KZQ6_BORA1 (Q2KZQ6) Mannose-6-phosphate isomerase  , 
partial (6%) [TC595486] 
1 TC598739 
Q8LP76_9SOLN (Q8LP76) HT-A protein (Fragment), partial (17%) 
[TC598739] 
1 TC599269 Unknown 
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1 TC599311 Unknown 
1 TC601277 Unknown 
1 TC601898 Q7TQ12_RAT (Q7TQ12) Aa1114, partial (9%) [TC601898] 
1 TC602662 Unknown 
1 TC603711 
Q9DEY1_CYPCA (Q9DEY1) Ovarian fibroin-like substance-1, partial 
(5%) [TC603711] 
1 TC606685 Unknown 
1 TC607876 Unknown 
1 TC610053 Unknown 
1 TC611036 Unknown 
1 TC611785 Unknown 
1 TC613062 
Q6PED9_MOUSE (Q6PED9) Rai16 protein (Fragment), partial (63%) 
[TC613062] 
1 TC616203 
Q33PR9_9GAMM (Q33PR9) Adenylyl cyclase CyaB, partial (10%) 
[TC616203] 
1 TC634117 
Q5NA53_ORYSA (Q5NA53) Glycogenin-like protein, partial (3%) 
[TC634117] 
1 TC635003 Unknown 
1 TC637917 Q5SSP7_MOUSE (Q5SSP7) T-box 2, partial (8%) [TC637917] 
1 TC641622 Unknown 
1 TC642107 Q81D10_BACCR (Q81D10) Phage protein, partial (21%) [TC642107] 
1 TC647139 
Q3C866_9CLOT (Q3C866) Helicase, C-terminal:DEAD/DEAH box 
helicase, N-terminal, partial (4%) [TC647139] 
1 Tcp11 
Rattus norvegicus t-complex protein 11 (mouse) (Tcp11), mRNA 
[NM_001007695] 
1 Tex264 
Rattus norvegicus testis expressed gene 264 homolog (mouse) 
(Tex264), mRNA [NM_001007665] 
1 Tex9_predicted 
PREDICTED: Rattus norvegicus testis expressed gene 9 (predicted) 
(Tex9_predicted), mRNA [XM_001054229] 
1 Tgfb1i4 
Rattus norvegicus transforming growth factor beta 1 induced transcript 
4, mRNA (cDNA clone IMAGE:6918096), complete cds. [BC059146] 
1 Thoc1 Rattus norvegicus THO complex 1 (Thoc1), mRNA [NM_001047850] 
1 Thrap5_predicted 
PREDICTED: Rattus norvegicus thyroid hormone receptor associated 
protein 5 (predicted) (Thrap5_predicted), mRNA [XM_216837] 
2 Tmed9 
Rattus norvegicus transmembrane emp24 protein transport domain 
containing 9 (Tmed9), mRNA [NM_001009703] 
1 Tmem110 
Rattus norvegicus transmembrane protein 110 (Tmem110), mRNA 
[NM_198774] 
1 Tmf1 
Rattus norvegicus TATA element modulatory factor 1 (Tmf1), mRNA 
[NM_053671] 
1 Tollip_predicted 
PREDICTED: Rattus norvegicus toll interacting protein (predicted) 
(Tollip_predicted), mRNA [XM_341961] 
1 Trak2 
Rattus norvegicus trafficking protein, kinesin binding 2 (Trak2), mRNA 
[NM_133560] 
1 Trhde 
Thyrotropin-releasing hormone-degrading ectoenzyme (EC 3.4.19.6) 
(TRH- degrading ectoenzyme) (TRH-DE) (TRH-specific 
aminopeptidase) (Thyroliberinase) (Pyroglutamyl-peptidase II) (PAP-
II). [Source:Uniprot/SWISSPROT;Acc:Q10836] 
[ENSRNOT00000007461] 
1 Trim63 
Rattus norvegicus tripartite motif protein 63 (Trim63), mRNA 
[NM_080903] 
1 Ttr Rattus norvegicus transthyretin (Ttr), mRNA [NM_012681] 
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 1 Tuba6 Rattus norvegicus tubulin, alpha 6 (Tuba6), mRNA [NM_001011995] 
1 Tubb2b Rattus norvegicus tubulin, beta 2b (Tubb2b), mRNA [NM_001013886] 
1 Tubb2c Rattus norvegicus tubulin, beta 2c (Tubb2c), mRNA [NM_199094] 
1 Tubb5 Rattus norvegicus tubulin, beta 5 (Tubb5), mRNA [NM_173102] 
1 Ube2e2 
PREDICTED: Rattus norvegicus ubiquitin-conjugating enzyme E2E 2 
(UBC4 [XM_341288] 
2 Ube2q_predicted 
PREDICTED: Rattus norvegicus ubiquitin-conjugating enzyme E2Q 
(putative) (predicted) (Ube2q_predicted), mRNA [XM_215612] 
5 Ucp2 
Rattus norvegicus uncoupling protein 2 (mitochondrial, proton carrier) 
(Ucp2), mRNA [NM_019354] 
1 Unc45b_predicted 
PREDICTED: Rattus norvegicus unc-45 homolog B (C. elegans) 
(predicted) (Unc45b_predicted), mRNA [XM_220771] 
1 Vil2 Rattus norvegicus villin 2 (Vil2), mRNA [NM_019357] 
1 Vim Rattus norvegicus vimentin (Vim), mRNA [NM_031140] 
1 Wdr27_predicted 
PREDICTED: Rattus norvegicus WD repeat domain 27 (predicted) 
(Wdr27_predicted), mRNA [XM_001055617] 
1 XM_215841 
Rattus norvegicus similar to hypothetical protein FLJ32800 
(LOC296118), mRNA [XM_215841] 
1 XM_222132 
Rattus norvegicus similar to Spindlin-like protein 2 (SPIN-2) 
(LOC288640), mRNA [XM_222132] 
1 XM_229703 
Rattus norvegicus similar to cDNA sequence BC003993 (LOC317034), 
mRNA [XM_229703] 
1 XM_230279 
Rattus norvegicus similar to protein kinase C and casein kinase substrate 
in neurons 3 (LOC311187), mRNA [XM_230279] 
1 XM_230768 
Rattus norvegicus similar to 60S ribosomal protein L7a (Surfeit locus 
protein 3) (PLA-X polypeptide) (LOC311565), mRNA [XM_230768] 
1 XM_236784 
Rattus norvegicus similar to sex-determination protein homolog Fem1a 
(LOC316131), mRNA [XM_236784] 
1 XM_340847 
Rattus norvegicus similar to myosin containing PDZ domain 
(LOC360570), mRNA [XM_340847] 
1 XM_342024 
Rattus norvegicus similar to DNA damage binding protein 1 (Damage-
specific DNA binding protein 1) (DDB p127 subunit) (DDBa) (UV-
damaged DNA-binding protein 1) (UV-DDB 1) (Xeroderma 
pigmentosum group E complementing protein) (XPCe) (X-associated... 
1 XM_343598 
Rattus norvegicus similar to titin isoform N2-A; connectin; CMH9, 
included; cardiomyopathy, dilated 1G (autosomal dominant) 
(LOC363258), mRNA [XM_343598] 
1 XM_345660 
Rattus norvegicus similar to RIKEN cDNA 1100001I23 (LOC366602), 
mRNA [XM_345660] 
1 Zbtb17 
Rattus norvegicus zinc finger and BTB domain containing 17 (Zbtb17), 
mRNA [NM_001012105] 
1 Zdhhc2 
Rattus norvegicus zinc finger, DHHC domain containing 2 (Zdhhc2), 
mRNA [NM_145096] 
265 
Appendix B: Genes selected as significant by class comparison analysis 
 
Parametric 
p-value 
Geom mean 
of ratios in 
class 1 : 
Failure 
Geom 
mean of 
ratios in 
class 2 : 
Unknown 
Fold 
difference 
of geom 
means 
Agilent ID Gene Name 
1.00E-07 0.648 0.367 1.766 A_44_P490277 ENSRNOT00000048403 
3.00E-07 1.108 0.594 1.865 A_44_P998312 NM_001037652 
4.00E-07 0.545 0.298 1.829 A_44_P234378 XR_006502 
5.00E-07 0.744 1.278 0.582 A_44_P250319 ENSRNOT00000031045 
5.00E-07 0.636 0.383 1.661 A_44_P232265 XM_346093 
6.00E-07 1.372 0.888 1.545 A_44_P196685 XM_341907 
7.00E-07 0.629 0.333 1.889 A_44_P222660 XM_226568 
7.00E-07 0.597 0.363 1.645 A_44_P447766 ENSRNOT00000050331 
1.10E-06 0.893 1.819 0.491 A_44_P992854 NM_057132 
1.10E-06 2.174 5.398 0.403 A_44_P210440 ENSRNOT00000014802 
1.10E-06 1.098 2.404 0.457 A_44_P929695 XM_228203 
1.20E-06 0.59 0.355 1.662 A_44_P351714 ENSRNOT00000043501 
1.40E-06 0.296 0.117 2.53 A_43_P14682 NM_022674 
1.70E-06 1.11 2.063 0.538 A_44_P131240 ENSRNOT00000050411 
2.30E-06 0.587 0.351 1.672 A_44_P342208 A_44_P342208 
3.00E-06 0.595 0.35 1.7 A_44_P203838 XM_225531 
3.30E-06 0.344 0.631 0.545 A_44_P860396 ENSRNOT00000047510 
3.30E-06 2.135 0.973 2.194 A_43_P10269 NM_001025712 
3.70E-06 0.85 0.515 1.65 A_42_P496649 DV727080 
4.70E-06 0.71 0.4 1.775 A_44_P651922 NM_017150 
4.70E-06 0.675 1.019 0.662 A_44_P348868 NM_019226 
5.30E-06 0.84 0.415 2.024 A_44_P511324 NM_053982 
5.70E-06 0.958 0.518 1.849 A_44_P1013385 ENSRNOT00000022065 
6.20E-06 0.937 1.78 0.526 A_44_P992854 NM_057132 
7.20E-06 0.748 0.304 2.461 A_43_P12806 NM_053439 
7.70E-06 0.578 0.361 1.601 A_44_P548455 ENSRNOT00000032995 
7.90E-06 0.383 1.049 0.365 A_44_P622201 BC098778 
9.40E-06 0.927 1.72 0.539 A_44_P992854 NM_057132 
9.70E-06 0.617 0.39 1.582 A_42_P793008 NM_130432 
1.01E-05 24.293 101.384 0.24 A_44_P864923 AW916836 
1.02E-05 2.828 9.214 0.307 A_44_P336664 CF108444 
1.02E-05 1.829 4.532 0.404 A_44_P226208 AI170501 
1.03E-05 1.059 0.565 1.874 A_42_P493785 ENSRNOT00000001419 
1.08E-05 1.211 0.773 1.567 A_44_P714524 CX570178 
1.09E-05 0.938 1.708 0.549 A_44_P992854_2348 NM_057132 
1.18E-05 0.06 0.218 0.275 A_44_P594411 CB804485 
1.18E-05 0.946 1.812 0.522 A_44_P992854 NM_057132 
1.23E-05 1.507 2.463 0.612 A_44_P1033739 XM_573823 
1.24E-05 0.171 0.82 0.209 A_44_P900646 TC627022 
1.34E-05 0.11 0.63 0.175 A_44_P930730 TC585294 
1.37E-05 0.92 1.763 0.522 A_44_P992854 NM_057132 
1.52E-05 0.258 0.139 1.856 A_44_P525250 XM_227370 
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1.55E-05 1.761 5.304 0.332 A_43_P20704 ENSRNOT00000050411 
1.56E-05 0.686 1.61 0.426 A_44_P109998 XM_227287 
1.70E-05 0.631 0.39 1.618 A_44_P368365 XM_235395 
1.74E-05 0.159 0.782 0.203 A_44_P579214 TC633900 
1.85E-05 0.928 1.78 0.521 A_44_P992854 NM_057132 
1.89E-05 0.614 0.428 1.435 A_44_P852623 ENSRNOT00000060788 
2.02E-05 0.266 0.173 1.538 A_44_P432965 NM_031840 
2.20E-05 1.269 2.067 0.614 A_44_P361380 ENSRNOT00000038715 
2.26E-05 0.823 1.559 0.528 A_43_P12215 NM_022386 
2.28E-05 1.715 1.035 1.657 A_44_P1042125 XM_001060585 
2.35E-05 0.358 0.716 0.5 A_44_P142352 ENSRNOT00000003707 
2.36E-05 0.725 1.627 0.446 A_44_P868828 TC628052 
2.38E-05 0.572 0.378 1.513 A_44_P302676 XM_221003 
2.43E-05 1.585 0.915 1.732 A_43_P10161 XM_213920 
2.49E-05 0.974 0.524 1.859 A_42_P632328 ENSRNOT00000003556 
2.59E-05 4.614 2.432 1.897 A_44_P387587 NM_022585 
2.63E-05 0.649 0.446 1.455 A_44_P391688 ENSRNOT00000034681 
2.65E-05 0.765 0.399 1.917 A_44_P360946 XR_008195 
2.66E-05 0.773 1.075 0.719 A_44_P446556 XM_342906 
3.07E-05 5.783 14.662 0.394 A_44_P550237 NM_017212 
3.07E-05 1.493 0.981 1.522 A_42_P547945 BC098813 
3.10E-05 0.532 0.351 1.516 A_44_P215788 NM_001005905 
3.22E-05 0.985 1.722 0.572 A_44_P992854 NM_057132 
3.26E-05 3.015 1.02 2.956 A_44_P118075 XM_575227 
3.46E-05 1.747 0.713 2.45 A_44_P214873 NM_024362 
3.59E-05 1.225 1.972 0.621 A_44_P288997 AW916759 
3.76E-05 1.42 0.112 12.679 A_44_P264230 XM_001062165 
3.81E-05 0.586 0.39 1.503 A_42_P728472 NM_001007600 
3.89E-05 0.855 1.821 0.47 A_44_P165817 NP798075 
4.14E-05 0.896 0.638 1.404 A_42_P709819 XM_001063185 
4.29E-05 5.716 3.546 1.612 A_42_P793598 NM_194354 
4.41E-05 0.65 0.476 1.366 A_43_P14875 NM_031324 
4.45E-05 0.77 0.48 1.604 A_42_P777285 AI013497 
4.46E-05 1.641 22.759 0.072 A_44_P435618_1878 NM_017333 
4.46E-05 1.331 0.147 9.054 A_44_P701240 TC620596 
4.58E-05 1.702 3.585 0.475 A_44_P153979 NM_013164 
4.62E-05 0.828 0.499 1.659 A_44_P745027 XR_009438 
4.92E-05 0.661 0.497 1.33 A_43_P10034 NM_053928 
5.11E-05 1.725 3.759 0.459 A_44_P188729 ENSRNOT00000046108 
5.18E-05 0.713 0.52 1.371 A_43_P11181 XM_001077170 
5.24E-05 3.478 1.775 1.959 A_42_P499282 NM_001031660 
5.61E-05 0.565 1.319 0.428 A_44_P342075 ENSRNOT00000027314 
5.84E-05 0.363 0.225 1.613 A_44_P189065 ENSRNOT00000027123 
5.87E-05 1.754 3.263 0.538 A_44_P466111 AB012231 
5.91E-05 0.938 0.68 1.379 A_44_P997815 NM_001079698 
5.96E-05 1.087 1.508 0.721 A_44_P203421 U45479 
6.20E-05 0.184 0.453 0.406 A_44_P837560 TC583130 
6.29E-05 1.045 0.674 1.55 A_44_P207907 NM_022498 
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6.30E-05 0.522 0.355 1.47 A_44_P290905 ENSRNOT00000049230 
6.30E-05 0.337 0.561 0.601 A_44_P340977 ENSRNOT00000047510 
6.30E-05 0.484 0.333 1.453 A_44_P698581 A_44_P698581 
6.44E-05 0.508 0.31 1.639 A_44_P199482 XR_005657 
6.64E-05 1.887 0.867 2.176 A_43_P16650 XM_214107 
6.80E-05 1.28 3.862 0.331 A_43_P12612 Y12259 
6.89E-05 0.523 0.696 0.751 A_44_P1059422 NM_001009268 
6.92E-05 1.178 0.77 1.53 A_44_P606810 TC593084 
6.97E-05 0.653 0.322 2.028 A_44_P304752 XR_008958 
7.07E-05 1.148 0.82 1.4 A_44_P329688 XM_240915 
7.14E-05 0.538 1.185 0.454 A_43_P11613 NM_012903 
7.30E-05 0.453 0.299 1.515 A_44_P192364 ENSRNOT00000057412 
7.37E-05 0.543 0.317 1.713 A_42_P780097 NM_001008280 
7.43E-05 0.499 0.723 0.69 A_44_P553980 ENSRNOT00000047510 
7.49E-05 1.092 0.816 1.338 A_44_P193221 CK471009 
7.71E-05 0.771 1.227 0.628 A_44_P482595 NM_053796 
7.80E-05 0.562 0.369 1.523 A_42_P487031 NM_001009539 
7.83E-05 0.938 2.439 0.385 A_44_P745617 TC603676 
8.00E-05 0.277 0.086 3.221 A_42_P751720 XR_009563 
8.67E-05 0.856 1.937 0.442 A_44_P400591 A_44_P400591 
8.72E-05 0.097 0.059 1.644 A_43_P16774 NM_001006995 
8.75E-05 0.728 0.544 1.338 A_42_P839036 ENSRNOT00000013359 
8.79E-05 0.334 0.922 0.362 A_44_P853879 TC624399 
9.06E-05 0.425 0.307 1.384 A_44_P271643 NM_053970 
9.30E-05 1.648 0.983 1.677 A_44_P343303 NM_019367 
9.37E-05 0.556 0.343 1.621 A_44_P867677 XR_005504 
9.66E-05 0.759 0.607 1.25 A_43_P10477 CF108377 
9.70E-05 0.64 0.441 1.451 A_44_P482749 XR_008366 
9.87E-05 0.95 0.552 1.721 A_44_P1054708 NM_001009538 
9.93E-05 1.22 2.358 0.517 A_44_P834734 AB026259 
9.93E-05 1.993 2.741 0.727 A_44_P853685 TC589959 
9.94E-05 0.668 0.456 1.465 A_44_P339867 NM_017199 
0.0001072 0.497 1.359 0.366 A_44_P434859 BC090353 
0.0001092 0.25 0.906 0.276 A_44_P158079 BI395434 
0.0001105 0.508 0.345 1.472 A_44_P523261 ENSRNOT00000049805 
0.000112 0.656 0.471 1.393 A_44_P389243 ENSRNOT00000000433 
0.0001123 1.57 0.984 1.596 A_43_P12047 NM_019380 
0.0001133 0.388 0.25 1.552 A_44_P1002452 NM_001009271 
0.0001135 3.389 6.42 0.528 A_42_P799113 NM_139104 
0.0001136 0.975 1.901 0.513 A_44_P363090 NM_001008725 
0.0001146 0.979 1.792 0.546 A_44_P992854 NM_057132 
0.0001147 1.178 0.834 1.412 A_42_P512252 NM_201421 
0.0001157 0.682 0.319 2.138 A_42_P674598 NM_013067 
0.0001168 0.505 0.35 1.443 A_44_P361504 ENSRNOT00000036109 
0.0001195 0.601 0.408 1.473 A_42_P596503 NM_053334 
0.0001215 0.223 0.93 0.24 A_44_P1018098 ENSRNOT00000019724 
0.0001224 0.17 0.633 0.269 A_44_P449108 AI043579 
0.0001245 1.379 0.967 1.426 A_44_P325376 XM_574706 
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0.0001265 0.651 0.939 0.693 A_44_P1059334 NM_133398 
0.0001267 3.05 7.281 0.419 A_44_P278113 ENSRNOT00000043693 
0.0001273 0.732 0.408 1.794 A_44_P959692 XM_001066878 
0.0001292 0.659 0.41 1.607 A_42_P827124 ENSRNOT00000007351 
0.0001293 1.729 0.534 3.238 A_44_P125226 AW532988 
0.00013 3.517 1.958 1.796 A_44_P667648 ENSRNOT00000010055 
0.000131 1.014 0.544 1.864 A_44_P728932 ENSRNOT00000028742 
0.0001314 0.592 0.39 1.518 A_44_P301863 ENSRNOT00000007403 
0.0001331 1.498 2.948 0.508 A_44_P337606 ENSRNOT00000016804 
0.0001364 0.577 1.342 0.43 A_44_P820184 AI030973 
0.0001369 0.286 0.659 0.434 A_44_P187830 ENSRNOT00000002851 
0.0001378 1.616 6.76 0.239 A_44_P254016 NM_016992 
0.0001378 0.966 1.964 0.492 A_44_P992854 NM_057132 
0.0001384 1.38 2.301 0.6 A_44_P436528 ENSRNOT00000014310 
0.0001386 1.122 2.241 0.501 A_44_P261450 ENSRNOT00000009894 
0.0001404 1.302 10.509 0.124 A_42_P631453 XM_216941 
0.0001434 1.186 0.786 1.509 A_44_P427523 NM_057140 
0.0001444 0.06 0.026 2.308 A_44_P400494 NM_053976 
0.0001445 1.093 0.806 1.356 A_43_P12732 NM_033097 
0.0001446 0.769 0.392 1.962 A_44_P450149 ENSRNOT00000042609 
0.0001461 2.655 1.521 1.746 A_42_P660068 NM_031350 
0.0001487 0.661 0.44 1.502 A_43_P17696 NM_001004257 
0.00015 0.519 0.331 1.568 A_44_P536545 XM_001055461 
0.0001504 0.8 0.527 1.518 A_42_P552233 XM_213765 
0.0001515 0.673 1.313 0.513 A_43_P22613 ENSRNOT00000018266 
0.0001528 0.848 0.479 1.77 A_42_P675659 NM_001004276 
0.0001537 5.155 1.245 4.141 A_44_P921710 A_44_P921710 
0.0001545 1.18 0.638 1.85 A_43_P10614 TC600099 
0.0001564 0.339 0.141 2.404 A_44_P786208 CF111551 
0.0001565 0.535 1.129 0.474 A_44_P196933 NM_001014031 
0.0001573 0.474 0.879 0.539 A_44_P442733 NM_022386 
0.0001594 2.009 1.049 1.915 A_44_P329357 NM_017112 
0.0001647 0.453 0.305 1.485 A_44_P182913 XR_008450 
0.0001653 1.04 2.104 0.494 A_44_P154245 ENSRNOT00000003146 
0.0001655 1.678 0.851 1.972 A_43_P13146 NM_131907 
0.0001674 2.593 3.827 0.678 A_44_P876215 CF109454 
0.0001682 2.156 1.4 1.54 A_43_P12438 NM_024387 
0.0001685 0.667 0.292 2.284 A_44_P483888 XM_001060262 
0.0001701 1.918 0.856 2.241 A_44_P583151 A_44_P583151 
0.0001703 0.621 0.436 1.424 A_44_P222865 ENSRNOT00000005711 
0.0001708 1.326 0.949 1.397 A_43_P16523 XM_341861 
0.0001709 0.754 1.847 0.408 A_44_P1059789 ENSRNOT00000010118 
0.0001718 0.721 0.415 1.737 A_44_P185138 A_44_P185138 
0.0001723 79.722 9.691 8.226 A_42_P669388 NM_001039011 
0.0001727 6.952 1.625 4.278 A_43_P15602 NM_134391 
0.0001739 0.922 1.539 0.599 A_44_P264988 ENSRNOT00000016784 
0.0001765 0.138 0.558 0.247 A_44_P900178 TC584409 
0.0001765 0.912 0.618 1.476 A_44_P1051965 NM_053877 
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0.0001815 2.15 4.277 0.503 A_44_P466108 AB012231 
0.0001816 0.904 1.848 0.489 A_44_P551919 ENSRNOT00000057681 
0.0001828 2.017 3.39 0.595 A_44_P536282 NM_001013130 
0.0001831 1.209 0.791 1.528 A_43_P10634 NM_001025123 
0.0001843 0.162 0.082 1.976 A_44_P236187 NM_022582 
0.0001867 0.624 0.356 1.753 A_42_P604121 NM_001012144 
0.0001884 0.147 0.945 0.156 A_44_P590051 AW917697 
0.0001884 0.87 1.917 0.454 A_44_P884555 BE113337 
0.0001902 2.419 1.013 2.388 A_44_P975513 TC588827 
0.0001914 3.919 8.831 0.444 A_44_P1043059 NM_001013130 
0.0001925 2.125 6.128 0.347 A_44_P463064 ENSRNOT00000043693 
0.0001928 1.157 2.057 0.562 A_44_P1044499 ENSRNOT00000006333 
0.000193 3.994 8.596 0.465 A_44_P685899 TC601880 
0.0001952 0.409 0.273 1.498 A_44_P226029 ENSRNOT00000016184 
0.0002013 1.53 0.82 1.866 A_44_P704874 AA963844 
0.0002062 0.143 0.553 0.259 A_44_P824467 TC599815 
0.0002067 2.292 1.435 1.597 A_42_P563553 XM_001081219 
0.0002067 0.504 0.345 1.461 A_44_P432139 NM_031099 
0.0002096 0.502 0.369 1.36 A_44_P473449 XM_227913 
0.0002105 0.708 0.488 1.451 A_43_P15307 NM_030859 
0.0002112 2.561 5.391 0.475 A_44_P792220 TC590891 
0.0002143 0.19 0.938 0.203 A_44_P251787 AW142969 
0.0002161 0.584 0.446 1.309 A_44_P222865 ENSRNOT00000005711 
0.0002176 3.499 6.148 0.569 A_44_P668313 ENSRNOT00000017233 
0.0002187 0.345 2.9 0.119 A_44_P901264 TC607281 
0.0002198 0.412 0.313 1.316 A_44_P337088 NM_133609 
0.0002214 1 1.42 0.704 A_42_P642507 ENSRNOT00000037829 
0.0002236 5.698 3.824 1.49 A_43_P10709 XM_215728 
0.0002255 0.147 0.818 0.18 A_44_P959890 AABR03000060 
0.0002268 0.507 0.34 1.491 A_44_P232113 A_44_P232113 
0.0002277 11.947 19.659 0.608 A_44_P333010 ENSRNOT00000014193 
0.000232 3.682 2.729 1.349 A_44_P561113 TC615156 
0.0002321 0.506 0.854 0.593 A_44_P245665 NM_053311 
0.0002328 0.246 0.43 0.572 A_44_P532389 CF110666 
0.0002348 0.619 0.409 1.513 A_44_P100996 NM_017150 
0.0002359 1.098 0.215 5.107 A_44_P913155 AW915016 
0.0002366 0.976 1.851 0.527 A_44_P261874 NM_175761 
0.0002384 1.809 1.245 1.453 A_44_P138347 NM_001034958 
0.0002443 2.253 5.507 0.409 A_44_P463071 ENSRNOT00000043693 
0.0002464 5.152 18.322 0.281 A_44_P177704 AF370889 
0.0002469 0.506 0.289 1.751 A_42_P644278 NM_001037349 
0.0002472 0.631 0.43 1.467 A_44_P283941 NM_001009600 
0.0002482 0.187 0.547 0.342 A_43_P19515 NM_001014207 
0.0002483 0.787 0.504 1.562 A_42_P506402 NM_145677 
0.0002486 0.985 0.654 1.506 A_44_P132470 NM_022511 
0.00025 0.286 0.172 1.663 A_44_P928928 ENSRNOT00000044499 
0.0002505 0.486 0.305 1.593 A_44_P537303 NM_022510 
0.0002521 0.955 1.426 0.67 A_44_P238257 NM_053920 
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0.0002547 0.709 0.999 0.71 A_44_P976320 TC593051 
0.0002628 0.178 0.824 0.216 A_44_P978172 TC602645 
0.0002628 0.935 1.239 0.755 A_42_P726994 XM_001072149 
0.0002634 0.198 0.733 0.27 A_44_P458987 AY325145 
0.000264 1.182 2.933 0.403 A_43_P21507 ENSRNOT00000049300 
0.0002649 0.787 0.565 1.393 A_44_P116172 ENSRNOT00000019107 
0.0002671 0.954 0.599 1.593 A_44_P271416 NM_138708 
0.0002683 1.508 1.103 1.367 A_44_P1033023 NM_013063 
0.0002704 0.232 0.63 0.368 A_44_P670611 TC632008 
0.0002726 0.966 0.519 1.861 A_44_P248083 XM_221978 
0.000273 2.021 2.922 0.692 A_42_P516640 NM_019124 
0.0002735 0.244 0.659 0.37 A_43_P11261 XM_234572 
0.0002739 0.456 1.464 0.311 A_44_P1012333 BC090353 
0.0002755 0.657 0.468 1.404 A_44_P1003072 NM_001025650 
0.0002793 1.032 1.751 0.589 A_44_P416633 NM_175754 
0.0002822 1.115 0.882 1.264 A_44_P213392 NM_057122 
0.0002859 10.514 34.313 0.306 A_44_P320617 NM_019131 
0.0002863 1.527 0.974 1.568 A_44_P1046705 ENSRNOT00000025008 
0.0002899 6.676 12.342 0.541 A_43_P16895 XM_224672 
0.0002909 36.413 141.416 0.257 A_42_P832832 NM_012530 
0.0002968 1.585 0.897 1.767 A_44_P555042 NM_001000169 
0.0002974 0.558 0.217 2.571 A_44_P714409 NM_001047907 
0.0003003 0.585 0.373 1.568 A_44_P455065 ENSRNOT00000045295 
0.0003037 0.184 0.145 1.269 A_44_P143567 NM_031840 
0.0003084 0.738 0.455 1.622 A_43_P11682 NM_013050 
0.0003151 0.934 0.626 1.492 A_44_P760650 ENSRNOT00000024085 
0.0003151 2.559 1.51 1.695 A_44_P988460 AW142021 
0.000317 0.621 2.902 0.214 A_44_P140378 ENSRNOT00000015232 
0.00032 0.637 0.277 2.3 A_44_P1042876 NM_031971 
0.0003219 0.792 0.964 0.822 A_44_P396522 NM_021840 
0.0003236 0.618 0.766 0.807 A_44_P227361 ENSRNOT00000008741 
0.0003237 2.451 4.11 0.596 A_44_P790431 ENSRNOT00000060252 
0.0003257 0.638 1.024 0.623 A_43_P11241 ENSRNOT00000055970 
0.0003319 0.716 1.052 0.681 A_42_P760177 XM_342906 
0.0003362 0.149 0.698 0.213 A_44_P420869 BM391518 
0.0003365 0.488 0.348 1.402 A_44_P203746 XM_344416 
0.0003413 0.941 1.493 0.63 A_42_P548791 NM_021762 
0.000342 1.123 0.849 1.323 A_44_P291060 ENSRNOT00000015257 
0.000346 0.944 0.69 1.368 A_44_P991484 CA510796 
0.0003462 1.128 1.574 0.717 A_44_P741147 AW917588 
0.0003479 0.228 0.125 1.824 A_44_P531129 M12822 
0.0003516 0.663 0.318 2.085 A_44_P319256 ENSRNOT00000056171 
0.0003551 3.825 1.003 3.814 A_44_P219447 BM986234 
0.0003557 1.527 1.108 1.378 A_44_P1033023_781 NM_013063 
0.0003559 0.496 0.329 1.508 A_44_P168184 AF507943 
0.0003598 0.733 1.223 0.599 A_44_P313431 ENSRNOT00000009755 
0.0003698 3.122 1.846 1.691 A_44_P358361 NM_001002821 
0.0003701 0.684 0.547 1.25 A_42_P519910 ENSRNOT00000021017 
271 
0.0003711 3.307 0.461 7.174 A_44_P299109 DV723665 
0.0003724 0.923 0.7 1.319 A_44_P1025944 NM_147140 
0.0003761 1.487 2.525 0.589 A_44_P622978 TC590816 
0.0003781 1.5 0.986 1.521 A_44_P457447 CF112427 
0.0003797 5.77 12.365 0.467 A_42_P588944 NM_012862 
0.0003873 0.722 0.432 1.671 A_44_P278829 XR_006025 
0.0003898 10.847 19.02 0.57 A_44_P1007347 NM_019386 
0.0003921 0.539 0.369 1.461 A_44_P535706 ENSRNOT00000017422 
0.0004022 0.809 0.569 1.422 A_42_P699937 NM_001034134 
0.0004052 12.474 1.408 8.859 A_44_P510951 ENSRNOT00000028443 
0.000406 2.185 1.357 1.61 A_44_P460797 AF020046 
0.0004067 1.068 1.407 0.759 A_44_P745393 ENSRNOT00000023274 
0.0004081 1.399 1.003 1.395 A_43_P13808 NM_001017477 
0.0004191 0.636 0.441 1.442 A_44_P222865 ENSRNOT00000005711 
0.0004193 6.874 57.055 0.12 A_44_P353708 ENSRNOT00000016663 
0.0004206 1.752 0.77 2.275 A_44_P289312 CB567518 
0.0004286 0.652 0.435 1.499 A_44_P458241 ENSRNOT00000024406 
0.000432 1.416 0.984 1.439 A_42_P770458 NM_134414 
0.0004337 3.073 1.522 2.019 A_43_P12741 NM_052798 
0.0004367 1.827 3.496 0.523 A_44_P1031034 NM_031745 
0.0004393 1.694 0.462 3.667 A_42_P577938 NM_001014218 
0.0004399 5.044 7.923 0.637 A_44_P505180 NM_057202 
0.0004401 1.384 2.066 0.67 A_44_P309215 NM_001024771 
0.0004435 1.067 1.575 0.677 A_44_P351563 A_44_P351563 
0.0004462 1.389 2.253 0.617 A_43_P15794 NM_053766 
0.000449 0.474 0.303 1.564 A_44_P397495 NM_024359 
0.0004502 0.697 0.479 1.455 A_44_P457053 XR_007987 
0.0004569 0.759 0.478 1.588 A_44_P522482 NM_001013928 
0.0004598 0.194 0.629 0.308 A_44_P261444 XM_343065 
0.0004599 2.978 5.425 0.549 A_44_P137187 ENSRNOT00000042098 
0.0004624 1.187 0.715 1.66 A_43_P10498 XM_237039 
0.0004634 1.279 0.637 2.008 A_44_P605194 XM_340890 
0.0004683 0.945 0.537 1.76 A_44_P281457 XM_001054883 
0.0004689 0.963 0.494 1.949 A_44_P1020018 ENSRNOT00000016882 
0.0004718 1.103 0.797 1.384 A_42_P645110 NM_001029919 
0.0004743 0.759 0.561 1.353 A_44_P461944 NM_001007714 
0.0004832 1.048 0.68 1.541 A_44_P288826 ENSRNOT00000025491 
0.000487 0.09 0.044 2.045 A_44_P154298 XM_573787 
0.000488 0.33 0.732 0.451 A_44_P714885 TC589847 
0.0004887 0.665 0.465 1.43 A_44_P112237 ENSRNOT00000052249 
0.0004887 0.677 0.464 1.459 A_44_P311247 NM_212515 
0.00049 0.553 0.413 1.339 A_44_P318941 XM_225467 
0.0004909 1.338 0.723 1.851 A_44_P941132 ENSRNOT00000030569 
0.0004926 3.139 1.996 1.573 A_44_P318029 ENSRNOT00000035618 
0.0004966 0.672 1.102 0.61 A_44_P1006988 ENSRNOT00000025335 
0.0004978 1.531 1.322 1.158 A_44_P494483 XM_215528 
0.0004985 1.186 1.542 0.769 A_44_P311945 ENSRNOT00000013471 
0.000499 0.625 0.444 1.408 A_44_P222865 ENSRNOT00000005711 
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0.0005041 0.333 0.232 1.435 A_43_P10069 DV717672 
0.0005044 0.58 0.375 1.547 A_43_P12406 NM_024151 
0.0005062 5.765 10.524 0.548 A_44_P451627 XM_237286 
0.0005085 0.739 0.382 1.935 A_44_P503579 NM_201415 
0.0005109 50.115 140.76 0.356 A_44_P1021630 ENSRNOT00000058312 
0.0005193 1.844 0.455 4.053 A_44_P394119 BG663439 
0.0005209 0.245 0.151 1.623 A_44_P183694 AB072614 
0.0005241 1.352 0.88 1.536 A_44_P243604 ENSRNOT00000055588 
0.0005308 3.899 6.584 0.592 A_44_P299247 NM_012778 
0.0005309 0.61 1.014 0.602 A_44_P477446 ENSRNOT00000043942 
0.0005328 3.973 6.483 0.613 A_44_P299247 NM_012778 
0.0005329 0.09 0.179 0.503 A_44_P233080 NM_012551 
0.0005337 0.658 0.405 1.625 A_44_P121682 XM_230870 
0.000536 1.501 0.349 4.301 A_44_P822078 XM_576832 
0.0005408 1.369 0.858 1.596 A_44_P494652 NM_001013431 
0.0005419 1.076 1.693 0.636 A_44_P258751 NM_031081 
0.0005452 0.239 0.152 1.572 A_42_P710738 NM_031620 
0.0005461 0.885 0.388 2.281 A_44_P157045 ENSRNOT00000045196 
0.0005473 0.812 0.474 1.713 A_44_P194925 ENSRNOT00000043365 
0.00055 0.564 0.754 0.748 A_44_P105791 BF548544 
0.0005565 0.894 0.466 1.918 A_42_P561580 NM_031113 
0.0005579 0.664 0.323 2.056 A_44_P1042876 NM_031971 
0.000562 0.364 0.675 0.539 A_44_P808557 TC604543 
0.0005674 1.57 1.118 1.404 A_44_P1033023 NM_013063 
0.0005693 0.588 1.221 0.482 A_44_P505500 ENSRNOT00000052393 
0.0005738 0.125 0.523 0.239 A_44_P1016061 DV729072 
0.0005842 1.138 1.517 0.75 A_44_P302012 ENSRNOT00000007173 
0.0005852 0.071 0.014 5.071 A_44_P975250 BC099121 
0.0005871 2.911 4.225 0.689 A_44_P748217 ENSRNOT00000046038 
0.0005956 0.849 0.339 2.504 A_43_P17988 NM_001025018 
0.0006055 0.706 0.55 1.284 A_43_P11046 TC581726 
0.0006068 1.143 2.011 0.568 A_42_P489167 XM_224963 
0.0006188 1.096 1.32 0.83 A_44_P1040854 NM_153628 
0.0006236 0.662 0.495 1.337 A_44_P116176 ENSRNOT00000019107 
0.0006237 0.347 0.233 1.489 A_44_P370645 ENSRNOT00000008329 
0.0006247 0.614 0.177 3.469 A_44_P1042876 NM_031971 
0.0006283 0.694 1.011 0.686 A_42_P638128 NM_012893 
0.0006297 1.096 0.664 1.651 A_42_P592059 ENSRNOT00000001922 
0.0006318 0.23 0.887 0.259 A_44_P741769 AI555513 
0.0006338 2.896 1.439 2.013 A_44_P556586 BC086580 
0.0006366 1.549 5.636 0.275 A_44_P152290 ENSRNOT00000007761 
0.0006397 2.824 0.699 4.04 A_43_P15470 NM_012701 
0.0006409 0.492 0.342 1.439 A_44_P165918 ENSRNOT00000061986 
0.0006414 0.895 0.581 1.54 A_44_P1006655 NM_053597 
0.0006515 0.916 1.599 0.573 A_44_P217774 NM_001009698 
0.0006579 0.5 0.327 1.529 A_44_P461657 XM_001071880 
0.0006591 0.78 0.56 1.393 A_44_P948037 NM_001039196 
0.0006702 1.206 0.809 1.491 A_43_P11040 NM_001009639 
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0.0006711 0.734 1.822 0.403 A_44_P312309 NM_001047087 
0.0006715 2.514 2.11 1.191 A_43_P15205 ENSRNOT00000061430 
0.0006795 3.769 1.25 3.015 A_44_P135424 XM_223116 
0.0006824 0.611 0.413 1.479 A_44_P370335 NM_001011911 
0.0006851 1.209 0.795 1.521 A_44_P1037886 NM_001033685 
0.0006855 0.269 0.709 0.379 A_43_P10405 ENSRNOT00000002523 
0.0006931 0.392 0.286 1.371 A_44_P234500 XR_006077 
0.0006933 1.588 3.094 0.513 A_44_P1046263 ENSRNOT00000022583 
0.0006943 1.143 0.762 1.5 A_44_P433367 AF546755 
0.0006943 0.871 0.682 1.277 A_44_P1022403 NM_001004204 
0.0007009 0.931 0.151 6.166 A_44_P175786 XM_228865 
0.0007016 0.083 0.169 0.491 A_44_P233080 NM_012551 
0.0007019 1.991 0.684 2.911 A_43_P11951 NM_019150 
0.0007079 0.87 0.602 1.445 A_43_P11423 XM_342470 
0.0007097 1.127 0.75 1.503 A_44_P158216 NM_022185 
0.00071 3.671 7.301 0.503 A_44_P463069 ENSRNOT00000043693 
0.0007128 0.656 0.445 1.474 A_44_P454993 XM_346127 
0.0007163 1.589 2.327 0.683 A_44_P159191 ENSRNOT00000025756 
0.0007208 0.635 0.964 0.659 A_43_P10601 XM_220207 
0.0007215 3.918 6.476 0.605 A_44_P299247 NM_012778 
0.0007277 0.646 0.851 0.759 A_44_P153206 NM_031515 
0.000728 0.681 1.338 0.509 A_44_P239985 NM_013217 
0.0007292 1.008 0.765 1.318 A_44_P390454 NM_017276 
0.0007296 1.423 0.757 1.88 A_44_P515360 L22079 
0.0007313 0.331 0.6 0.552 A_43_P14802 ENSRNOT00000024714 
0.0007316 0.908 1.477 0.615 A_44_P386840 NM_001013209 
0.0007354 0.78 0.389 2.005 A_44_P944832 BG671311 
0.0007392 2.26 3.308 0.683 A_43_P11924 NM_017338 
0.000741 0.068 0.038 1.789 A_44_P416695 NM_001004022 
0.0007431 1.82 1.003 1.815 A_44_P220301 ENSRNOT00000061270 
0.0007464 9.266 23.758 0.39 A_44_P489468 ENSRNOT00000030661 
0.0007495 2.262 1.529 1.479 A_44_P716323 TC591828 
0.0007501 1.181 0.874 1.351 A_43_P15303 NM_030836 
0.0007565 0.756 1.17 0.646 A_44_P411362 NM_001039026 
0.0007576 0.23 0.12 1.917 A_44_P461130 NM_183333 
0.0007586 0.551 0.707 0.779 A_44_P822616 ENSRNOT00000000206 
0.0007637 0.886 0.502 1.765 A_44_P100565 A_44_P100565 
0.0007641 0.803 0.61 1.316 A_44_P1046566 ENSRNOT00000004150 
0.0007686 0.815 0.46 1.772 A_44_P194928 XM_213602 
0.0007756 2.185 2.991 0.731 A_44_P607486 ENSRNOT00000006604 
0.0007756 1.032 0.673 1.533 A_44_P520509 NM_001033868 
0.0007863 7.244 10.812 0.67 A_43_P21455 ENSRNOT00000014917 
0.0007939 0.482 0.35 1.377 A_44_P393422 NM_001013188 
0.0007996 38.447 159.751 0.241 A_44_P994686 NM_012676 
0.0007998 1.712 3.107 0.551 A_44_P615732 ENSRNOT00000017156 
0.0008021 0.087 0.197 0.442 A_44_P233080 NM_012551 
0.0008066 0.473 1.037 0.456 A_44_P651794 ENSRNOT00000034463 
0.0008103 12.067 2.062 5.852 A_44_P424218 ENSRNOT00000017151 
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0.0008159 1.181 2.543 0.464 A_44_P801044 NM_001025775 
0.0008183 2.309 1.108 2.084 A_44_P1060444 XM_216368 
0.0008223 0.912 0.491 1.857 A_44_P280410 NM_183325 
0.0008245 1.483 2.58 0.575 A_44_P492321 ENSRNOT00000023710 
0.0008271 0.881 0.563 1.565 A_44_P374011 NM_001017489 
0.0008273 3.685 7.419 0.497 A_44_P851230 BF558478 
0.0008282 0.613 0.422 1.453 A_44_P603427 BC104707 
0.0008457 1.202 0.786 1.529 A_44_P336714 XM_341545 
0.0008476 1.465 3.048 0.481 A_44_P649177 ENSRNOT00000017391 
0.0008498 0.57 1.239 0.46 A_43_P16715 NM_001024903 
0.0008532 0.663 1.022 0.649 A_43_P11226 XM_217381 
0.0008595 19.682 2.38 8.27 A_44_P533672 BG670971 
0.0008611 0.717 0.488 1.469 A_44_P473220 XM_344177 
0.0008641 2.707 1.324 2.045 A_43_P22696 A_43_P22696 
0.0008691 3.961 6.366 0.622 A_44_P299247 NM_012778 
0.0008726 0.242 0.493 0.491 A_44_P160113 AW918729 
0.0008742 0.531 0.354 1.5 A_44_P992404 NM_001039004 
0.0008769 0.464 0.991 0.468 A_44_P994454 ENSRNOT00000006370 
0.0008791 0.791 0.468 1.69 A_44_P266340 AW918765 
0.0008836 0.466 1.036 0.45 A_44_P252417 NM_022281 
0.000884 0.537 0.904 0.594 A_44_P836445 NM_001014255 
0.000886 3.275 2.127 1.54 A_43_P16740 ENSRNOT00000020532 
0.0008876 1.052 0.794 1.325 A_42_P525962 ENSRNOT00000005402 
0.0008878 0.173 0.66 0.262 A_44_P652332 NM_001025023 
0.0008896 0.181 0.398 0.455 A_44_P542887 NM_001014207 
0.000898 1.185 0.787 1.506 A_43_P17564 NM_001013044 
0.0009006 1.381 0.916 1.508 A_44_P510659 NM_019380 
0.0009066 1.43 6.28 0.228 A_43_P16346 U89745 
0.0009075 1.158 1.518 0.763 A_44_P309052 NM_001008853 
0.0009099 2.08 0.966 2.153 A_43_P10593 NM_032612 
0.0009113 1.891 0.339 5.578 A_44_P473020 AF321133 
0.0009123 0.787 1.106 0.712 A_42_P800669 BF289687 
0.0009146 0.992 0.73 1.359 A_44_P1054213 NM_013083 
0.0009199 0.488 0.363 1.344 A_44_P494862 NM_001008309 
0.0009207 0.576 0.405 1.422 A_42_P544965 NM_031104 
0.0009226 0.301 0.79 0.381 A_44_P352123 NM_001014215 
0.0009235 1.072 0.652 1.644 A_44_P334709 NM_022672 
0.0009309 0.372 0.295 1.261 A_44_P149036 NM_017138 
0.0009324 0.804 1.355 0.593 A_44_P533778 NM_030830 
0.0009348 0.574 1.476 0.389 A_44_P747226 TC620374 
0.0009367 0.303 1.137 0.266 A_44_P639148 TC605165 
0.0009367 2.121 1.49 1.423 A_43_P10326 CF110545 
0.0009437 4.067 6.81 0.597 A_44_P299247 NM_012778 
0.0009481 0.72 0.393 1.832 A_44_P200630 AA851208 
0.0009491 0.863 0.643 1.342 A_44_P191784 NM_031969 
0.0009521 0.08 0.506 0.158 A_44_P730758 TC609403 
0.0009522 2.17 0.77 2.818 A_44_P190226 ENSRNOT00000019919 
0.0009556 0.353 0.163 2.166 A_42_P641234 NM_001008303 
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0.0009583 0.627 0.389 1.612 A_44_P446539 ENSRNOT00000011456 
0.0009585 1.394 1.004 1.388 A_44_P995085 NM_001007801 
0.0009597 1.368 0.74 1.849 A_44_P777199 NM_001008354 
0.0009631 2.75 4.731 0.581 A_42_P524370 NM_053369 
0.0009668 0.221 0.512 0.432 A_44_P566856 TC639666 
0.0009714 0.625 0.444 1.408 A_42_P639337 NM_001014272 
0.000974 1.862 0.905 2.057 A_44_P376683 BF548232 
0.0009758 1.034 2.247 0.46 A_43_P20159 ENSRNOT00000033355 
0.000983 0.868 0.597 1.454 A_44_P533172 AI535535 
0.0009837 0.982 3.155 0.311 A_44_P796993 TC626901 
0.0009876 1.968 5.095 0.386 A_43_P18603 ENSRNOT00000024296 
0.00099 0.592 0.853 0.694 A_44_P1057074 XM_221050 
0.0009937 3.106 1.057 2.939 A_42_P666809 DV725602 
0.0009963 0.615 0.407 1.511 A_44_P238891 ENSRNOT00000014993 
0.0009988 2.723 1.304 2.088 A_44_P538989 NM_001014010 
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